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Abstract 
Rab27a is a small GTPase belonging to the Ras superfamily. Normally involved in vesicle 
transport and docking, numerous studies from the past two decades have documented a 
positive correlation between its overexpression in tumour cells and the invasiveness of the 
cancer. These findings strongly suggest that Rab27a could be a novel cancer drug target, 
yet, the dearth of clinically successful drugs targeting other oncogenic members of the Ras 
superfamily reflects the difficulty of applying canonical medicinal chemistry techniques to this 
class of proteins, structurally flexible and have complex protein-protein interaction (PPI) 
networks. 
The development of new biophysical methods in drug discovery holds promise in delivering 
where past methods have struggled. In this thesis, two top small molecular hits from a 
fragment assay against Rab27a were developed as part of structure-activity relationship 
(SAR) studies using a crystallised protein construct as guidance. Peptide binders were also 
sought, and a dipeptide was identified as the first positive control for Rab27a with a kd of ~8 
mM by SPR, and its affinity was improved by lactam bridging. 
The PPIs of Rab27a were also investigated as part of the development of photocleavable 
crosslinkers for a novel chemical biology approach to interactome proteomics. A prototype 
lysine-targeting covalent crosslinker was designed, synthesised and validated with 
recombinant protein followed by Rab27a-spiked lysate. It was subsequently incorporated 
into a bespoke proteomic protocol and tested against HeLa lysate transfected with Twin-
Step Tag (TST)-Rab27a. The results were analysed using label-free quantification (LFQ) in 
MaxQuant and peptide modifications inspected with PEAKS. The analysis workflow is 
discussed and critically analysed, offering many fruitful avenues for the future iterations of 
the protocol. 
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1 Introduction 
This thesis is concerned with two divergent approaches to investigate native and non-native 
ligands of the oncogenic GTPase Rab27a. The first section discusses the discovery of small 
molecule and peptide inhibitors for Rab27a, whilst the second part focuses on the 
development of a photocleavable crosslinker for use in proteomic mass spectrometry to 
pursue its endogenous effectors. The structure of the introductory chapter reflects this, 
starting with an overview of structure-guided attempts to find therapeutic inhibitors for the 
Ras superfamily, of which Rab27a is a member, alongside a discussion of the relevance and 
challenges faced when targeting Rab27a. It is followed by a short primer in quantitative 
proteomics, with particular focus on the use of crosslinkers to stabilise protein-protein 
interactions (PPIs) for mass spectrometry detection. 
1.1 Clinical Relevance of Rab27a 
Small monomeric GTPases are a class of guanosine-binding proteins (G-proteins), of which 
the Ras superfamily is the most well-studied. The five main subfamilies are Ras, Rab, Rho, 
Arf and Ran, and their roles span across the entire range of cellular processes. Over 60 Rab 
proteins exist in the human proteome and are involved in many aspects of vesicle 
trafficking.1-2,3-4 
Rab27a and Rab27b are the two isoforms of Rab27. They are similar in structure and 
sequence with approximately 70% sequence homology.5 Although they have been shown to 
bind to all the same effectors, there is evidence that they prefer to perform distinct roles 
within the same trafficking cascade.5-7 This thesis will focus on Rab27a, in particular the 
nature of its dysregulation in cancer. 
Rab27a is expressed in a variety of secretory cell types and is involved transporting and 
docking vesicles in various endocrine and exocrine exocytotic and endocytotic processes.4, 8-
12
 The knockout mutation of Rab27a in humans causes a genetic disease called Griscelli 
syndrome type II that is characterised by albinism and severe immunodeficiency, invariably 
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resulting in a reduced lifespan.13 These effects are due to impaired melanosome transport in 
melanosomes and defective secretion of lytic granules in T lymphocytes.12, 14-15 The specific 
phenotype of this disease suggests a wide degree of redundancy in the functions of Rab 
GTPases. There is no current cure for Griscelli syndrome. Of more clinical interest is the 
dysregulation of Rab27a in chronic and progressive diseases like cancer, which is common 
to other members of the Ras superfamily.16-22 This thesis will focus on targeting Rab27a 
in cancer. 
1.1.1 Rab27a in Cancer 
The large majority of drug discovery and chemical biology activity in the Ras superfamily 
field has focussed on inhibiting Ras, largely driven by the superabundance of hyperactive 
Ras subfamily members in cancer (over 20% of all cancers).23-27 No clinically-approved 
drugs targeting the Ras oncogene have emerged since its discovery, and small GTPases 
have remained elusive drug targets due to their flexible, flat topologies and numerous 
PPIs.28 Encouragingly, recent fragment-based drug design (FBDD) and improved 
biophysical methods have led to hits with promising selectivity and induced phenotypes, 
offering fresh hope to pursue these previously intractable proteins. On the contrary, other 
subfamilies have remained relatively unexplored; for example, only few inhibitory molecules 
have been reported for Rab proteins to date, despite being the largest subfamily. 
Most publications of Rab27a’s role in cancer show a positive correlation between the 
expression levels of Rab27a and several aspects of tumour progression that include tumour 
grade (a measure of cell differentiation), cell viability, invasiveness, proliferation and 
metastasis.  Studies have also demonstrated the Rab27a-mediated secretion of pro-
metastatic factors which modify the tumour environment to make it more amenable to 
invasion,29 and its knockdown has decreased the activity and aggression of several cell lines 
and tumours both in vitro and in vivo. 30-43 
Conversely, the papers by Dong et al.44 and Worst et al.45 are of interest because they alone 
present a negative correlation between Rab27a levels and tumour progression, the opposite 
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of the prevalent trend. Although this seems paradoxical, these studies only demonstrated 
correlation and not causation, and suggests that competing mechanisms may be at play, 
depending on the cancer subtype. 
Tumour-suppressing miRNAs operate by inhibiting the translation of oncogenic proteins. 
Several recent studies have reported the effect of tumour-suppressing microRNAs (miRNAs) 
on Rab27a expression.35, 38, 43, 46-49 In all the studies, an increase in the intracellular levels of 
miRNAs correlated with the decrease of Rab27a and thus tumour-derived exosomes, as well 
as a reduction in tumour progression. Rab27a has also been found to be involved in 
exosomal secretion of tumour-suppressing miRNAs35. As Rab27a has a well-established 
role in exosome secretion, its inhibition may decrease the disposal of factors allowing the 
survival of cancerous cells.5, 9, 50-51 
There is mounting evidence that Rab27a plays a significant contributive role in many cancer 
types. The studies above nominate Rab27a as a potential cancer biomarker and a target for 
therapeutic inhibition, and the evidence is enough to warrant further studies in its druggability 
and for further elucidation of its mechanisms in health and disease. 
1.2 Structure-guided targeting small GTPases 
Due to their related structures, Rab27a presents similar if not greater challenges than other 
members of the Ras superfamily. Given the structural similarities between the Ras 
GTPases, it is worth examining studies that have tackled other members of the family to give 
an idea of the scope and challenges facing the ligand discovery for Rab27a. 
1.3 GTPase Structure and Function 
Ras superfamily members share a highly conserved fold of six β-sheets, interconnected by 
loops, and five α-helices.2, 52 Figure 1 shows the general structure of GTPases.53 Two 
flexible switch regions (switch I and II) surrounding the nucleotide binding pocket are largely 
responsible for the differing conformations in the GDP and GTP-bound forms. The picture is 
complicated by further dynamic conformational states within each nucleotide-bound form, 
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particularly the GTP-bound form. The original idea that these proteins exist in rigid inactive 
and active states was thrown into question when 31P NMR spectroscopy of H-Ras 
demonstrated the existence of two main conformational states (I and II) for the GTP form 
alone. State II is thought to be the effector-binding conformation, but the physiological role of 
state I is not clear.54-57 
 
Figure 1 Structure of K-Ras-GDP with nucleotide-binding regions highlighted: P-loop (10-17, green), switch I 
(29-38, blue) and switch II (58-76, red), α-helices (white) and β-sheets (yellow), Mg2+ (purple), highly conserved 
threonine (T35 in K-Ras, cyan), and GDP (orange). [PDB code: 4LPK] 
Importantly, the large majority of structural studies to date have been performed with 
truncated proteins without the C-terminal hypervariable region and its associated lipid 
modifications. In addition, the effect of membrane anchorage on these two states has not yet 
been explored. This raises the question of the physiological importance of the two 
conformational states in vivo, since active Ras is membrane-bound inside cells. Further 
investigation of protein dynamics in a membrane environment would be useful in illuminating 
this matter. 
1.3.1 The GTPase Cycle 
GTPases act as molecular switches in signalling cascades and their active and inactive 
states are toggled by the guanine nucleotide bound to them. The ‘on’ state is facilitated by 
loading with GTP, and its concomitant hydrolysis to GDP converts it to the ‘off’ state. It is the 
GTP-bound form that binds to effectors and facilitates downstream actions, whilst the GDP 
form does not usually bind to effectors. The presence and absence of the nucleotide’s 
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terminal γ-phosphate governs its temporal affinity to effectors by affecting conformational 
changes in the switch regions. This switch activity is regulated by numerous auxiliary 
proteins in the GTPase cycle (Figure 2).3 
Ras superfamily proteins are singly or doubly prenylated at the C-terminus. These lipid 
groups are important for their localisation on relevant membranes when in their active 
state.58 When inactive, the protein is stabilised in the cytosol by GDP dissociation inhibitors 
(GDIs) until the next round of activation. Guanine nucleotide exchange factors (GEFs) 
accelerate activation through the exchange of GDP for GTP via a nucleotide-free 
intermediate and GTPase-activating proteins (GAPs) catalyse the hydrolysis reaction. 
 
Figure 2 Generalised GTPase Cycle (1) Prenylation at the C-terminus. (2) GEF-mediated exchange of GDP to 
GTP via a nucleotide-free intermediate. (3) The active GTP-loaded Rab can bind to affectors and propagate 
downstream signals. (4) A GAP protein catalyses the hydrolysis of GTP to GDP, whereupon a GDI picks up the 
now inactive GTPase and stabilises it in the cytosol, facilitating intermembrane transport. 
In principle, blockade at any stage of the GTPase cycle (Figure 2) could lead to inhibition. 
Direct approaches to target Ras proteins include targeting the nucleotide binding pocket, 
stabilisation of Ras complexes associated with the inactive state, or stabilising interactions at 
the PPI interface.26 More indirect methods of disabling the GTPase cycle have the potential 
to circumvent some of the druggability challenges of the Ras proteins; however, they are 
beyond the scope of this thesis and the reader is directed to other reviews.59-61 
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1.4 Structure-Based Design of GTPase Inhibitors 
Structure-based drug design (SBDD) requires detailed spatial information of the target 
protein(s). In this respect, x-ray crystallography offers the most immediate appreciation of 
protein topology and visual guidance to establish a structure-activity relationship (SAR) for a 
ligand series. It also facilitates the construction of virtual pharmacophores and docking 
models, paving the way for in silico screening. 
Alongside the risk of artefactual binding to crystallographic constructs, a particularly 
important consideration for GTPases is the tendency for crystallisation to trap a protein in 
one specific low energy conformer. This is generally not an accurate representation of the 
equilibrium mixture of conformers in solution. Furthermore, the flexibility of Ras superfamily 
members is readily apparent in their NMR spectra where a full assignment is often not 
possible, limiting the quality and amount of information that is obtained.  
In spite of these challenges, significant progress has been made towards discovery of novel 
Ras superfamily ligands through structure-guided approaches. Representative examples 
from each category are discussed below. 
1.4.1 GTPase Active Site Inhibitors 
Targeting the active site of any GTPase is intrinsically difficult due to the conserved nature of 
the nucleotide binding site and optimised affinity it has for guanine nucleotides. Even if a 
competitive molecule existed, it would be a pan-inhibitor and this would not be desirable as 
GTPases are involved in a broad range of functions and general toxicity would result. 
A notable exception is the oncogenic K-Ras G12C mutant that has a mutated cysteine close 
to the nucleotide binding pocket and thus offers a disease-specific tethering site.62 A few 
studies have exploited this G12C mutation, for example 1 (SML-8-73-1, Figure 3), a GDP 
analogue which acts as a conformational lock for the inactive GDP form.63-64 In a similar 
vein, Wiegandt et al. produced conformationally locked GTPases by tethering 2a (aGDP) 
and 2b (aGTP, Figure 3) with cysteine-engineered Rab5.65 Whilst this approach may 
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produce useful tools for probing Rab biology and druggability, inhibitors approaching the 
structure of nucleotides are likely to suffer from poor cell permeability. 
 
Figure 3 Two examples of covalently reactive nucleotide analogues for conformationally locking cysteine-
mutated GTPases. 
1.4.2. In Silico Approaches 
Virtual high-throughput screening (vHTS) can screen libraries of up to millions of 
compounds, comparable to the largest HTS but with significantly fewer resources in a much 
shorter time. In a typical example, a 3D representation of the protein binding site is built 
based on a crystal structure; molecules from a virtual library are computationally docked into 
the virtual pocket and ranked on the possession of (major) conformers with favourable 
complementary binding interactions. Nevertheless, this structure-based rationale suffers 
from the same caveats as conclusions based on crystal structures in general and is limited in 
predicting novel binding modes in flexible proteins. 
Alternatively, a ligand-based screen may be performed against a virtual pharmacophore 
based on the predicted intermolecular interactions of a known ligand. The advantage of this 
is that it does not require knowledge of the crystal structure or a binding mode.66 
Gao et al. docked a library of >140,000 into a surface groove of Rac1 (a Rho GTPase) in the 
Rac1-Tiam1 (a GEF) interface and obtained 3 (NSC23766, Figure 4) as a hit, which inhibited 
Rac1-GEF interactions in vitro with an IC50 of ~50 µM.67-69 Montalvo-Ortiz et al. subsequently 
improved upon this structure with 4 (Ehop-016) which had an enhanced IC50 of 1.1 µM for 
Rac inhibition.70 Adding to this work, the same group also identified 5 (Rhosin) as an inhibitor 
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of the interaction between RhoA and LARG (a GEF), which exploited the tryptophan residue 
in the LARG binding surface of RhoA.71 
 
Figure 4 Structures of GTPase-targeting molecules derived from in silico screens. 
Related approaches have targeted GTPase-effector interfaces. For example, Shima et al. 
undertook a computational docking screen of >40,000 compounds against M-RasP40D. Out 
of 97 virtual hits, only one competitive inhibitor was found (Kobe0075) with a Ki of ~50 µM to 
H-Ras-GTP by a radioactive pull-down assay. A subsequent virtual similarity search of 
~160,000 compounds again yielded only one active hit 6 (Kobe2602), though this was less 
potent. Both compounds also inhibited the growth of human colon carcinoma xenografts in 
vivo. A more soluble analogue (Kobe2601) was shown to bind to the Ras-Raf interface by 
HSQC NMR.72 
1.4.3 Fragment-based Approaches 
Whilst a traditional HTS involves screening a library of 105-106 drug-like compounds, 
fragment-based drug design (FBDD) has emerged as a more ligand-efficient method for 
obtaining hit scaffolds. The size of a typical fragment has a molecular weight of less than 
300 Da and allows for a much smaller compound library to cover the same breath of 
chemical space. Crystal structures greatly enables the growing and linking of initially weak-
binding fragments (typically mM Kd) to increase affinity. In optimal cases, a well-designed 
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1,000-10,000 fragment library can offer 100-1,000 times higher validated hit rates than a 
traditional HTS, and the reader is referred to several recent reviews that describe in detail 
the rise and challenges of FBDD.73-80 
Sun et al. performed a 11,000 fragment screen by NMR spectroscopy against 15N labelled 
GDP-K-Ras, obtaining 140 hits with a variety of scaffolds. The top hits were successfully co-
crystallised with GDP-K-Ras and all were found to occupy the same binding pocket. 
Following inspection of the crystal structure, the authors grew their chosen fragment into a 
neighbouring cleft by appending isoleucine and proline to an aniline moiety to obtain 7 and 8 
respectively (Figure 5). This improved the binding affinity from ~1 mM for the fragment to 
~200 μM with isoleucine.81 
 
 
 
 
Figure 5 Progression of a ligand series by Sun et al. All fragments were found to induce a similar pocket on 
the surface of K-Ras-GDP. Panel A shows unliganded K-Ras-GDP with the absence of the pocket. A biaryl hit 
was selected for growth into an adjacent, positively charged pocket (B). The attachment of an isoleucine residue 
to obtain 11 gave the best results, but proline analogue 12 was crystallised (C). 
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Maurer et al. also published a fragment screen against GDP-K-Ras with NMR, using 
saturation transfer difference (STD) and HSQC experiments to obtain their top hit 9 (DCAI, 
Figure 6), which was co-crystallised with the target. However, no further fragment 
development was undertaken.82 Gao et al. used NMR techniques to target the RhoA-LARG 
interaction, yielding fragment hit 10 (R1, Figure 6).83 
 
Figure 6 Examples of ligands obtained by NMR screens. 
In contrast, fragment screening against the Rab GTPase-GEF complex could provide 
ligands that stabilise a non-productive complex that stalls exchange activity. Winter et al. 
screened against a heterodimeric structure of H-Ras-SOS (son of sevenless, a GEF that 
binds to Ras) using X-ray crystallography and obtained small molecules that formed ternary 
complexes by binding to the H-Ras-SOS interface. However, neither the fragment hits nor 
the optimised analogues inhibited SOS-induced nucleotide exchange.84 This highlights the 
fact that it is important to establish biochemical activity in hit compounds as weakly-binding 
fragments obtained through FBDD may not be inherently biochemically active. 
1.4.4 Tethering Approaches 
The development of covalent inhibitors is becoming an increasingly accepted pathway for 
drug discovery.85-89 The selectivity of the inhibitor is determined by the spatial positioning of 
the affinity component and the warhead; it does not require a very potent binder. 
Ostrem et al. performed a disulfide tethering screen against the cysteine of the cancer-
specific G12C K-Ras mutant and obtained allosteric ligands that stabilised the inactive GDP 
form: 11 is an example.90 Similarly, Winter et al. identified maleimides such as 12 that inhibit 
SOS-mediated nucleotide exchange by targeting a mutated C118 residue in the nucleotide 
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pocket that only becomes accessible for reaction during SOS-mediated GDP-GTP 
exchange.84 
 
Figure 7 Examples of covalent ligands derived from tethering screens. 
1.4.5 Peptidomimetic Approaches 
The specificity of native PPIs arises from binding partner complementarity between two 
protein surfaces. Synthetic peptides have a high intrinsic potential for inhibiting PPIs as they 
are made of the same combinatorial building blocks. Binding hotspot sequences are often 
coiled into a relatively rigid α-helical structure; however, in isolation as a peptide they often 
become linear and have much lower affinity due to the increased entropic penalty upon 
binding. Further, peptides often suffer from poor membrane permeability which makes them 
unsuitable for intracellular targets. There have been many studies on improving the physical 
properties of potentially therapeutic peptide inhibitors, but universally-applicable solutions 
have so far been elusive.91-93 
The conformation dynamics of peptides can by controlled by introducing an alkyl linker, 
appropriately positioned to induce helicity. This can be achieved in a variety of methods, but 
two that been extensively studied are hydrogen bond surrogates (HBS)94-98 and peptide 
stapling.95, 99-101 
For HBS, a single turn of the α-helix is fixed at the N-terminus by replacing a hydrogen bond 
with an alkyl chain to induce helicity through the rest of the peptide. The group of Arora 
synthesised HBS peptides derived from an α-helical region of SOS. Their optimised 
structure 13 (HBS 3, Figure 8), was found to reduce SOS-induced activation of Ras.102 
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In contrast, peptide stapling fixes two turns of the α-helix using an alkyl chain formed by 
ruthenium-catalysed metathesis of two unnatural amino acids with terminal alkenes - usually 
at positions i and i + 3. In some cases, this can also increase cell permeability of the 
peptide.99 Leschiner et al. adopted this approach to make stapled peptides based on an α-
helix of SOS. Ensuring that the peptide staple would lie on the opposite side from the PPI, 
the authors obtained 14 (SAH-SOS1, Figure 8) and achieved binding affinities of 100-175 
nM by fluorescence polarisation (FP).103 
 
Figure 8 Structures of HBS and hydrocarbon stapled peptides. 
Spiegel et al. synthesised short fluorescein-conjugated peptides taken from binding motifs of 
Rab effectors and screened them by FP against several Rab proteins. Only the singly 
stapled structure, 15 (StRIP3), was found to bind Rab8a loaded with 5'-guanylyl 
imidodiphosphate (GNP or GppNHp), the non-hydrolysable analogue of GTP, and to 
compete with Rab8a-effector binding in vitro.101 Later, in 2016, the authors created a doubly 
stapled version that improved its affinity, resistance to protease hydrolysis and 
bioavailability.100 
1.5 Small Molecule Inhibitors of Rab27a 
Small inhibitory molecules of Rab27a are few, with only four papers claiming to have found 
positive hits. Figure 9 displays the structures of the ligands reported to target Rab27a. They 
vary widely in the depth and breadth of their validation, but so far none of them have been 
explicitly structure-validated by x-ray crystallography or NMR. As such, the actual target and 
mode of action of these compounds is unknown. 
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Figure 9 Structures of the putative small molecule inhibitors of Rab27a in the literature. 
During 2013-16, three papers were published by Hwang Jae Sung’s group. As a group 
working in a Molecular Skin Biotechnology laboratory, the authors conducted the studies 
with a view to produce new skin-lightening agents by disabling Rab27a’s role in melanosome 
transport as opposed its regulation in pathological states. 
In 2013, Kim et al. performed a docking study of 273 natural products from the Korea Food 
and Drug Administration (KFDA) against the Rab27a-Slac2a (melanophilin) interface. From 
the ten top-scoring compounds, the authors chose to focus on 15 (hesperidin) as it was 
already approved for cosmetic use.104 15 was tested in cell-based and phenotypic assays 
where it was positive for melanosome aggregation, suggestive of Rab27a-Slp2 inhibition, 
and was found to inhibit three tyrosinases that are involved in synthesising melanin pigment, 
but did not have any effect on melanin secretion. Finally, the authors claimed that 15 caused 
increased brightness in a cultured human skin model. 
In 2015, Joung et al. published a hit from a pharmacophore-based in silico screen.  
Superimposing the crystal structures of Rab27a-Slp2 [PDB: 3BC1] and Rab27b-Slac2a 
[PDB: 2ZET], they constructed a virtual pharmacophore based around Arg29 in Slac2a 
which was judged to be a strongly interacting residue in the putative Rab27a-Slac2a 
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interface. This model was used to screen against a virtual compound library of 190,000 
compounds. After filtering for drug-likeness, a total of 25 compounds progressed to a 
melanosome transport cell assay, in which 16 (BMD-20) performed the best. This was the 
only non-virtual validation that the authors performed; there were no attempts to prove 
binding to Rab27a.105 Follow-up work by Kang et al. included the development of a series of 
sulfonamide analogues based on 16, but once again relied only on phenotypic tests with 
cells.106 
In 2016, Park et al. claimed that 2-methyl-naphtho[1,2,3-de]quinolin-8-one 17 (MNQO) 
decreases the RNA expression levels of Rab27a, Slac2a and myosin Va in melanocytes. 
The authors did not state how they obtained their candidate compound, but tested it for 
melanosome localisation, melanin content and melanin production in a reconstructed human 
skin model, and was further shown to decrease UVB-induced skin pigmentation in brown 
guinea pigs.107 
None of the above studies performed any biophysical assays to demonstrate binding to 
Rab27a or any of its related proteins, but relied purely on phenotypic tests to verify their 
hypothesised mechanisms. It remains to be seen whether inhibition of Rab27a can be 
exploited for skin lightening. A topical application is envisaged, as an endemic distribution 
would likely incur side effects and may even compromise the immune system as for Griscelli 
syndrome. However, there is not enough evidence to suggest that those molecules are 
acting on target. 
In late 2016, Johnson et al. published a class of inhibitors called Neutrophil Exocytosis 
Inhibitors (Nexinhibs) that block the Rab27a-Slp1 interaction. 32,000 compounds from two 
Maybridge libraries were screened against an in-house time-resolved FRET (TR-FRET) 
assay. Twenty hit compounds were tested in cell assays and for ROS scavenger activity, 
after which 18 (Nexinhib20) was obtained as the best performing compound. It was validated 
for Rab27a-Slp1 binding by co-precipitation, pull-down and ELISA assays and underwent 
TR-FRET counterscreens against the Rab11-Munc13-4 and Rab27a-Munc13-4 interactions. 
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In an in vivo mouse model, pre-treatment with Nexinhib20 before insult with 
lipopolysaccharide (LPS) endotoxin decreased plasma levels of neutrophil secretory 
proteins, suggesting anti-inflammatory properties.108 
18 (Nexinhib20) appears to be the best in its class. However, inspection of the chemical 
structures of the Nexinhibs reveals a concerning number of function groups that are known 
to cause problems: α,β-unsaturated ketones are susceptible to addition by nucleophiles, 
while nitro groups cause toxicity after metabolic conversion.109 Further, there is insufficient 
evidence of on-target binding from the limited TR-FRET counterscreens and the lack of 
biophysical assays to characterise binding, such as by NMR. 
Significantly, members and collaborators of the Tate group have conducted in-house tests 
on 16 and 18 by waterLOGSY and surface plasmon resonance (SPR) assays and found no 
binding to Rab27a. This corroborates the fact that none of the above studies had credible 
validation of target-specific activity and leaves open to question the origin of their observed 
effects.  
1.6 Rab27a Effectors 
An effector is a molecule that binds to a specific protein and modulates its biochemical 
activity. For GTPases, this usually means a protein that binds to its active state to propagate 
a signalling cascade. As the second part of this thesis seeks to investigates unknown 
endogenous interactions for Rab27a, it is worth inspecting the identities of its known 
effectors. 
There are currently thirteen known effectors of Rab27a: eleven that bind to GTP-Rab27a 
and two that bind to GDP-Rab27a, excluding proteins solely involved in regulating the GTP-
GDP cycle (GDIs, GAPs, GEFs). Rab27a’s effectors are not as widely expressed as Rab27a 
itself. Typically, only 2 or 3 types of effector are found in one cell type, thus possibly 
controlling cell-type-specific roles for Rab27a. It may explain how Rab27a can have such a 
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wide range of roles in a wide range of cell types. Note that all effectors of Rab27a also bind 
to Rab27b, but they prefer to participate in distinct stages of exocytosis.5-7, 110 
The effectors of GTP-Rab27a can be grouped in into three classes according to the nature 
of their binding domains. Slp1-5 and rabphilin contain the N-terminal Slp homology domain 
(SHD) as well as the C-terminal phospholipid-binding domains C2A and C2B. Slac2-a, 
Slac2-c and Noc2 have only the SHD, whereas Munc13-4 only has the C2 domains (Figure 
10).7, 50, 111-114 
 
Figure 10 Binding regions of the GTP-Rab27a effectors. Amino acid lengths are shown on the right hand side. 
Image adapted from M. Fukuda.50 
Booth et al.’s recently proposed new interactor ATP1a1 lack both the SHD and C2 
domains115 and binds independent of the nucleotide states. Coronin-3 and IQGAP1 have 
been proposed as effectors of GDP-Rab27a.8, 116-117 The Slp and Slac2 effectors have 
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several alternative names in common circulation. Table 1 lists the effectors, their 
pseudonyms and references. 
Name Alternatives Gene Domains Ref 
Slp1 JFC1 
Exophilin-7 
SYTL1 SHD, C2A, C2B 118-120 
Slp2 Slp2a 
Exophilin-4 
SYTL2 SHD, C2A, C2B 112, 121 
Slp3 Slp3a 
Exophilin-6 
SYTL3 SHD, C2A, C2B 122-123 
Slp4 Granuphilin 
Exophilin-2 
SYTL4 SHD, C2A, C2B 124-126 
Slp5 Exophilin-9 SYTL5 SHD, C2A, C2B 127-128 
Rabphilin Rabphilin 3A RPH3A SHD, C2A, C2B 129-132 
Slac2-a Melanophilin 
Exophilin-3 
MLPH SHD 133 112, 132 
Slac2-b Exophilin-5 EXPH5 SHD 5, 50 
Slac2-c MYRIP 
Exophilin-8 
MYRIP SHD 134 
Noc2 Rab effector Noc2 RPH3AL SHD 129-130, 135 
Munc13-4  UNC13D C2A, C2B 6, 118, 136-
138
 
Coronin-3 Coronin-1C CORO1C “ 8, 117 
IQGAP1  IQGAP1  116 
ATP1a1  ATP1A1  115 
Table 1 Known protein binders to Rab27a. Most are effectors which recognize only the GTP-loaded protein. Coronin-3 binds 
only to GDP-Rab27a and there is limited evidence that Slp4 has affinity for both nucleotide states. SHD = Slp homology 
domain, RBD = Rab-binding domain. 
Conversely, little is known about Rab27a-specific GAPs and GEFs. While GAPs tend to 
have a relatively broad spectrum, GEFs are often specific to a particular family of proteins or 
even a single subfamily member, though there is limited structural information to explain 
their binding selectivity.139-141 Rab3GEP is the only known GEF for Rab27a, and EPI64 and 
EPI64B are proposed to be GAPs (Table 2). 
 
33 
 
Name Alternative Gene Role Ref 
EPI64 
 
TBC1D10 TBC1D10A GAP 51, 142-
144
 
EPI64B  FLJ13130 
 
TBC1D10B  Broad spectrum 
GAP 
145
 
Rab3GEP  DENN 
MADD 
MADD GEF 146 
Table 2 Known GAPs, GEFs and GDIs of Rab27a. 
  
34 
 
1.7 Introduction to Quantitative Proteomics and Crosslinking Mass 
Spectrometry for Interactomics 
1.7.1 The Use of Mass Spectrometry in Studying Protein-Protein Interactions 
PPIs and their spatiotemporal changes facilitate nearly all biochemical processes in living 
organisms. They are of enormous interest to the scientific community as the knowledge of 
interaction networks in normal and pathological states are key for the elucidation of 
signalling pathways and the discovery new targets for disease treatment. 
The plethora of techniques that have been employed to survey PPIs reflect their relative 
difficulty to study. This is likely due to their enormous heterogeneity: their varying degrees of 
transiency and diverse topologies along with promiscuity and redundancy means that the 
goal of finding a single comprehensive strategy has been elusive. 
Most traditional methods require the synthesis of a recombinant bait protein that requires 
immobilization e.g. protein microarrays,147 affinity-purification,148 tagged fluorophores (to 
enable study by FP or FRET), affinity tags149 or with NMR-active isotopes.150 Several in vivo 
techniques also exist, such as yeast-2-hybrid (Y2H), protein-fragment complementation 
assay (PCA), mammalian protein–protein interaction trap (MAPPIT). Furthermore, in silico 
text mining and analyses based on phylogenetics can predict which PPIs may be fruitful to 
study. More detailed discussion on the classical methods of discovering PPIs and their 
advantages and disadvantages may be found in several reviews.151-156 
Mass spectrometry (MS) is the technical basis on which the field of proteomics, the global 
protein profiling of cells, tissues or organisms, is based. By extension, it is also becoming the 
relied-upon technique for the study of interactomes.157-159 Its rise and spreading adoption 
rides upon advances in technology as well as the improvement of search algorithms and 
bioinformatic software. The two together offer an incredibly powerful, efficient and versatile 
platform for scientists, empowering them to answer questions of wider scope in fewer 
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experiments. Both discovery and targeted approaches are possible, and different ionisation, 
fragmentation and detection regimes can be tailored to suit the experiments’ needs.160-161 
Many factors can determine the quality and reproducibility of MS data. Mass spectrometers 
themselves differ in their sensitivity, mechanisms of ionisation, fragmentation and data 
collection, and many software packages can be used to process and analyse the data 
output. These factors can considerably influence the conclusions drawn and it is important 
for the researcher to have insight in all processes to interpret the data. This is a growing field 
that is still building momentum, so we will no doubt see many improvements in all fronts in 
the years to come.162 
The following introductory minireview is intended for non-experts and provides an overview 
of the techniques and practical aspects of quantitative proteomics before covering the use of 
covalent crosslinkers to study interactomes. 
1.7.2 Bottom-up, Top-down and Shotgun Proteomics  
MS involves measuring the mass to charge ratio (m/z) of gas-phase ions. The many 
iterations of improvements since the 19th century have rendered modern machines capable 
of detecting a wide range of masses with extremely high precision and sensitivity. With 
today’s ionisation capabilities, molecules as large as intact proteins and even 
macromolecules can be detected. Tandem mass spectrometry (MSn, n = 2, 3) involves two 
or more consecutive rounds of mass detection, and fragmentation by collision induced 
dissociation (CID) or electron transfer dissociation (ETD) ahead of MS2 and MS3 enables de 
novo sequencing of peptides. After data collection, bioinformatic software assembles the MS 
output into tables of identified proteins and quantities. 
Top-down proteomics is where MS1 detects the mass of the intact protein and MS2 detects 
fragments of the protein. This method detects proteoforms and is better for low MW proteins. 
However, there are advantages to be had from digesting into peptides before sample 
injection. This is called bottom-up proteomics and it remains the more prevalent technique, 
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especially as it is generally more sensitive despite more limited sequence coverage and the 
possible loss of labile PTMs. Figure 11 depicts the difference between the two. The bottom-
up strategy will be assumed in the rest of this thesis.163 
In bottom-up, the first mass spectrometer (MS1) detects the m/z of peptides, which are sent 
for fragmentation. The products of the fragmentation process are then detected by the 
second MS (MS2). The fragmentation pattern elucidates its amino acid sequence, which can 
be sequenced de novo or matched to sequence databases or peptide spectral libraries. Most 
proteins can be identified by a unique sequence of only seven amino acids.164 Post-
translational modifications (PTMs) can be detected by modifying the search parameters, 
though without enrichment they may be difficult to detect because of their low abundance 
amongst a large dynamic range.  
 
Figure 11 Diagram depicting top-down and bottom-up proteomics. In the bottom-up approach, proteins are 
digested into peptides before mass detection. In top-down proteomics, no pre-digestion occurs and the full mass 
of the protein is detected before fragmentation. Image by Magnus Palmblad. 
Shotgun proteomics refers to the method of analysing highly complex samples (such as 
lysates) by combining high performance liquid chromatographical (HPLC) separation before 
partitioning to the mass spectrometry stage (LC-MS/MS). 
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1.7.3 Data-dependent and Data-independent acquisition 
Discovery proteomics is performed with samples of high complexity with the intention of 
monitoring global changes in the proteome, and deliberately allows for detecting unforeseen 
changes or new proteins. Associated with the shotgun method, it is HTP and generally uses 
data-dependent acquisition (DDA) where only the most abundant ions are analysed in each 
detection cycle.; this occurs continuously until the end of the elution run. 
Consequently, shotgun proteomics with DDA offers large coverage of the proteome but will 
be affected most by issues of dynamic range and reproducibility. DDA precludes absolute 
quantification because ion selection is biased towards the most abundant ions, and the cut-
off for the number of ions allowed through to detection is arbitrary, many ions are missed, 
and this cannot be controlled or predicted. However, relative quantification may be achieved 
by means of isotope labelling and label-free quantification.165 
At the other extreme, selected reaction monitoring (SRM) is a sensitive and quantitative 
method where the mass spectrometer is programmed to select only precursor ions for 
targeted studies, such as for biomarkers166-169. Data-independent acquisition (DIA) is a 
newer intermediary technique that scans every ion within a window of m/z range per cycle, 
and then iterates with the next range until the entire range is covered.167, 170-173 
A table summarising the attributes of DDA, DIA and SRM can be found in a review by Hu et 
al.171. At the time of writing, DDA is the most common method of ion selection due to its 
simplicity, flexibility and cost. However, the advantages of DIA’s higher reproducibility and 
precision of quantification means we may see an increase in its adoption in discovery 
proteomics, particularly if its ease of analysis is improved. Better data acquisition techniques 
along with more powerful instrumentation will reduce the need for enrichment and pre-
fractionation steps, leading to less sample loss and more biologically representative data. 
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1.7.4 Enrichment Strategies 
Modern mass spectrometers are now very sensitive, enabling the detection of minute 
quantities of proteins in complex mixtures. However, in discovery proteomics where ideally 
every protein in a sample is identified and quantified, it is not so much the complexity of the 
mixture but the dynamic range that is the problem: the concentration of the most abundant 
proteins can be 107–1012 times higher than the least;174 conversely, it is often the rarer 
proteins that are of interest. Without enrichment, this can be problematic with DDA: the high 
background prevalence of common proteins such as actin or haemoglobin can suppress the 
detection of other proteins, even if the latter on its own is above the detection threshold. 
Enrichment and fractionation methods reduce the dynamic range by removing proteins that 
are not of interest, or by separating out samples based on physical properties. The simplest 
example is the LC component of LC-MSMS; this technique is routine for shotgun proteomics. 
Alternatively, enrichment can occur on the protein or peptide level. The solubility of proteins 
differs wildly. If complete coverage is important, then cellular fractionation can be performed,  
though this is more often used for investigating the localisation of proteins, and each fraction 
must be carefully solubilised. Proteins can also be fractionated based on size by running on 
an SDS-PAGE gel and cutting out the bands in a lane (1D) or a spot (2D). In-gel digestion is 
then performed to release the peptides.175-177 
Fractionation of peptides is also possible using parameters such as charge, polarity, 
hydrophobicity and size for separation. This can be done with ion exchange chromatography 
(IEX), RP-LC with high or low pH eluents, and isoelectric focusing (IEF). The most common 
combination is strong cation exchange (SCX) chromatography followed by neutral RP-LC. 
More than one can be used in combination, allowing multi-dimensional fractionation.175 177 
Affinity pull-down (PD) involves a solid support coated with a moiety that strongly attracts a 
chemical label affixed on a protein, which can be endogenous (e.g. biotin) or introduced (e.g. 
His-tag). The main advantage of this approach is that, with a suitable affinity handle it is 
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possible to enrich proteins of very low abundance. Various forms of affinity handles include: 
(i) peptide-tagged proteins (spiked-in or transfected),178-179 (ii) PTMs180-186 and (iii) activity- 
and affinity-based probes.187-192 
1.8 Techniques for Quantitative Proteomics 
The ability to quantify changes within a proteome under different conditions provides crucial 
information on the dynamic behaviours of protein networks. Both label-free and isotope-
labelled methods are in common use today with the premise of achieving accurate, precise, 
HTP and reproducible quantification. Each method has its own distinct merits and are 
elaborated below. 
1.8.1 Stable Isotope Labelling 
Peptides labelled with heavy isotopes such as 2H (deuterium), 15N, 13C or 18O behave 
chemically in a near identical manner but are seen as separate peaks by MS. This makes 
them invaluable as standards, where experimental samples can be mixed with the heavy-
labelled standard in a fixed ratio. This method tolerates technical inconsistencies between 
samples and experiments because a verifiable control is present in every sample, 
distinguished by a predetermined mass shift for each peptide. There is also scope for 
multiplexing by mixing samples labelled with different isotopes combinations, which gives 
more data per run and reduces sample preparation time.193-196 
Stable isotope labelling with amino acids in cell culture (SILAC) involves feeding cells with 
isotopically enriched media. Here, heavy (15N and 13C) lysine and arginine are commonly 
used for metabolic incorporation into the proteomes of cell cultures. Only a few passages are 
required for near full integration, though this method only works for cell lines and excludes 
any that can synthesise their own amino acids which would result in substoichiometric 
labelling.193, 197-200 
Peptide labelling methods, usually at N-termini and lysine side-chains, are more universally 
applicable and include dimethyl labelling (reductive methylation of amine groups with heavy 
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and light methyl groups),194, 201 isotope-coded affinity tags (ICAT)196, 202 and isobaric labelling 
such as isobaric tags for relative and absolute quantitation (iTRAQ)203-205 and tandem mass 
tags (TMT).206-207 
1.8.2 Label-free quantification 
Label-free quantification (LFQ) does not use any form of chemical or metabolic labelling and 
samples are run individually, Figure 12 shows the mixing regimes of label-free, SILAC and 
isobaric labelling strategies.195 Relative quantification is achieved by matching peptide 
identifies across different samples based on retention time and comparing either ion 
intensities (area under the curve (AUC) or maximum peak height) or spectral counts 
(number of identified MS/MS hits). 
 
Figure 12 Mixing regimes in label-free and isotope-labelled quantification methods. LFQ samples are run 
individually and require no mixing. Metabolically labelled samples are mixed at the protein stage so that both 
experiment and standard are treated identically during sample preparation. Conversely, isobaric labelling is 
performed on peptides after digestion so they can by mixed at the last stage, which has a risk of increased 
sample variation. Image by Zhou et al.195 
LFQ boasts shorter workflows, lack of expensive labelling reagents and a higher throughput 
than the above-mentioned isotope-labelling methods. However, the latter have traditionally 
been preferred over LFQ for their superior reproducibility and more accurate quantification. 
In the past, lower quality mass spectrometers in combination with less sophisticated 
bioinformatic algorithms meant that run-to-run variability and the stochastic nature of DDA 
hampered the alignment and consistent identification of the same peptide across multiple 
samples.195, 208-214 
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However, major improvements in MS technology and processing software has made LFQ an 
increasingly attractive option, and it is seeing increased adoption in research groups 
worldwide. 
1.9 Crosslinking Mass Spectrometry 
Crosslinking mass spectrometry (CLMS or XLMS) is a technique that uses covalent 
crosslinkers to stabilise PPIs so that binder partners can be identified by MS. Unlike 
immunoprecipitation, XLMS potentially allows for HTP identification of both transient and 
stable interactions either on a targeted or proteome-wide scale. Further, it is possible to 
identify modified residues, providing topographical information on the interface.158, 215-225 
Three modes of crosslinks are possible. Figure 13 shows the nomenclature that will be used 
in this thesis – there currently is no standardised terminology.215 Type 0 are monoreacted 
crosslinkers that have failed to react to a partner protein and become either hydrolysed or 
quenched at the unreacted end. Type 1 crosslinks occur when both ends of one crosslinker 
reacts on the self-same protein, essentially stabilising its own 3D structure. This may be 
useful for protein structure elucidation, but for interactomics it could block the chance of 
inter-crosslinking. 
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Figure 13 Types of crosslinks formed with peptides. 
Type 2 inter-crosslinks are the typically the most sought-after - if both peptides on either side 
of the crosslink are unique, the interacting pair of proteins may be identified. The choice of 
spacer arm length and warhead reactivity is pivotal as each combination is optimal only for a 
subset of PPIs.  
1.9.1 XLMS Workflows 
A typical XLMS workflow is illustrated in Figure 14. If the crosslinking is to take place in a 
prepared lysate, the lysis buffer must have a low surfactant concentration that preserves 
PPIs, but is able to solubilise a significant proportion of the proteome and must be free of 
any basic amines; Tris buffers are not suitable. The crosslinker is then added, and the 
reaction is quenched. Enrichment steps may occur before or after enzymatic digestion, after 
which the samples are run and processed. 
Type 0
Singly reacted 
Peptide only on 
one side
Type 1
Intra-crosslinked
Both ends attached to 
the self-same peptide
Type 2
Inter-crosslinked
Peptides from 
different proteins on 
either side
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Figure 14 Example of a XL-MS workflow featuring pull-down of type 2 interlinks. Image by Tran et al. 217 
1.9.2 Crosslinker Considerations in XLMS 
1.8.2.1 Reactivity and Specificity 
Targeting lysines gives statistically the best chance of forming crosslinks across the 
proteome. The lysine composition of proteins is about 7%, making it a fairly common amino 
acid. Serine, leucine, valine and glycine occur at similar percentages, whilst alanine is the 
most common at 9%.226. However, the majority of lysines will be found on the surface of 
proteins as the solvation of its charged side chain is favourable, whereas more lipophilic 
residues have a higher propensity of residing in internal folds (the lipophilic effect). As such, 
lysine is the most common surface residue,226 so targeting them gives a statistically 
favourable chance of forming side-chain crosslinks across the proteome. 
For Rab27a at 221 residues and an average of 6% of lysines, we would predict it to contain 
(0.06 x 221) 13 lysine residues, close to the real figure at 12. It is anticipated that most are 
surface-accessible and thus able to react with crosslinkers (section 5.4.3). 
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Crosslinking molecules for XLMS should be specifically reactive towards the chosen residue 
sidechain and resistant to hydrolysis. The use of homobifunctional N-hydroxysuccinimide 
(NHS) esters to target lysines is widespread. NHS esters are largely specific towards 
lysines, though reaction against serine, tyrosine and threonine have been observed.227-228 
Maleimide and disulfide compounds are used to target cysteines, the advantage of which is 
that it pairs the most reactive sidechain, the sulfhydryl moiety, with one of the most stable 
(and thus specific) warheads.229 However, as cysteine residues occur less commonly than 
lysines, this method may not be suited to PPIs with few nearby cysteines. Two studies to 
date have targeted acidic residues aspartic and glutamic acids with hydrazides e.g. 23 
(DHSO) in Figure 16).230-231  
The main drawback to crosslinking residue side-chains is the inability to target hydrophobic 
surfaces. Photocrosslinking, either in the form of photoreactive probes232 or in engineered 
proteins with photoreactive side-chains233, is a crosslinking strategy that can overcome this, 
but is beyond the scope of this thesis. 
1.8.2.2 Length 
Crosslinkers come in a wide range of length and complexity. Zero-length crosslinkers leave 
no trace of themselves once crosslinked to a target protein e.g. 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC); alternatively, formaldehyde forms very short and 
reversible crosslinks between lysines.234-235 However, zero-length and short linkers may fail 
to capture weaker interactions as they require the reacting side-chains to be very close, and 
the reagents may suffer from non-specificity due to their high chemical reactivity.  Longer 
crosslinkers will be able to cover a wider range of lysine distances. 
Studies have shown that DSS, which has a length of 11.4 Å when fully extended, is capable 
of bridging two lysine Cαs (C-alphas) of a distance up to 30 Å. 236 Clearly, the maximum 
distance will increase as the end-to-end length of the crosslinker. However, specificity will 
need to be balanced with versatility when it comes to deciding the size of a linker. Short 
crosslinkers are more likely to capture true interactions; longer ones may give rise to intra-
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protein loops (type 2, Figure 13)237. The physical properties of the crosslinker must also be 
considered; they would ideally operate at physiological conditions. 
1.9.3 MS-Cleavable Crosslinkers 
Identifying type 2 inter-crosslinks (Figure 13) is key in many studies of XLMS but there are 
many challenges to overcome to achieve this goal, particularly in a large-scale proteome 
level. The number of possible peptide combinations scales quadratically with the number of 
peptides in a mixture. As such, the computational search space becomes prohibitively large 
at a proteome level and puts the onus on accurate and precise mass detection in order to 
assign correct matches.216, 238 
This problem is circumvented if peptides on either side of the crosslinker can be fragmented 
separately. Unfortunately, crosslinked peptides do not fragment as predictably as linear ones 
and it may not be possible to identify the peptide source if the linkers themselves do not 
easily fragment such as 19 (DSS) and 20 (BS3) in Figure 15.  
 
Figure 15 Examples of non-cleavable crosslinkers. 
To combat this, a wide variety of MS-cleavable crosslinkers have been developed with the 
inclusion of a labile bond, which is cleaved at a much lower energy than the peptide 
backbone. The MS-cleavable bond fragments first, separating the two peptides. Strategies 
using MS2, MS3 and reporter ions have been employed. In an MS2 instrument, the peptides 
also fragment in the same round and sequencing is finally possible by deconvoluting 
characteristic patterns of fragmentation. In MS3, the masses of the cleaved peptides are 
measured before a second round of fragmentation and third mass detection. Data gathered 
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with MS3 is easier to analyse, but MS3 is time-consuming, can give low-resolution results 
and the machines are expensive and not as widespread.216 
Figure 16 shows examples of MS-cleavable crosslinkers aimed to discover PPIs and 
structural studies. The symmetrical nature of the crosslinkers ensures that the same adducts 
will result on every peptide, thereby simplifying analysis. Crosslinker 21 (BuUrBu) is cleaved 
on either side of a central urea group, forming characteristic doublets for every modified 
peptide.239-241 However, sulfoxides are now the most widely used cleavage moieties, 
whereupon the C-S bonds are labile under collision induced dissociation (CID). Liu et al. 
demonstrated the utility of this approach in discovery interactomics by applying 22 (DSSO) 
for proteome-wide protein network discovery.219 
 
Figure 16 Examples of MS-cleavable crosslinkers that have been used to study PPIs. Their MS-cleavage 
sites are marked by red dashed lines. 
1.9.4 Enrichment of Crosslinked Peptides 
Crosslinked proteins, and thus peptides, occur in low abundance, exacerbating the pre-
existing issue of dynamic range. This is because not every reactive residue will be 
successfully crosslinked due to factors such as steric hindrance, the local chemical 
environment and competing hydrolysis reactions at physiological pH. The issue is 
particularly acute for interlinks between already low-abundant proteins, so an effective 
enrichment strategy is critical if type 2 linked peptides are to be found (Figure 13). 
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The enrichment techniques employed for crosslinked peptides overlap with many of the 
strategies described earlier in the chapter, like gel excision and fractionation. Several 
methods that take advantage of the physically distinct nature of type 2 interlinks. 
Size-exclusion chromatography (SEC) can be used to concentrate cross-linked molecules of 
interest since they have twice the molecular weight on average of single peptide. 
Crosslinked peptides have more N-termini and arginines and are more highly charged under 
acidic conditions, and thus elute later in strong cation exchange chromatography (SCX). For 
the same reasons, they have higher charge states once ionised that can be subsequently 
selected for fragmentation and acquisition by MS. Further, crosslinked peptides usually are 
more hydrophobic than non-crosslinked peptides and elute later in RP-HPLC.216 
Pull-down enrichment of the crosslinker incorporates an affinity handle such as biotin, for 
example in 24 (BDP-PIR)242-246, 25 (CBDPS)247 and 26 (Leiker)248-249 (Figure 17), though 
there is a risk of the added bulk hindering PPIs. Alternatively, the crosslinker may 
incorporate an azide or alkyne group to facilitate click-tagging of the affinity handle, for 
example click-enabled linker for interacting proteins 27 (CLIP)250, as well as 28a and 28b 
(azide- and alkyne-A-DSBSO), which also has an acid-labile acetal group which releases the 
intercrosslinked peptide after pull-down. However, the added steps will inevitably entail some 
sample loss, which may put some low-abundant species below detection thresholds.251 
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Figure 17 Examples of crosslinkers containing a biotin group that facilitates pull-down without further 
modification of the linker. Asterisks indicate where CH2 is replaced with CD2 in their heavy isotopic forms and red 
dotted lines indicate MS-cleavable bonds. 
Finally, the ability to produce a reporter ion during MS fragmentation can supplant some of 
the need for offline purification. A reporter ion is an ion of a characteristic mass that is 
produced reliably from the crosslinker during fragmentation. Detection of this reporter ion 
can allow the MS to choose whether to send ions for detection, resulting in a lower 
background signal. Examples include the middle component of 24 (BDP-PIR, Figure 16) and 
the NO2 moiety in 27 (CLIP) (Figure 18). However, not all MS instruments are capable of 
selecting ions for detection based on the presence of a reporter. 
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Figure 18 Examples of crosslinkers, with either an alkyne or azide group to allow post-crosslink click-
labelling with an affinity group. 
1.9.5 Photocleavable Crosslinkers 
Various photocleavable crosslinkers have been made for structural studies, including 
MALDI-cleavable 29 (BiPs) by Petrotchenko et al., cysteine-targeting linkers 30 by Milanesi 
et al.252 and 31 by Omran et al.253 (Figure 19). However, photocleavable crosslinkers that 
have been designed for PPI discovery are in their infancy. The Bruce group have extended 
their range of PIR crosslinkers to include a photocleavable form called pcPIR, where the two 
mass-cleavable regions have been replaced by photocleavable 2-nitrobenzyl group (Figure 
20).254-255 
 
Figure 19 Photocleavable crosslinkers used to study protein structure 
As with other PIR crosslinkers, pcPIR contains a biotin affinity tag for pull-down enrichment 
of intercrosslinked peptides and releases a characteristic reporter ion. Inline photocleavage, 
where UV light is directed at the ESI spray tip, cleaves both sites after LC separation but 
before ionisation. The virtue of this method is that peptides are cleaved after LC separation 
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whilst still in aqueous solution which can produce ions in higher charged states, leading to 
better fragmentation and identification of crosslinked peptides. 
Although MS-cleavage is a powerful and enabling technique to the identification of type 2 
crosslinks, gas phase dissociation of the crosslinker can produce ions of low charge states 
which do not fragment as efficiently and are less amenable for detection. This also means 
that pairs of peptides can be analysed together, which would not be the case if 
photocleavage had occurred prior to sample injection.254-255 
 
Figure 20 Scheme showing the structure, reaction and photoinduced rearrangement of photocleavable 
PIR (pcPIR) from the paper by Yang et al.254 The crosslinker contains two NHS ester warheads, two 
photocleavage sites, a biotin affinity tag for pull-down enrichment and a reporter group for MS selection. An in-
line UV laser photocleaves the linker just before ionisation, releasing both peptides and the reporter on. 
pcPIR, as with its predecessors, remains a long molecule of considerable bulk, and it is 
questionable as to whether this hinders the formation of PPIs. In an in vivo application in E. 
coli cells, more than 1600 modified peptides were discovered and only 53 intercrosslinked 
peptides were validated. This does not compare favourably with the group’s latest isotope-
labelled reincarnation of PIR linkers (24, BDP-NHP), with which they quantified 941 
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nonredundant cross-linked pairs from a total of 1213 identified ones, though it should be 
noted that search algorithms and data analysis software have had major improvements in 
the intervening seven years.242 
As the technological capabilities of MS increases, so too will bioinformatic algorithms that 
make use of the increased data output. Sensitivity will increase, preparation times will 
become shorter and processing speed faster. The growth of these two areas in combination 
with the development of more sophisticated chemical tools looks set increase the PPI space 
that is detectable by XLMS. It will be exciting to see the progression of this field in the next 
decade. 
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2 Project Aims 
This thesis is centred around finding molecules that interact with Rab27a. It has two distinct 
threads: one that is in search for man-made chemical entities that inhibit its interactions with 
effectors, and the other develops a chemical biology approach in conjunction with 
crosslinking mass spectrometry (XLMS) in order to probe its endogenous intracellular 
protein-protein interactions (PPIs). 
The aims and objectives of each thread are laid out in turn. 
2.1 Towards an Inhibitory Ligand for Rab27a 
Chapter 3 describes the design and synthesis of small molecule analogues which build upon 
two top hits from a fragment screen using a thermal shift assay. It then discusses 
constraining a downsized helical section of the effector Slp2a to achieve a short peptidic 
inhibitor that fits into a putative druggable pocket in Rab27a 
Aims:  
 
• Discover a specific ligand for Rab27a that can be developed either into a tool 
molecule for probing the druggability of Rab27a. 
• Find a Rab27a-binding peptide that inhibits Rab27a-effector interactions using the 
Rab27a-Slp2-a co-crystal structure as a starting point. It was envisaged that the 
peptide would block effectors sharing the same interface. 
  
53 
 
2.2 Rab27a Interactomics – Photocleavable Crosslinkers with 
Proteomics 
Chapter 4 discusses the design, synthesis and gel-based validation of a prototype UV-
cleavable crosslinker, NitroXL, and Chapter 5 explores its integration into a proteomic 
workflow for discovering the endogenous effectors of Rab27a. 
Aims:  
• Develop a homobifunctional crosslinker that can be cleaved in two with UV light.  
• The crosslinker itself would be non-specific but sample complexity will be 
reduced by pulling down affinity-tagged Rab27a from a lysate. 
• Establish a proteomic workflow incorporating NitroXL that is quantifies binding 
partners pulled down by Rab27a in the presence and absence of crosslinker. 
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3 Inhibitory Ligands for Rab27a 
3.1 Introduction 
Rab27a has been shown to play an active role in numerous cancers and is an attractive 
novel target for anti-metastatic therapies. Existing inhibitors claimed in the literature have 
lacked evidence of target engagement and furthermore have failed to show binding in the 
Tate group’s hands (Chapter 1). As no structurally validated and biologically efficacious 
inhibitor of Rab27a has yet been found. It was the aim of this project to identify one. 
It was of interest to inhibit Rab27a directly rather through its regulatory proteins. This 
includes targeting its GTP-bound form to block interaction with effectors, or targeting the 
GDP-bound protein to slow its activation by nucleotide exchange. As well as high selectivity 
and potency, it would be desirable for the inhibitor to possess drug-like properties,256 which 
would be important for sufficient uptake and bioavailability in cellular and in vivo testing at a 
later stage. However, it would not be realistic to expect early analogues to possess the 
qualities of a final oral drug, but aqueous solubility was considered at every stage as it 
affected the usability of the analogues in binding tests. 
Structure-guided ligand development offers an efficient method of improving ligand hits as x-
ray structures offer an intuitive visual guide for structure-activity relationship (SAR) studies. 
Unfortunately, unlike K-Ras and even other Rabs, wild type Rab27a does not crystallise on 
its own.  
NMR would be a reasonable alternative to study its binding interactions, but this is made 
more difficult by the fact that Rab27a undergoes conformational changes in solution at a rate 
comparable with NMR acquisition. This means that may of its peaks are not present in its 
NMR structure, posing a significant challenge to assigning them (PhD thesis by M. 
Jamshidiha). 
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Fortunately, one heterodimeric crystal structure exists in the Protein Data Band (PDB), by 
Chavas et al. It is formed of Rab27a and a truncated version Slp2-a, which is one it its 
effectors. (Figure 21; PDB: 3BC1). The presence of Slp2-a appears to stabilise Rab27a and 
provide key crystal contacts to enable crystallisation.121 
 
Figure 21 PyMol-rendered image of the Rab27a-Slp2-a co-crystal by Chavas et al (3BC1). Rab27a is in dark 
blue and Slp2-a is in lime green. The SF4 pocket in Rab27a highlighted in pale blue.  
It should be noted that the Rab27a sequence in 3BC1 deviates from its endogenous 
structure in several ways. It is missing its C-terminal section (and hence all of its PTMs) and 
has several substitutions: C123S and C188S, which replace two surface cysteines with 
serine to avoid complications with oxidation, and Q78L which greatly reduces the hydrolytic 
activity of the GTPase. This, alongside with using of GNP as the loaded nucleotide (Figure 
22, effectively locks Rab27a in approximately its active conformation.  
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Figure 22 Structures of GTP, GNP and GDP. GNP is a non-hydrolysable analogue of GTP and cannot be 
converted to GDP. It locks whatever GTPase it inhabits into a locked form.  
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Despite these limitations, and the fact that the Slp2-a helix obscures the very interface that 
we wished to explore, this crystal structure was an important starting point for the group’s 
efforts both to create crystallisable forms of Rab27a as well as to investigate ways to block 
Rab27a-effector interactions. 
3.1.1 Previous Work 
3.1.1.1 Fusion-Rab27a 
In revealing the nature of Rab27a’s interactions with Slp2-a, the structure of 3BC1 began to 
suggest ways in which the Rab-effector interface could be targeted.  
Firstly, it was noticed that a couple of residues in Slp2-a appeared to reside in a pocket in 
Rab27a in an area in the SF4 region of the protein (highlighted in cyan in Figure 21). This 
region is variable amongst small GTPases, and alignment studies in Mostafa Jamshidiha’s 
PhD thesis showed that the local sequence is specific to Rab27a. Conversely, many other 
regions, especially surrounding the nucleotide pocket, are conserved. It was hypothesised 
that this SF4 pocket could be druggable in the classical sense i.e. that a small molecule 
designed to fit or induce the pocket could be an inhibitor against the Rab27a-Slp2-a 
interaction, and any other effectors that share the same interface. 
Mostafa Jamshidiha, a co-worker in the Tate group, developed and optimised a protocol for 
synthesising recombinant GNP-Rab27a from bacteria and made all recombinant protein 
mentioned in this thesis. Further, all recombinant forms of Rab27a and its variants (Fusion-
Rab27a, biotin-Rab27a, Rab27a-Slp4) used in subsequent experiments were loaded with 
GNP (see Figure 22) and shared the same omissions and mutations as the Rab27a protein 
in 3BC1, with the exception of Q87L. 
Taking inspiration from Chavas’s heterodimer, Jamshidiha also modified the sequence of 
3BC1 to generate a crystallisable fusion protein that covalently linked the N-terminus of 
Rab27a to the lower portion of the Slp2-a helix in a manner that left the SF4 pocket empty 
(Figure 23). This protein was named Fusion-Rab27a.  
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Figure 23 Crystal structure of Fusion-Rab27a in relation to 3BC1. The Rab27a-Slp2-a heterodimer (3BC1) 
was modified to create a single crystallisable protein named Fusion-Rab27a by removing the top part of the Slp2-
a helix and joining the remainder to the N-terminus of Rab27a with a glycine/serine linker. The resulting construct 
was able to be crystallised, as shown by the PyMol visualisation on the right hand side. Fusion-Rab27a crystal 
structure by M. Jamshidiha. 
The conformation of Fusion-Rab27a as revealed by x-ray crystallography was similar to that 
of 3BC1, including that of the SF4 pocket. Thus, it was hypothesised that the empty pocket 
may favour the binding of inhibitors that mimicked the Slp2-a helix.  
3.1.1.2 Fragment Screen by Differential Scanning Fluorimetry 
A well-designed fragment library can explore the same or greater variation of protein 
interfaces as a traditional HTS library, whilst being orders of magnitude smaller in size. 
Individual compounds in fragment libraries are also comparatively smaller and look very 
much like building blocks of existing drugs. The downside is that the intrinsic affinities of hit 
fragments are low, so detection methods must be very sensitive. Even if this is the case, it is 
advised to cross-validate the results with as many biophysical tests as is feasible to minimise 
the number of false positives, as each test has its idiosyncratic biases. 
Prior to the work described in this thesis below, the Tate group performed a fragment screen 
using Differential Scanning Fluorimetry (DSF)257-258 against recombinant GNP-Rab27a with a 
fragment library from Maybridge that contained 2500 fragments. Also called thermal shift, 
this assay detects the change in the melting temperature of a protein in the presence of a 
ligand. Any ligand can be accommodated as long as they do not interact with the fluorescent 
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dye or contribute their own fluorescence. The melting temperature, Tm, is the midpoint value 
of the thermal unfolding transition.259 A molecule that binds to the protein will usually 
stabilise its conformation and thus raise its melting temperature (ΔTm). 
 
Figure 24 Schematic of the DSF fragment screen. 19 initial hits were obtained from 2500 fragments. Cross-
validation by waterLOGSY gave six top fragments, which were crystallised within Fusion-Rab27a. Their averaged 
changes in melting temperatures (in Celsius) are given in the figure and the highlighted structures were 
progressed for SAR studies. Full details may be found in M. Jamshidiha’s PhD thesis. 
3.1.1.3 WaterLOGSY Validation of Initial Hits 
The nineteen compounds with the largest increase in Tm were tested using an NMR 
experiment called waterLOGSY. Six compounds (32-37, Figure 24) out of 19 were 
determined to be active with this technique.  
WaterLOGSY, which stands for “water-Ligand Observed via Gradient SpectroscopY, is a 1D 
ligand-observed NMR experiment that tests if a small molecule, preferably one containing 
some aromatic protons, is a weak to moderate binder of a macromolecule (it will not work for 
very strong binders).  
~2500 fragment library
thermal shift assay
top 19
waterLOGSY NMR
top 5
x-ray crystallography
ΔTm = 2.8 ΔTm = 1.47 ΔTm = 2.34 ΔTm = 1.03 ΔTm = 2.33
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The waterLOGSY pulse sequence involves selectively saturating the water signal. Through 
the nuclear Overhauser effect (NOE), it discriminates bound ligands from free ligands based 
on their different relaxation pathways due to the large difference in tumbling rates when in 
close proximity to a protein or free in solution. 
WaterLOGSY was the chosen technique in part because it is sensitive enough to detect 
binders with millimolar kd.. A key advantage for its use for Rab27a is that no structural 
information is required for the protein, which is too dilute to show up in the spectrum, and no 
modifications or tags are required for the protein or ligand.  
Its drawbacks include being resource-heavy and low through-put. It requires large amounts 
of protein and it takes 40-50 minutes to acquire a full set of experiments for one ligand. 
Furthermore, the binding information obtained is qualitative with no indication of binding 
modes or locations.258, 260-261 
3.1.1.4 Inspection of the Crystallised Hits 
Each of the six compounds were successfully crystallised in the Fusion-Rab27a crystal 
structure and occupied in one out of two unique locations. 34 and 36 were selected as the 
representative analogues for each location as their scaffolds offered the widest scope for 
future customisation (Figure 25A). 
Figure 25 shows cartoon structures and schematic diagrams with a superposition fragments 
34 and 36. The two Fusion-Rab27a units face one another in a manner similar to that of 
Rab27a-Slp2-a by Chavas et al. [PDB: 3BC1].121 Both fragments appeared to reside in a 
narrow channel formed by the proximity of the two Slp2 helices along with the sides of 
Rab27a. It is unclear from the crystal structure if the fragments interacted more with the helix 
or with Rab27a. For the purposes of analogue development, we will talk about the fragments 
in relation to one protein unit only, under the hypothesis that the fragments were interacting 
more with Rab27a than the Slp2-a helix. 
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The top binding spot occupied by 36 was close to the SF4 pocket, and it was conjectured 
that upward growth towards the pocket might increase its affinity against effectors. 34 was 
positioned near to the N-terminal end of the Slp2a, though quite close to the pair of short β-
sheets that are residual sequences from the protein construct and do not occur in the 
endogenous protein. 
Larissa See, a Masters student in the group, pursued the benzyl alcohol 36, whilst I 
developed mainly the aminopyrazole fragment 34. The following section details the synthesis 
and the rationale behind the analogues synthesised for structure-guided SAR studies.  
 
Figure 25 (A) Crystal structure of Fusion-Rab27a with the two distinct positions occupied by the top 5 fragments 
illustrated by the benzyl alcohol (34) and aminopyrazole fragments (36). The two Rab27a structures are white, 
the covalently linked Slp2-a segments are pale blue. (B) Structures of the two top hits advanced through to SAR 
studies. (C) A schematic of the binding positions in the Fusion-Rab27a crystal structure. (D) Cutaway of the 
crystal structure of Fusion-Rab27a and the same two fragments. The arrows represent proposed directions of 
fragment growth. 
3.2 Structure-Guided Fragment Development 
3.2.1 Inspection of the Crystallised Fragments 
The residues of Fusion-Rab27a surrounding fragments 34 and 36 were inspected more 
closely (Figure 26). 
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Figure 26 Close-up of the structures of the fragment 34 (A) and the fragment 36 (B) crystallised in Fusion-
Rab27a. The exogenous serine residue thought to be interacting with 34 at the N-terminus of Fusion-Rab27a is 
circled. 
The aminopyrazole 34 appears to interact with a short β-sheet at the N-terminal end of the 
Slp2-a structure, though this is not part of the endogenous protein. The serine residue at the 
end of the small β-sheet (circled in Figure 26) may be hydrogen-bonding to the free amine 
from pyrazole ring. Additionally, S83 from Rab27a could be hydrogen-bonding via a water 
molecule to the sp2 nitrogen atom from the pyrazole ring if it faced the other way (the middle 
bond joining the two rings may be rotatable). The rest of the nearby amino acid side chains 
are hydrophobic in nature – L84, A87, F88, and could be interacting via van der Waals 
forces and π-stacking of aromatic rings. 
The benzyl alcohol 36 resides further up the channel and approaches the SF4 pocket. A 
hydrophobic region with F, A and L from Rab27a sit below it, the same one that sits above 
the 34. R90 and Y122 from Rab27a lie close to the proposed position of the benzyl alcohol 
moiety (Figure 26B). Y122 is particularly important, as Chavas et al. found that its 
substitution with alanine prevented its crystallisation with Slp2-a.121 It was envisaged that If 
this fragment could be developed to block the interaction between Y122 and Slp2-a, it could 
become a potent inhibitor of the Rab27a-Slp2-a interaction. 
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3.2.2 Analogue Development for Fragment SAR 
Figure 27 A and B show the analogues developed for the aminopyrazole and benzyl alcohol 
fragments. 38 - 42 were synthesised in an effort to bind to the lower hydrophobic pocket, 
with polar substituents to try to form H-bonding interactions to R90. 43 – 54 were molecules 
synthesised by Larissa See to grow fragment 35 into the SF4 pocket and to interact with 
Y122. They sought to explore the hydrogen-bonding of the fragment by methylating benzylic 
and phenolic alcohols in turn to establish key SARs. Details of these analogue series can be 
found in Larissa See’s MRes thesis. 
 
 
Figure 27 Summaries of the fragment analogues synthesised for SAR studies. 
A 
B 
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3.2.3 Synthetic Routes 
The following section discusses the synthesis of the fragment analogues synthesised to 
explore their SARs. 
58 and 59 were synthesised from the aminopyrazole 34 (Figure 28). Due to the difficulty of 
controlled alkylation of primary amines, a reductive amination strategy was employed to put 
a methyl and an ethyl onto the sole amine substituent. The amine was first acylated by 
conventional means and then reduced with lithium aluminium hydride (LAH). Unfortunately, 
the crude mixture for 39 could not be purified, but 38 was obtained with 15% yield. 
 
Figure 28 Synthesis of analogues obtained by reductive alkylation of primary amine. 
For 40, a new 5-membered heterocyle was synthesised ab initio. Following a Claisen 
condensation between the aromatic ester 60 and acetone, the 1,3-diketone 61 was 
condensed with hydrazine to give pyrazole 62 and then methylated with methyl iodide 
(Figure 29). 
 
Figure 29 Synthetic route for the doubly methylated pyrazole analogue. 
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Aminothiazole 41 was made to test the effect of a different heterocyclic core. Although the 
reaction was expedient, the physical properties of the analogue were less than desirable. 41 
was not very soluble, and there is evidence of these groups being pan-assay interference 
compounds (PAINS), which prevented further development.262 42 was synthesised by 
condensing a 1,3-keto-nitrile 64 with ethyl hydrazine. 
 
 
Figure 30 Synthesis of aminothiazole and ethylpyrazole analogues. 
Finally, I synthesised 55, 56 and 57 from 65 via acetal protection followed by Suzuki 
coupling, finished with acetal deprotection, though yields were only enough for NMR analysis 
for 56 and 57 (Figure 31). 
 
Figure 31 Acetal protection, Suzuki coupling and deprotection for benzyl alcohol analogues. 
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3.2.4 DSF Validation of Analogues 
The top fragment hits and synthesised analogues were tested for binding to recombinant 
Rab27a by DSF. Table 3 shows the melting temperatures of Rab27a when tested with the 
original fragment hits 32, 34 - 37 and synthesised analogues 41, 42, 58, 59 and 62. ΔTm was 
defined as the average melting temperature, Tm, minus the Tm of Rab27a with 2% DMSO. 
Fluorescence traces and replicate values can be found in Appendix A.  
Compound Tm ΔTm* 
Buffer only 60.5 -0.2 
2% DMSO 60.7 0.0 
32 60.3 -0.4 
34 60.4 -0.2 
35 60.4 -0.3 
36 60.4 -0.3 
37 60.3 -0.4 
41 N/A N/A 
42 60.4 -0.3 
58 61.1 0.4 
59 60.4 -0.3 
62 N/A N/A 
Table 3 Results of a DSF assay showing melting temperatures of recombinant Rab27a in the absence and 
presence of top hits from the fragment screen and synthesised analogues for SAR studies. The values shown are 
averages of quadruplicate data. *ΔTm = Tm – Tm (2% DMSO). 
Melting temperatures could not be calculated for 41 or 62 due to the non-sigmoidal shape of 
their fluorescence traces. Interestingly, the shape of the curve for 41 appeared to have two 
turning points, suggestive of the compound being able to stabilise two different 
conformations of the protein. However, the majority of compounds tested had negative ΔTm, 
including the top fragment hits from the screen. This contradicts the results of the screen, but 
these esults were consistent even after multiple rounds of testing. 
Because of these major inconsistencies, the DSF assay was not used for further 
investigations of Rab27a ligands. Following from this, an SPR screen was developed by 
other members of the group in conjunction with the Institute of Cancer Research at the 
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latter’s facility in Sutton, and the technique was used to test the compounds in the next 
section of this chapter. 
3.3 Peptide Binders 
Peptides offer an alternative to small molecules as inhibitory binders. As they are composed 
of the same building blocks as proteins, the potential for binding complementarity is intrinsic. 
Intuitively, it should merely require the right sequence, possibly requiring additional 
stabilisation, to have selected affinity for an interface. An advantage of using peptides is their 
relative ease of construction. Being combinatorial, they do not require bespoke synthetic 
routes like small molecules do and numerous automated procedures exist for their synthesis, 
the most prominent being solid phase peptide synthesis (SPPS) with N-Fmoc-protected 
amino acids. However, creating small peptides to emulate the binding properties of large 
proteins is challenging, and many peptides have physical properties that make them 
unsuitable for drug use. 
As with the fragment screen, the goal was to create a peptide that would inhibit Slp binding 
by targeting the Rab27a-specific region in the SF4 pocket. The binding interactions of Slp2-a 
in 3BC1 were inspected. At 59 residues (although only a small fraction of the total protein of 
936 residues), it is too long to count as a small molecule inhibitor. A short peptide would be 
more suitable as this would likely have fewer issues of synthesis, solubility and cell    
permeability. The downside to short peptides is their conformational freedom; they almost 
always require chemical stabilisation to maintain secondary structures such as  
α-helices.99, 263 
3.3.1 Dipeptide WF 
It was proposed that a short peptide could be obtained by downsizing the helix whilst 
maintaining its binding affinity to the proposed SF4 hotspot. Figure 32 illustrates this thought 
process. 
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Figure 32 Downsizing the structure of Slp2-a to obtain a smaller, more ligand-efficient binder of the SF4 
pocket (highlighted in light blue), capable of inhibiting effector interactions. 
The regions of Rab27a that bind to the lower helix of Slp2-a are more conserved and less 
useful for finding a Rab27a-specific inhibitor. When the crystal structure of 3BC1 was 
inspected, it appeared that the side chains of adjacent tryptophan (W) and phenylalanine (F) 
residues were most strongly interacting with Rab27a in the SF4 pocket, based on the depth 
of the pocket that surrounded them (Figure 33). It was hypothesised that the dipeptide WF 
could be a weak binder for Rab27a. 
 
Figure 33 A closer look at how the side chains of W and F lie in the SF4 pocket of Rab27a (3BC1). 
Doubly capped Ac-WF-NH2 was synthesised by SPPS. Uncapped variants were considered 
unsuitable as they would introduce charged groups in solution that are not present in the 
native structure. Hence, WF was used for all subsequent experiments, and all references to 
“WF” now refer to the acylated and amidated dipeptide. 
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3.3.2 WaterLOGSY of WF 
When WF was tested for binding by DSF, it showed no increase in the melting temperature 
of Rab27a (Appendix A). However, it tested positive for binging by waterLOGSY. Figure 34 
shows the results. The images show overlays three NMR experiments in the aromatic region 
of the dipeptide (the alkyl region is largely obscured by the suppressed water signal). The 
green trace is a scaled down 1D HMR spectrum of 1 mM WF in 10% D2O in 50 mM HEPES, 
150 mM NaCl and 5 mM MgCl2. The blue trace is the waterLOGSY spectrum of 1 mM WF 
alone, and the red trace is of 1 mM WF plus 10 µM of protein. The protein signal is too weak 
to see in the spectrum. An inversion, or partial inversion, of the red trace is observed for 
molecules that bind to the protein.  
 
Figure 34 WaterLOGSY results for the dipeptide WF. The NMR spectra show a portion of the aromatic region 
and are superpositions of the 1D proton spectrum, the waterLOGSY spectra of the ligand alone and of both 
protein and ligand. The 1D spectrum has been scaled down by 0.1; it is for reference only. Binding is positive if 
the presence of protein causes the waterLOGSY signal to become less negative or to invert. Inversion occurs for 
WT Rab27a. It occurs to a lesser extent for Rab27a and even less so for Rab27a-Slp4, which has its SF4 pocket 
occupied. The crystal structures above are of Fusion-Rab28 and of 3BC1, but the structure Rab27a-Slp4 is 
thought to be similar to the latter. 
As shown in Figure 34, WF binds to both wt-Rab27a and Fusion-Rab27a, proteins which 
have the SF4 pocket open, but not to the Rab27a-Slp4 complex, in which the SF4 pocket is 
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occupied. This was a promising indication that the dipeptide binds in or close to the SF4 
pocket. 
SPPS is an expensive way to make a large quantity of a dipeptide, largely due to the high 
ratio of resin to peptide output even if the yield is high. Thus, to synthesise a large batch for 
further validation and as positive controls in future experiments, a solution-phase synthesis 
was devised and performed (Figure 35). Acylated tryptophan and amidated phenylalanine 
were coupled in solution with DIC and HOBt. After filtering the by-product and purification by 
column chromatography, the dipeptide was obtained with a yield of 8%. 
 
 
Figure 35 A one step solution-phase synthesis of doubly capped WF. 
3.3.3 Surface Plasmon Resonance (SPR) Assay 
In the absence of structural information on endogenous Rab27a and the need to obtain 
quantitative data on binding molecules, the technique of surface plasmon resonance (SPR) 
was chosen to overcome the drawbacks of waterLOGSY. 
SPR is a high-throughput and sensitive technique that gives a high quantity of information in 
a single run. It tracks the change in absorption of a laser directed at the interface of a prism 
and a thin gold chip onto which the target protein adsorbed. When molecules bind to the 
protein on the chip, the absorbed wavelength changes. SPR assays have many advantages. 
It can be fully quantitative with the use of titrations, it gives kinetic data on the on/off binding 
of molecules and it is capable of real-time observation of binding. Further, it does not require 
structural data of the protein of interest and neither does the protein nor the binders require 
fluorescent, isotopic or radioactive labels. The chip can also be reused.264-265 
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However, SPR is not a trivial assay to set up and run. It requires a significant amount of 
preparation and optimisation and bears significant overhead costs. It is very sensitive to 
variations in the conditions (e.g. DMSO percentage), and poorly solubilised compounds may 
aggregate and give spurious results. This is a key issue for fragment screens as weak 
binders require higher test concentrations. Solubility tests can be run beforehand, but this 
would add to the workload. 
Charlotte Sutherell and Mostafa Jamshidiha from the Tate group, alongside Martin Rowlands 
from the Institute of Cancer Research (ICR), developed an SPR assay with recombinant 
biotin-Rab27a and Fusion-Rab27a adsorbed on Neutravidin-coated chips. WF was tested in 
this set-up and was found to bind consistently to Rab27a with a sensogram shape indicating 
specific binding to Rab27a. Extrapolation of the binding titration gave a rough kd of 8 mM. 
Although this classifies WF as a very weak binder, it demonstrates the sensitivity of SPR and 
corroborates the positive binding results from waterLOGSY. WF also bound to Fusion-
Rab27a, though more weakly. The dose-response graphs and sensograms are shown in 
Figure 36. 
 
Figure 36 SPR results for WF. WF was tested by SPR for binding against wild type Rab27a and against Fusion-
Rab27a. It was a specific binder of both, as evidenced from the sensogram shape (clean binding and 
dissociation), albeit weakly. The maximum response was higher for wt Rab27a than for Fusion-Rab27a. The 
extrapolated kd of WF against wt Rab27a was 8 mM. Images by Martin Rowlands (ICR). 
Unfortunately, WF could not be crystallised with Fusion-Rab27a, likely due to its weak 
binding. However, the results for WF were nevertheless a major breakthrough as it now 
provided us with a positive control. Jamshidiha, along with Nathan Brown from ICR, 
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subsequently used the dipeptide as the ligand model in an in silico screen; further details 
may be found in Jamshidiha’s PhD thesis. In this chapter, the next task was to increase 
WF’s binding affinity. 
3.3.4 Extending WF - Short Linear Peptides 
Figure 37 shows the structure of the truncated Slp2-a of 3BC1. Examining the structure on 
either side of WF (circled), we chose to investigate whether including amino acids on either 
side would improve affinity and/or solubility. Other modifications trialled also included 
reversing the WF to FW, and using D-tryptophan instead of the native L-tryptophan. 
 
 
Figure 37 Sequence of the Slp2-a protein fragment in the heterodimer crystal 3BC1. The WF residues are 
circled. Beyond E56, the residues are not visible in the crystal structure, more likely due to flexibility. 
Table 4 displays the short linear peptides (70-85) synthesised by SPPS and the qualitative 
result from waterLOGSY tests. Images of the NMR spectra can be found in Appendix B. 
Ref Peptide Binds to wt-Rab27a? 
- WF Yes 
70 FW No 
71 wF* Yes (insoluble) 
72 fluorescein-WF Yes 
73 QWF No 
74 GWF No 
75 H-WAF Yes 
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76 H-WFY Inconclusive 
77 WFYE Inconclusive 
78 WFYK Inconclusive 
79 QWFYE No 
80 GQWFYE No 
81 WFYEAK No 
82 WFYQAK No 
83 WFYQHK No 
84 WFYEAKA No 
85 YY (negative control) No 
 
Table 4 Short linear peptides synthesised by SPPS and tested by waterLOGSY. All peptides are acetyl and 
amide capped unless specified. Please see Appendix B for NMR traces. *with D-tryptophan 
It became much more difficult to interpret waterLOGSY spectra once the sequence 
exceeded four amino acids. Not only did the aromatic region become crowded with peaks, 
the increased number of very intense and relatively broad NH signals started to overlap with 
many peaks in the region. 
Aside from WF itself, only 71 (wF, with D- instead of L-tryptophan), N-terminally labelled 72 
(fluorescein-WF) and 75 (WAF) appeared to show binding by waterLOGSY. However, 71 
suffered from poor solubility and the result for 72 was questionable as the fluorescent tag is 
half as large as the proposed binding epitope and was synthesised at low yield. The addition 
of fluorescein essentially appends a highly non-polar group to WF and may have induced 
non-specific binding to hydrophobic regions of the protein surface.  
The main conclusion of this work was that peptides of greater than three amino acids in 
length have a decreased chance of being a binder to Rab27a. This may be because the 
additional amino acids do not interact with the surface of Rab27a but rather are integral to 
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maintaining the secondary and tertiary structure of the Slp2-a helix. Thus, including them 
alongside WF will not increase the binding affinity because the additional loss in entropy will 
not be made up for by an increase in binding enthalpy. 
3.3.5 Stapled Slp2-a Peptides 
When the WF motif is part of the Slp2-a helix, its conformation is constrained by the rest of 
the protein. If it is assumed that WF binds in the SF4 pocket, then it is possible that the 
weakness of the dipeptide’s interaction is because of its conformational flexibility. Because 
there is more entropic loss upon binding for a flexible molecule, binding becomes 
thermodynamically less favourable. Ways were sought with which to constrain the peptide to 
adopt the favoured conformation. 
Peptides have been successfully constrained through a variety of stapling methods (see 
Chapter 1). Previously, Tiffany Chan, a Masters student in the Tate group, attempted to 
staple the top portions of the Slp2-a helix by replacing K47 and Q52 (numbering from 3BC1) 
with (S)-pentenylglycines or with cysteines, to be cyclised via ring closing metathesis and 
with para-dibromoxylene respectively. Unfortunately, both methods of cyclisation gave very 
low yields and the cyclised peptides did not show binding by DSF, waterLOGSY or protein-
observed HSQC.  
3.5.5 Lactam-bridged peptides 
Alkene-stapling methods are often expensive, not least because of the cost of ruthenium 
catalysts and in either obtaining or synthesising enantiomerically pure pentenylglycines and 
alanines. Using a microwave adds potential complications and increases the need for 
optimisation, further adding to expenses. A peptide-stapling method that avoids some of 
these issues is lactam bridging, which describes a technique where an amide bond is formed 
between the side chains of a lysine and an acidic residue (aspartic or glutamic acid) spaced 
in an i, i + 3 fashion.266-267 
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Here, no unnatural amino acids are involved and the synthetic method incorporates a simple 
intervention at the last stage of an automated solid phase peptide synthesis (SPPS) run. 
The Fmoc-protected K and D/E amino acid reagents must have highly acid-labile protecting 
groups that can be cleaved under orthogonal conditions. Instead of the usual Boc, the amine 
in K is protected with methoxymethyltrityl (Mmt) or methyltrityl (Mtt). D and E are protected 
by 2-phenylisopropyl ester instead of the more usual t-butyl, which needs more strongly 
acidic conditions to remove. Thus, deprotection by 3% TFA in DCM reveals the free amine 
and carboxylic acid groups whilst leaving all standard protecting groups intact. These 
specifically deprotected reactive groups are then joined by usual peptide coupling methods 
such as DIC/HOBt or PyBOP (Figure 38), before cleavage from the resin by conventional 
methods. 
 
Figure 38 Deprotection and cyclisation steps for lactam-stapled α-helical peptides. 
The 310 helical backbone surrounding WF in Slp2-a has close to a 90° bend in it (Error! 
Reference source not found.). Thus, it would not make sense to extend the sequence 
much beyond either side of WF as a straight helix would not be favoured, certainly not past 
the Q towards the N-terminus. For this reason, the lactam bridge was introduced 
predominately as a conformational constraint rather than as a means to induce secondary 
structure. Harrison et al. showed that the highest helicity is obtained with the sequence 
KXXXD. Here, we chose to prioritise helicity over length of the amino acid sequence.267 
Hence, this template was adopted for all lactams synthesised for this project. 
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The minimum length of amino acids required for an i, i+3 lactam helix was 5 amino acids 
long. K and D at either end were fixed, and of the three inside, W and F were also fixed. The 
remaining amino acid was a free choice and this was at first exploited in an attempt to 
increase the solubility. 
Three short lactams-bridged peptides were successfully synthesised (Figure 38). Longer 
lactams were also attempted, including of other portions of the Slp2 helix (89-92). However, 
these suffered either from solubility, yield or conversion issues solubility issues (Table 5). 
Further, when the lactam-cyclisation reaction was analysed by LCMS, most samples 
appeared to be only partially reacted even after multiple additions of fresh coupling agent. It 
was difficult to achieve greater than 50% conversion even for the smallest lactams. 
 
 
 
 
 
 
 
Table 5 List of lactam-bridged peptides synthesised. The majority suffered from poor conversion or solubility. 
Amino acids in bold indicate the lactam-bridged residues. 
The three WF-containing lactams 86-88 were tested by SPR (by Charlotte Sutherell and 
Martin Rowlands), first for non-specific binding and then titrated to obtain a binding affinity in 
the form of a dissociation constant, kd. 
Binding titrations to 86 (QWF) and 88 (WFR) were obtained (Figure 39). Unfortunately, 87 
was a non-specific binder and was not tested further. Their relatively low solubility prevented 
them from being tested at higher concentrations so their rough kd values were obtained by 
extrapolation of the curve. However, they did appear to bind more strongly than WF. 
 
Sequence Purified 
86 
87 
88 
K Q W F D 
K R W F D 
K W F R D 
Yes 
Yes 
Yes 
89 E E Q K A I M D V L Q R A A L K  
90 
91 
92 
E E Q E A I M K V L Q R 
K E E Q D A I M K V L Q R 
A E Q K H I R D V L Q R 
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Figure 39 SPR results from two lactam-bridged peptides 
This result suggests that other amino acid combinations within the lactam bridge could be 
improve the binding of WF. The third amino acid could be placed in any combination of 
XWF, WXF and WFX, and so a wide range of permutations is possible. Given the prevailing 
issues of low solubility and binding affinity, future work should start by focusing on ones that 
increase solubility or otherwise modify the bond angles in the restricted helix to cover more 
conformational space, for example Lys, Asp, Glu, Pro, or even unnatural amino acids.268 The 
lactams would need testing by SPR, ideally at higher concentrations, and against a control 
protein to show that binding is specific. Other assays would also be required for cross-
validation. 
3.4 Conclusions 
In this chapter, attempts were made to develop a small molecule inhibitor and a short 
peptide inhibitor of Rab27a. 
Following from a DSF fragment screen and validation against recombinant Rab27a by 
Mostafa Jamshidiha and other members of the Tate group, analogues were synthesised for 
the fragment hits 34 and 36 for SAR studies. When tested using DSF, most analogues gave 
no shift in the melting temperature. However, the original hit fragments also failed to 
reproduce their behaviour in the screen.   
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It was concluded that the results from the DSF screen could not be reproduced, and as a 
result thus the group turned towards developing an SPR assay in collaboration with ICR to 
obtain high-throughput and quantitative results. 
In hindsight, DSF was likely a suboptimal choice of an assay for a fragment screen against a 
protein like Rab27a. Rab27a is a flexible protein that interchange between different 
conformers in solution. It is possible that different binders stabilise different conformations, 
which could cause the Tm to fluctuate or even decrease from control conditions. Further, it 
was possible that the fragment’s binding to the crystal structure was entirely artefactual, 
caused by the narrow water channel in the middle where the two protein units met. If this 
was the case, then it nullifies the rationale behind the SAR studies. 
A fragment screen requires higher concentrations of test molecules to see binding. 
Insolubility and aggregation may become an issue at these higher concentrations (>1 mM). If 
the screen were to be repeated, it may be pertinent to screen the library compounds for 
solubility and auto-fluorescence under the assay conditions in order to rule out those types 
of false-positives. A lower ligand concentration may also be considered.  
Like many small GTPases, development of inhibitors for Rab27a presents significant 
challenges. To succeed with Rab27a, not only will new technology be required, but also new 
ways of approaching drug design. Techniques like SPR, in silico and fragment screening are 
relatively modern and have not yet enjoyed decades of active use. These and the advent of 
other new, highly sensitive biophysical detection methods such as NMR, fluorescent 
polarisation (FP) and microscale thermophoresis (MST) are methods that are enjoying more 
use in the scientific community. 
As for the peptide side, much remains to be explored. The dipeptide WF gave a surprising 
positive initial result; despite being a weak binder with a kd of ~8 mM, it has shown 
consistent binding to Rab27a and to Fusion-Rab27a by waterLOGSY and SPR. Work by 
other members of the group is currently ongoing to mine its potential, for example by 
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attaching an acrylamide warhead to turn it into a covalent binder to Rab27a’s surface 
cysteines which reside along the rim of the SF4 pocket. 
There is scope to be explored on the lactam-bridged peptides, with many other permutations 
that could be synthesised with W, F and an amino acid of choice. A variety of properties may 
be achieved with different combinations. It is unknown as of yet whether the lactam 
approach will be successful, so this idea remains for a future project. 
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4 Development and Synthesis of Photocleavable 
Crosslinkers 
4.1 Introduction 
The subject of this chapter is the design, synthesis and validation of a photocleavable 
crosslinker intended for use in a proteomics workflow that can identify and quantify the both 
transient and stable interaction partners to Rab27a.  
Co-immunoprecipitation (co-IP) is traditionally used for pulling down protein complexes with 
solid-supported antibodies. The immobilised complexes are washed carefully to minimise 
disruption of PPIs. However, this technique is unable to capture transient interactions. Even 
stronger interaction may easily be lost; every binding equilibrium comprises rates of and this 
equilibrium (comprised of kon and koff) will always favour dissociation after pull-down. 
Therefore, only stable interactions remain even with mild wash buffers. Further, the surface 
of the protein-antibody interface may exclude some interactions. 
The chemical biology approach of XLMS (Chapter 1) has been developed in part with a 
purpose to rectify these drawbacks, and crosslinkers have been used for both protein 
structure studies and for mapping protein interaction networks. With the correct attuning of 
the warhead reactivity, they are able to crosslink only proteins that come into close proximity.  
The introduction of a photocleavable moiety to a crosslinker for use in XLMS enables the 
possibility of releasing the binding partners cleanly from the immobilised POI or from one 
another, depending on the set-up. It essentially adds an orthogonal purification step for 
simplifying the analysed mixture. 
The ultimate aim of this project is to develop an expedient means of elucidating Rab27a’s 
binding partners to investigate further its roles in health and disease. Once the methodology 
is established, it could be applicable to any protein of interest (POI). 
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4.2 Proposed Workflow 
The initial concept is presented in Figure 40, which formed the basis for the rationalisation of 
our early designs. For reasons that will be discussed later, the proteomic experiments 
described in Chapter 5 used a slightly different set-up. 
A biotin affinity tag for Rab27a was originally envisioned to be pulled down by NeutrAvidin 
coated agarose beads as in many other workflows within the Tate group. This was first used 
as a spike-in bait protein, before later being replaced by transfected Twin Strep Tagged 
(TST-)Rab27a.  
 
Figure 40 An illustration of the concept behind photocleavable crosslinkers. For this method to work, the 
POI must have an affinity tag, e.g. biotin, for enrichment purposes. Addition of a crosslinker covalently stabilises 
PPIs occurring in the mixture. Solid-supported NeutrAvidin pulls down the POI along with its linked partners. 
Application of UV light releases the effectors into solution, giving a clean mixture that is then digested and 
analysed. 
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4.3 Crosslinker Design Considerations 
The putative photocleavable crosslinker requires careful consideration a number of factors 
including warhead reactivity, length, photocleavage properties, water solubility, stability in 
water, facile synthesis and ease of introducing further functionalities. These properties are 
discussed in turn below. Figure 41 summarises the ideal properties the proposed crosslinker 
(XL). 
Figure 41 Summary of the considerations for the design of bifunctional crosslinker. The NHS ester and 
maleimide warheads represent the two most common electrophilic groups for targeting lysines and cysteines 
respectively. They are both shown here to illustrate the choice. 
The warhead is an electrophilic moiety that forms the covalent bond to a nucleophilic 
residue. It must be selectively reactive for its target residue but be insensitive to variations in 
that residue’s reactivity caused by different protein environments. As water is the most 
numerous albeit weak nucleophile, warhead reactivity must be balanced against hydrolysis. 
The latter cannot be prevented, but it would suffice if the rate of hydrolysis was significantly 
slower than the rate of residue conjugation. 
The scaffold of the molecule needs to be stable enough that it does not lose its integrity in 
storage as a DMSO stock, nor in aqueous solution for the duration of the experiment. The 
full workflow would include crosslinking, quench, UV irradiation, proteomic sample 
preparation and sample running, which span a period of time approaching 72 h in aqueous 
solution at physiological pH. 
photocleavable core
λ ~ 350 nm
high quantum yield
NHS Ester Warhead
Lys-specific
hydrolyses slowly
linker length
not too long or short
stable scaffold
robust under 
experimental and 
storage conditions
solubility
dissolves in 
buffer
Maleimide Warhead
Cys-specific warhead
hydrolyses slowly
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Once the crosslinker is attached at one end, the other must also react before it is 
hydrolysed. The efficiency of crosslinking will depend on how well matched the length of the 
crosslinker is to the distance between reactive residues on the PPI. Very short linkers give 
higher resolution data but may miss many interactions. This suggests that long and flexible 
crosslinkers could be more versatile because they can span a greater range of distances. 
However, long linkers might increase the likelihood of self-reacting (type 1 crosslinks), and 
may have undesirable physical properties, and the bulk might prevent PPIs from forming. 
The photocleavable core should be cleaved with high quantum yield upon application of a 
strong source of UV of a wavelength of around 350 nm. However, it needs to be relatively 
stable under ambient light such that it survives sample handling. In the laboratory, samples 
can be covered with foil or put into cupboards wherever possible, but this does not eliminate 
exposure to light. 
The choice of photocleavable core and its synthetic route should leave ample scope for 
further functionalisation; this will become relevant during further development and 
optimisation of the initial prototype. Changes could include: potential addition of useable 
groups e.g. fluorophores, affinity labels, clickable moieties, ease of changing linker lengths 
and warheads. 
Rab27a contains five cysteines, one of which is internal and two are prenylated at the C-
terminus leaving only two free for labelling. In contrast, Rab27a has twelve lysines 
distributed across its sequence (Figure 42; additionally Figure 71 from Chapter 5). 
Therefore, it was decided that the crosslinker was to target lysines exclusively using N-
hydroxysuccinimide (NHS) esters as both warheads 
A commonly used and commercially available non-cleavable crosslinker is disuccinimidyl 
suberate (DSS) with MW 368.34 and a length of 11.4 Å. This will be considered the control 
molecule, and our initial designs were based on the idea of inserting a photocleavable core 
into the middle of the structure. 
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Figure 42 shows an example of a pair of lysines, K11 from Rab27a (green) and K26 Slp2-a 
(yellow) that we would expect to be crosslinked. The bond distance measurement in PyMOL 
comes to 6.6 Å, so it was envisaged that a mid-length linker like DSS should have no 
problem linking them together.  
 
Figure 42 PyMOL-rendered image of 3BC1 showing the lysines on Rab27a and a closeup lysines K11 in 
Rab27a and K26 from Slp2-a. The distance between the nitrogen atoms in the structure is 6.6 Å and would be 
suitable for crosslinking by a mid-length linker such as DSS (11.4 Å).  
4.4 Synthetic Routes 
Many choices of photocleavable groups that have been investigated in the literature.253, 269-270 
Figure 43 displays the some commonly used structures that cleave when exposed to 
radiation at 350 nm. 
O
X
O
X
benzoin
O O
X
coumarinphenacyl
O
O X
NO2
O R
O
nitrobenzyl benzophenone
 
Figure 43 Common photocleavable groups with X showing the leaving group after UV irradiation. 
Synthetic routes for coumarin, benzoin and 2-nitrobenzyl, crosslinkers were designed and 
executed as far as time allowed. There was no specific reason for choosing these scaffolds 
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over others. Indeed, future studies should consider other well-established moieties. Figure 
44 shows their photocleavage mechanisms.269-270  
 
Figure 44 Cleavage sites and mechanisms for the 2nitrobenzyl, coumarin and benzoin cores. 
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The routes for nitrobenzyl and coumarin were designed by Thomas Lanyon-Hogg (Figure 45 
and Figure 46). Each synthesis presented unique problems, but time constraints meant that 
not all roadblocks could be cleared in time.  
In the coumarin route, 3-ethylaminophenol 93 was condensed with neat ethyl acetoacetate 
to form the coumarin species 94. The nucleophilic substitution reaction of t-butyl 
bromoacetate to form the coumarin intermediate 95 took a long time, likely due to the weakly 
nucleophilic nature of the amine. The allylic oxidation of 95 using selenium dioxide was 
successful but only produced analytical quantities of the alcohol 96. 
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Figure 45 Synthetic routes for the proposed coumarin and benzoin crosslinkers. The solid arrows indicate 
successful reactions; dotted arrows refer to reactions that were not performed or were unsuccessful. 
BTI = [bis(trifluoroacetoxy)iodo]benzene 
The proposed benzoin route offered the most scope for functionalisation at either or both 
aromatic rings. The only requirement was that the benzyl alcohol aryl ring be more electron-
rich than the carbonyl side for more efficient photoreaction.271 The benzaldehyde starting 
material was successfully protected with thiol with a protocol adapted from DeMartino et 
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al.272 However, the deprotonation and subsequent addition to the dimethoxybenzaldehyde 
was unsuccessful, likely due to the difficulty in achieving double deprotonation. More 
optimisation will be required for the addition of the deprotonated dithiane to the 
benzaldehyde, and would likely involve protecting the benzyl alcohol beforehand.  
Because of time constrains, efforts became focussed on the 2-nitrobenzyl core, which had 
the shortest synthetic route. The resulting crosslinker was successfully synthesised and was 
dubbed NitroXL. 
4.4.1 Synthesis of NitroXL 
Figure 46 displays the synthetic scheme for NitroXL. Starting from nitroterephthalic acid, diol 
106 was synthesised according to literature procedures.273 However, the titanium-mediated 
addition of methyl groups to dialdehyde 107 was not trivial. Although methods for Grignard-
type additions to benzaldehydes is routine, few references exist for double alkylation of 
aromatic dialdehydes. Nearly all examples in the literature involved titanium, suggesting that 
only titanium organometallic complexes are reactive against this system. 
 
Figure 46 Synthetic route for the nitrobenzyl-based crosslinker NitroXL. 
It was found that the age and quality of the TiCl4 reagent strongly influenced the outcome of 
this reaction. Initial attempts with an old and insufficiently sealed bottle gave no reaction, but 
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a fresh bottle gave the product at a modest yield. This in turn started to give decreasingly 
poor yields after a couple of months. Scaling up the reaction from 50 to 200 mg of starting 
material made little if any improvement on the yield. First-time use of ultra-pure TiCl4 gave 
the most successful reaction but the yields decreased thereafter. This suggests that the 
integrity of TiCl4 is paramount for this reaction and that everything would ideally be 
performed in a glovebox. As such, the reaction was performed multiple times to accumulate 
the di-alcohol intermediate. 
The subsequent addition steps with succinic anhydride and then N-hydroxyl succinimide  
(NHS), to give 109 and NitroXL respectively, were straight-forward. Both sample handling 
and yields greatly improved with larger scale (20 mg vs 100 mg). These molecules were 
difficult to purify to a satisfactory purity by silica column; hence they were purified by reverse-
phase (RP) LCMS. The final double NHS-ester product NitroXL survives the aqueous nature 
of the LCMS purification if the solvent is removed immediately after the preparative runs. 
4.5 Validation of NitroXL 
NitroXL was synthesised and purified by LCMS. It was dissolved at 100 mM in DMSO, 
aliquoted and stored at -20 °C during the time that the experiments were performed. For 
long-term storage, the aliquots were transferred to -80 °C.  
Before trialling NitroXL in proteomics, it was necessary to validate its capability of the tasks it 
was designed for. In light of the desired properties discussed above, the questions that 
needed answering were: 
1. Can NitroXL be cleaved by UV into its expected products? 
2. Can it crosslink a recombinant heterodimer? 
3. Can it crosslink proteins in lysate? 
The following experiments were designed to address these questions. 
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4.5.1 Cleavage Under UV by LCMS 
NitroXL was first tested for UV cleavage by LCMS. For the control sample, 1 mM of NitroXL 
was dissolved in 10% DMSO in water and analysed immediately. This is the concentration 
that will be used for crosslinking, following various examples in the literature. Although this 
the concentration was too low to produce a meaningful UV absorption spectrum, mass 
spectrometry is a much more sensitive technique as seen by evidence of the intact 
crosslinker in the mass spectrum (Figure 47). 
 
Figure 47 LCMS mass spectrum of a sample of NitroXL without UV irradiation. Circled is the molecular ion 
corresponding to the intact NitroXL crosslinker. 
Another sample of 1 mM NitroXL in 10% DMSO and HEPES buffer was irradiated for 30 
minutes under UV in a specially designed UV device called a Caprobox by caprotec 
bioanalytics GmbH. This was a cooled rack for PCR tubes below a small bank of UV lamps; 
unfortunately, this machine is no longer manufactured. The two expected cleavage products, 
the nitroso aryl and succinic acid, (refer to Figure 44 for the mechanism) were present in the 
mass spectrum (Figure 48); conversely, no evidence of the parent compound was detected. 
This shows that NitroXL photocleaves as expected. 
90 
 
 
 
Figure 48 LCMS mass spectrum of a sample of NitroXL with 30 minutes of UV irradiation in the Caprobox. 
Circled are the masses of the two proposed cleavage products found in the spectrum. 
4.5.2 NitroXL and Recombinant Protein 
4.5.2.1 Self-Crosslinking of Recombinant Rab27a by DSS 
It was originally intended to spike-in N-terminally biotinylated Rab27a into cell lysates and to 
exploit the biotin handle to purify the covalently linked complexes. To establish the ballpark 
concentration of protein, a range of concentrations of pure Rab27a (without biotin) was 
tested with 1 mM of DSS to see at what concentrations we would see significant quantities of 
covalent dimerization.  
Figure 49 shows the silver stain of crosslinked Rab27a at a range of concentrations. Silver 
stain was used because of its higher sensitivity compared with Coomassie Blue. It was 
reacted with 1 mM of DSS in every sample except the control and quenched with 50 mM 
Tris. 1 µM of Rab27a without DSS gave one band in the gel. A mysterious lower band 
appeared upon addition of DSS, and a higher MW one appears at 10 µM, which likely 
corresponds to dimerised Rab27a due to increased proximity between each protein. Lanes 
D and E suggests that 0.1 µM of Rab27a is around the detection limit of the silver stain. 
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Figure 49 Silver stain of varying concentrations of recombinant Rab27a with and without 1 mM of DSS. 
The blue arrow points to a band thought to be a dimer of Rab27a, whereas the red arrows point to a new lower 
MW band, conjectured to be Rab27a reacted with crosslinker. The change in band position may be to do with its 
change in isoelectric point. 
4.5.2.2 NitroXL vs DSS – Silver stain 
Recombinant Rab27a-Slp4 (a truncated version of Slp4 at 17 kDa, similar to the Slp2-a in 
3BC1) was reacted with NitroXL and irradiated for 1 h 30 min under the UV lamp in a TLC-
visualisation box. Although the Caprobox worked well previously, it could only process very 
small sample sizes in PCR tubes, and so alternative methods of UV reaction were sought. 
The non-cleavable crosslinker DSS was used as a control. Because both DSS and NitroXL 
are apolar molecules, they required an additional 10% DMSO to increase their solubility. 
Figure 50 shows the silver-stained SDS-PAGE gels of the Rab27a-Slp4 complex crosslinked 
with DSS and NitroXL. A new band is seen upon the addition of either crosslinker at around 
40 kDa, which fits with the sum of the masses of Rab27a and Slp4 fragment (23 + 17 kDa). 
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Figure 50 Silver stained polyacrylamide gel showing the effects of DSS and NitroXL with and without UV 
irradiation. The red arrow points at the crosslinked Rab27a-Slp4 complex appearing to be fainter in the sample 
crosslinked with NitroXL after UV irradiation. This may be an indication that photocleavage is occurring. 
A Western blot was not possible because there was no reliable Slp4 antibody, and the 
recombinant Rab27a lacked the C-terminal segment that is the recognition site of all 
Rab27a- antibodies. One could argue that the top band in lane 7 with NitroXL and UV 
irradiation is fainter than the one without UV. This could indicate a relative loss of the 
crosslinked species, suggesting the separation of the complex’s constituent proteins. 
4.5.2.3 Time Course - Irradiation of NitroXL-Crosslinked Rab27a-Slp4 
With evidence to suggest the photocleavage of NitroXL-crosslinked Rab27a-Slp4, it was 
thought pertinent to investigate the length of UV irradiation required for complete cleavage. 
Figure 51 shows the SDS-PAGE gel of a time course experiment with Rab27a-Slp4 
crosslinked NitroXL undergoing a range of UV exposure times. All lanes contained Rab27a-
Slp4 at 1 µM, and lanes 2-5 were reacted with 1 mM NitroXL and quenched with 50 mM 
glycine (final concentration).100 µL of the resulting solution was pipetted into a well in a 
clear 96-well plate that was positioned on crushed ice and placed 1- 3 cm under a 352 nm 
UV lamp in a SpectrolinkerTM XL-1500 UV Crosslinker (Spectroline) for the specified time, or 
left on the bench at room temperature in the dark. 
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Figure 51 A silver-stained polyacrylamide gel of 1 µM Rab27a-Slp4 crosslinked with 1 mM of NitroXL and 
exposed to UV for 0, 10, 30 and 60 minutes Spectrolinker XL-1500. 
There is a clear decrease in intensity of the band at 40 kDa after 10 min, after which there is 
no change. Of the even higher molecular weight bands, the one at 70 kDa, did not fade until 
after 30 min. 
It is not known why we do not see a time-dependent decrease in band intensity of the new 
bands. It could be aggregates forming, or perhaps the proteins become photo-crosslinked. 
4.5.3 NitroXL Crosslinking in Lysates 
4.5.3.1. Western Blot analysis of crosslinked loading controls 
Antibodies raised against Rab27a are typically raised against its C-terminal region. 
Bacterially-produced recombinant Rab27a and biotin-Rab27a lack this region, and therefore 
cannot be detected using such antibodies. Nor were there reliable antibodies against any of 
its known effectors at the time of writing. 
Rather than blotting against the biotin moiety of biotin-Rab27a, which was time-consuming to 
synthesise, it was thought that crosslinking in lysates could first be detected by Western Blot 
against loading controls. The benefit of using loading control proteins is that they are 
ubiquitous and abundant so their results should not be particularly sample or cell-line 
dependent. If one or more were found to work, then they could be used as a crosslinking 
control for later experiments. 
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 shows Western Blots against the common loading controls: GAPDH, HSP90, tubulin and 
VDAC2. MDA-MB-231 lysate was crosslinked with 1 mM DSS only (1 h, quench with 50 mM 
glycine for 20 min).  
Figure 52 Western Blots of MDA-MB-231 lysate with and without 1 mM DSS blotted against five loading 
controls. All parts of the blots that are not shown were entirely blank. 
There was a significant change in the bands for all the proteins tested. This by itself already 
shows that the presence of DSS is modifying the proteins to a large extent. For HSP90 and 
VDAC2, and the lower molecular weight (WB) band for monomeric protein disappeared, and 
higher MW bands appeared. However, there were no bands to be seen at all for GAPDH 
and tubulin.  
This could be due to efficient coverage of the protein’s lysines enough to disrupt protein-
antibody binding, or because multiple proteins become crosslinked together and are no 
longer recognised, or they have such a high molecular weight that they travelled negligibly in 
the 12% gel and were excised from the WB membrane. It is also possible that the 
crosslinked proteins had aggregated and never entered the gel. 
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4.5.3.2 UV Time course of NitroXL-linked lysate, Western Blot against HSP90 and 
tubulin  
The next step was to perform a UV time course to establish crosslinking and photocleavage 
of NitroXL for proteins in a lysate. Considering the results from the precious section, HSP90 
and tubulin were selected as for WB analysis. MDA-MB-231 lysate (1 mg/mL) was 
crosslinked with 1 mM NitroXL and quenched with 50 mM glycine. Both control and 
crosslinked samples were irradiated for 0, 10, 20 and 30 minutes in the Spectrolinker. The 
samples were run on a 12% SDS-PAGE gel, transferred to a WB membrane and blotted 
against HSP90 and tubulin. Figure 53 shows the visualised WB. 
 
Figure 53 Western Blots of MDA-MB-231 lysate crosslinked with NitroXL subjected to varying exposures 
of UV. The top blot shows bands recognised by α-HSP90, the bottom by α-tubulin.  
Without any crosslinker, neither the bands for HSP90 nor tubulin change appreciably with 
the application of UV. For HSP90, higher MW bands appear strongly after reacting with 
NitroXL. Like for the NitroXL-crosslinked Rab27a-Slp4 complex, an exposure time of 10 min 
produced the most dramatic reduction in band intensity of the crosslinked proteins, and 
changed little after that. The bottommost band corresponding to monomeric HSP90 appears 
to increase in intensity, especially at 30 minutes. The fact that it is slightly higher than the 
control band is likely due to the added mass of the crosslinker, at ~400 Da per linker.  
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For tubulin, no bands appear at all after NitroXL is added, but faint bands appeared with UV 
irradiation. Again, these are higher than the control bands, likely for the same reasons as 
above. Taken together, this result is indicative of NitroXL cleavage. 
4.5.3.3 Against NeutrAvidin (biotin-Rab27a spiked MDA-MB-231 lysate) 
The time-course experiment was subsequently performed on MDA-MB-231 lysate spiked 
with biotin-Rab27a and blotted against NeutrAvidin-HRP, which recognises the biotin moiety. 
The resulting blot is shown in Figure 54. The appearance of higher MW bands is suggestive 
of crosslinking, but UV-dependent decrease in intensity of those bands is still not seen. Nor 
is it clear if the bands are increasing in intensity. A repeat of the experiment (Figure 55) gave 
similar inconclusive results. 
 
Figure 54 Western Blots of MDA-MB-231 lysates crosslinked with NitroXL, subjected to varying 
exposures of UV. The top blot shows bands recognised by α-HSP90 (control) and the bottom blot by 
NeutrAvidin-HRP which detects the spiked in biotin-Rab27a. 
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Figure 55 A repeat of the experiment in Figure 54. 
A number of factors could be at play. The biotin-Rab27a is a recombinant protein that is 
biotinylated on an extension of the N-terminus. It also lacks the C-terminal section which 
normally include the lipidation sites that anchors active Rab27a to membranes, where the 
effector interactions occur. All the recombinant Rab27a used for this thesis are loaded with 
GppNHp, which is a non-hydrolysable GTP mimic. However, any limitations in its mimicry 
would result in the disruption of GAP, GEF and effector interactions.   
Further, the higher MW bands caused by the presence of NitroXL had a grey background 
rather than discrete bands. This suggests that although biotin-Rab27a is being modified by 
NitroXL, the majority are not picking up binding partners and a significant portion was 
crosslinking indiscriminately. 
4.5.3.4 Conclusions from Western Blots 
The Western Blot results show NitroXL is capable of crosslinking proteins in lysates. Some 
proteins like HSP90 show UV-dependent cleavage, but it is less clear with the biotin-
Rab27a, and others are not detected at all once crosslinked. Since the results of these 
Western Blots are very much dependent on the recognition of epitopes by antibodies and the 
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crosslinker can change or affect these epitopes, they are only able to give qualitative 
indications of how some band intensities change with UV irradiation. This does not preclude 
detection by MS, which does not rely on epitope structures. 
Despite Western Blots not giving comprehensive results, they have shown that NitroXL is 
capable of crosslinking proteins and that UV irradiate decreases the intensity of some higher 
MW bands and paves the way towards the use of NitroXL in proteomics. As MS is a much 
more sensitive technique that also inherently lends itself to quantitation, it will give us more a 
comprehensive appraisal on the development of this methodology. 
4.6 Transfection of TST-tagged proteins 
The requirement of the protein of interest to have an affinity handle is central to this 
methodology, as enrichment would not be possible without it. However, it then follows 
necessarily that the protein of interest will not be in the endogenous form. How, then, can it 
be ensured that the modified version will behave like the native one, and associate with all 
the right proteins? This is an important question, but not a trivial one to answer. It might also 
be possible that this approach will work with some proteins but not others, depending on 
how the tag interferes with its PPIs and localisation. 
The main limitation with the spike-in method was that, not only did the Rab27a have an extra 
biotinylated sequence at the N-terminus, the recombinant protein was missing its prenylated 
C-terminal section, which is important for its affinity to membranes and GDIs. This is 
because bacterially produced proteins cannot be lipidated in situ. Conversely, if an N-
terminally tagged Rab27a is expressed in a mammalian cell, it would emerge with the 
correct PTMs. This would likely approximate the native protein better. Furthermore, it could 
be already pre-associated with its interaction partners after lysis, so that crosslinking may 
become more efficient. Ectopic expression of the native sequence would also result in a 
more representative distribution of nucleotide loading state, whereas the recombinant 
proteins were loaded with GNP.  
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4.6.1 The Twin Step Tag 
Of the numerous options of peptide affinity tags that are available, the Twin Strep tag (TST) 
was chosen because it has been reported to give a very clean pull-down with Streptactin, an 
engineered form of streptavidin that binds TST more much more strongly than lone Strep 
tags, but bound proteins can also be eluted with high concentrations of biotin.274-276 Plasmids 
of TST-KRas and TST-PDE6δ (synthesised by Dr. Antonios Konitsiotis) were available in the 
group. A mammalian expression vector containing a sequence of N-terminally tagged TST-
Rab27a, with the TST sequence and linker was taken from the TST-KRas plasmid, was 
purchased from InVitrogen (Appendix D).  
Biotin was a strong contender for the affinity tag, but this would have involved additionally 
transfecting cells with BirA, an enzyme that is necessary for the transfer of biotin onto the 
appropriate peptide motif. It was decided that the complications of double transfection 
outweighed the disadvantages of the TST tag, which was mainly its large size - 
approximately 30 residues. 
4.6.2 Validation of Transfections by Western Blot 
Both MDA-MB-231 and HeLa cells were tested for transfection efficiency using 
Lipofectamine 2000 and OptiMEM. The transfection efficiency was found to much higher for 
HeLa cells, so HeLa cells were used for the remainder of this thesis. 
HeLa cells were transfected with TST-Rab27a, TST-PDE6δ and TST-K-Ras plasmids to test 
for successful expression and antibody recognition of the tagged proteins. Crosslinking 
behaviour was also checked by reacting samples with DSS as with previous validation 
experiments. The proteins were blotted against Streptactin-HRP, which recognises TST, and 
against α-Rab27a and α-PDE6δ, α-HSP90 as a control. No reliable α-KRas antibody was 
available, so its transfection efficiency was observed with Streptactin-HRP alone. 
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Figure 56 shows the Western blot of transfected HeLa lysates with and without DSS, blotted 
with Streptactin-HRP and with α-HSP90. There is a clean and dark band in every lysate that 
has not been crosslinked with DSS, indicating successful expression of TST-tagged protein.  
 
 
Figure 56 Western Blots showing the successful transfection of HeLa cells with TST-KRas, TST-PDE6δ 
and TST-Rab27a plasmids blotted with StrepTactin-HRP and anti-HSP90. The plasmid amounts were for 
each 10 cm circular plate. Each lysate was tested with and without DSS. Streptactin-HRP was used to visualise 
the bands. Every band or smear correlates to the presence of the TST, which does not occur endogenously. The 
lysates were also blotted against HSP90 as a control.  
Figure 58 displays blots of the lysates successfully blotted with α-Rab27a, α-PDE6δ, and α-
HSP90 and shows that the transfected protein is present as well as the TST tag. All the 
crosslinked lysates show distinct bands or smears at higher MWs except for K-Ras and 
PDE6δ where their bands become fainter. This is a promising indication of crosslinked 
proteins, and in the case of the Streptactin-HRP blot, also an indication of what can be 
pulled down by the Streptactin-coated beads that will be used later for pull-downs. In this 
particular blot, there was still a lot of TST-Rab27a that did not seemed to become 
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crosslinked. This suggests that under these particular conditions, the vast majority of protein 
that gets pulled down will be modified but not crosslinked TST-Rab27a proteins.  
The amount of TST protein was not quantified in any of these samples; however, there 
appeared to be a significantly higher concentration of TST-Rab27a in the lysate when using 
6 µg of plasmid DNA per 10 cm plate, compared to 3 µg. In the experiments occurring after 
Figure 57, the amount of TST-Rab27a plasmid added was reduced to 1 µg per 10 cm plate, 
which gave more than adequate quantities of TST protein; further, less cell death had 
occurred at the point of lysis. 
 
Figure 58 Western Blots showing the successful transfection of HeLa cells with TST-K-Ras, TST-PDE6δ 
and TST-Rab27a plasmids blotted with anti-HSP90, - Rab27a and -PDE6δ. Again, the plasmid quantities 
were for each 10 cm circular plate. Each lysate was tested with and without DSS. The lysates were blotted with 
α-Rab27a and α-PDE6δ as there was no good α-KRas antibody available at the time. The lysates were also 
blotted against HSP90 as a control. The bands coincided with the ones show with Streptactin-HRP, though a new 
band appeared for Rab27a. This may be the endogenous Rab27a or a non-specific interaction. 
It is not certain why Rab27a appears as two bands – it may be possible that the small band 
with the smaller MW corresponds to endogenous Rab27a, whereas the main band is TST-
Rab27a; alternatively, it was a non-specific interaction. 
These Western Blots indicate that the transfection protocols were successful and that the 
lysates produced were adequate for use as the basis for subsequent proteomic experiments. 
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4.7 Pull-down Experiments with MagStrep Beads 
4.7.1 Bead Volume Optimisation 
Commercially available Streptactin-coated magnetic beads were chosen for enriching TST 
proteins. Called MagStrep, these beads are fine magnetic particles coated with Streptactin 
protein. A key advantage of MagStrep beads is that, by being magnetic, they are easily 
pelleted from suspension using a magnetic Eppendorf rack. There is no need to centrifuge, 
and smaller bead volumes can be accommodated compared with non-magnetic beads like 
agarose. However, they are expensive and not reusable, so an experiment was performed to 
gauge the appropriate bead volume, which here refers to the volume of a 50% bead 
suspension, for 100 µL of lysate at 1 mg/mL. 
Figure 59 shows the Western Blots HeLa lysate transfected with TST-Rab27a, with and 
without crosslinking by DSS and pulled down with a range of MagStrep bead volumes. The 
beads were incubated with the lysates at 4 °C for 2 h and released by boiling the beads at 
95 °C for 10 min into a 1:4 mixture of loading buffer to lysis buffer. 
 
Figure 59 Western Blots showing how much Rab27a protein is pulled down by 0, 5, 10 and 15 μL bead 
suspensions of MagStrep beads, which are magnetic particles coated with Streptactin. PD refers to the pulled 
down proteins; SN refers to the supernatant left over after pull-down. All were blotted with α-Rab27a. 
The result show that all of 5, 10 and 15 µL of beads per 100 µL pulled down a similar 
amount of protein by Western Blot, and only in the remaining supernatants were there any 
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difference between the lanes, with the samples with no beads at all having slightly thicker 
bands. 
In light of this, it was decided that 5 µL per 100 µL was sufficient for further experiments as 
the most efficient and cost-effective bead volume. 
4.7.2 Pull-Down with Crosslinked Protein – DSS v NitroXL 
An experiment was set up this time with NitroXL as the crosslinker to investigate the pull-
down efficiency of crosslinked and photocleaved TST-Rab27a. Lysate from HeLa cells 
transfected with TST-Rab27a was crosslinked with DSS or NitroXL, quenched with 50 mM 
glycine and then subjected to UV irradiation as before. Subsequently, 5 μL of MagStrep 
beads were added to 100 µL of crosslinked lysate. Western Blotting with α-Rab27a was 
performed for the whole lysate (not pulled down), the pull-down fraction and the supernatant. 
In Figure 60, the bands in the blots were darker with DSS than with NitroXL in all the 
crosslinked samples. It may be possible that NitroXL obscures the binding epitope of 
Rab27a. However, some higher MW bands were pulled down even in the NitroXL-
crosslinked lysates, though they are fainter than the DSS-crosslinked samples. The 
application of UV (30 min) did not affect the band intensities with DSS samples, but with 
NitroXL the band for Rab27a appears to be larger in the photocleaved PD lane. 
The lack of bands in the samples with NitroXL relative to DSS might be because the greater 
bulk of NitroXL obscures epitope recognition by the antibody. It may even be that some 
NitroXL was degraded by the loading buffer or by the boiling process. Again, the use of 
mass spectrometry would resolve this issue because no loading buffer will be used and the 
proteins will be released by in-gel digestion. 
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Figure 60 Western Blots showing how much NitroXL-crosslinked protein is pulled down by 5 μL 
suspension of MagStrep bead before and after UV irradiation. 
4.8 Conclusions 
A prototype photocleavable crosslinker called NitroXL was designed and successfully 
synthesised and its crosslinking abilities were tested with pure Rab27a, Rab27a-Slp4 
complex using silver-stained SDS-PAGE gels, against loading controls, biotin-Rab27a 
spiked into MDA-MB-231 lysates and in TST-Rab27a transfected HeLa lysate by Western 
Blotting. 
In almost all cases, crosslinking by NitroXL behaved similarly to DSS, and upon UV 
irradiation the higher MW bands decreased in intensity, particularly after 10 min, and the 
monomeric band often increased in intensity. Thus, NitroXL fulfils most of the desired 
requirements that were set out in the design brief in being a mid-length linker that 
incorporates well-known NHS ester warheads to selectively target lysines and a commonly 
used photocleavable core that cleaves after exposure to UV at around 350 nm.  
On the other hand, it lacks water-solubility and requires 10% DMSO for dissolution, on par 
with DSS. Also, the synthetic route leaves little flexibility for later functionalisation. However, 
it has a relatively straight-forward synthetic route that was simple to synthesis in large 
quantities. 
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In total, NitroXL satisfied the brief enough to be used as a test crosslinker in proteomics. 
After obtaining feedback from the full proteomic workflow, it is projected that further iterations 
of the crosslinker design and crosslinking protocols will resolve the outstanding issues. 
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5 Incorporation of NitroXL in a Proteomics Workflow 
This chapter reports on the proteomic experiments performed with the prototype 
photocleavable crosslinker NitroXL, the development and validation of which are detailed in 
the previous chapter. It focuses on the establishment of a proteomic workflow involving 
crosslinking and photocleavage of NitroXL with TST-Rab27a-transfected HeLa cell lysates. 
The experimental set-up and expected results are described, and the resulting data is 
discussed in detail. This chapter uses single-letter abbreviations of amino acids. 
5.1. Experimental Set-up 
In the previous chapter, the prototype photocleavable crosslinker NitroXL was demonstrated 
to crosslink TST-Rab27a in lysate that could be pulled down, and for the crosslinked proteins 
to exhibit photocleavage under UV irradiation as shown by silver stained SDS-PAGE gels 
and Western Blotting. Thus, in fulfilling the majority of its design brief, NitroXL was 
progressed to being tested by proteomics. 
NitroXL was envisaged to be used in the same conditions as its validation experiments: 1 
mM for 1 h, followed by a glycine quench. All proteomic experiments in this chapter uses 
TST-Rab27a-transfected HeLa lysate at 1 mg/mL, and all crosslinking reactions required 
10% DMSO for NitroXL and DSS to have acceptable solubility. 
A protocol was developed with a view to crosslink ectopically expressed TST-Rab27a to its 
interaction partners in cell lysate, pull down its crosslinked complexes and identify and 
quantify the partner proteins. HeLa cells were transfected with TST-Rab27a and were lysed 
in a buffer containing 1% Triton, 10% glycerol, 50 mM HEPES, 100 mM NaCl and 5 mM 
MgCl2 (“Lysis Buffer”) after 24 h. The lysate was adjusted to 1 mg/mL and aliquoted into nine 
identical samples of 100 μL with added 10 μL DMSO. The samples were grouped into three 
triplicate sets that were to undergo the following treatments: 
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Set A (samples 1-3) -  No NitroXL, no UV 
Set B (samples 4-6) -  NitroXL, no UV 
Set C: (samples 7-9) – NitroXL, 1 h UV 
Figure 61 depicts the experimental set-up. 
 
 
Figure 61 Diagram of the set-up for the proteomic analysis of crosslinked TST-Rab27a-transfected 
lysates. The three experimental conditions are tested in triplicate. 
1 mM NitroXL was added to sets B and C (1 μL from 100 mM stock in DMSO) and the 
samples were rotated in the dark at room temperature for 1 h. Glycine was added to a final 
concentration of 50 mM. Samples in set C were irradiated with 365 nm of UV light for 1 h. 
The pull-down was performed with MagStrep beads and on-bead tryptic digestion was 
performed overnight. Due to the light-sensitive nature of NitroXL, samples were covered in 
foil wherever possible. A detailed protocol may be found in Chapter 7. 
Because the affinity handle was on the target protein and not on the crosslinker, it was 
envisaged at this stage quantification would be performed with unmodified and type 0 
(attached to hydrolysed crosslinker) peptides, which was assumed to be in the majority, and 
Set A Set B Set C 
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would be obtained from the enrichment of proteins in set B vs set C. Type 2 inter-crosslinked 
peptides would not be identified or quantified. LFQ would be performed in MaxQuant, and 
PEAKS Studio 8.5 will be used to identify the presence and qualitative abundance of 
NitroXL-related modifications.  
5.2 Experiments Performed 
Three sets of experiments will be analysed in this chapter. They consist of the following pairs 
of crosslinkers and digestion enzymes: 
1. NitroXL-trypsin (Sets A, B and C) 
2. NitroXL-chymotrypsin (Sets A1, B1 and C1) 
3. DSS-trypsin (Sets D and E, but with the same conditions as A and B respectively) 
Trypsin is the most commonly used digestion enzymes. It cleaves specifically after arginine 
and lysine, which are two common amino acids which together occur often enough to 
produce peptides of a suitable length and charge for ionisation and fragmentation in MS. 
Though normally effective, these advantages are lessened when lysine-targeting 
crosslinkers are in use. Once linked to a crosslinker (type 0), the lysine is no longer 
recognised or cleaved by trypsin. This has the effect of a missed cleavage, and modified 
digested peptides are on average twice as long, increasing the difficulty of its ionisation and 
fragmentation in the standard instrumentation used for bottom-up MS, and therefore the 
difficulty in detecting the modifications. 
Proteases with alternative cleavage sites have been used to mitigate this issue. 277 Thus, 
chymotrypsin was used as the digestion enzyme for otherwise the same experimental set-
up, which cuts peptides specifically after F, W, Y and less specifically to L. Neutrophil 
elastase was also attempted – cleaving after V and A – but the digestion process was 
unsuccessful. In the future, more proteases can also be tested to optimise the coverage of 
different proteins. 
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A small control experiment was also performed with DSS, non-cleavable and more flexible 
crosslinker, to investigate differences in modification sites between NitroXL and DSS. but 
without samples undergoing UV irradiation. 
5.2.1 Expected Results 
In set A, because the lysis buffer is relatively mild, the method for this set is essentially the 
same as a co-immunoprecipitation experiment. Thus, we would expect to see unmodified 
peptides of predominantly TST-Rab27a, followed by strong non-covalent binders to TST-
Rab27a and finally nonspecific proteins that bind to the beads alone. As the TST does not 
occur endogenously and StrepTactin has been specifically engineered for TST affinity, the 
background level of non-specific binders to Rab27a is expected to be low. 
In set B, NitroXL is added but the samples are not subjected to UV irradiation. This means 
that the photocleavable core should stay intact throughout the entire experiment. Figure 62 
shows the expected adducts arising from NitroXL; the only adducts expected to appear are 
MonoOH and MonoGly, the hydrolysis and glycine adducts of singly reacted NitroXL 
respectively. With no application of UV, TST-Rab27a should be pulled down along with its 
covalently attached partners. Proteolytic digestion will cleave both TST-Rab27a and its 
partners into peptides. Thus, set B is the only set that should contain peptides of Rab27a 
effectors, and the set with the highest expected number of proteins. 
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Figure 62 Expected adducts arising from NitroXL and DSS, their chemical compositions and their 
monoisotopic adduct masses. 
Set C was treated with NitroXL and then irradiated with 365 nm UV light for 1 h before pull-
down. The photocleavable core of NitroXL is expected to cleave and release the crosslinked 
partners before TST-Rab27a is separated out by the beads. It is expected that the dataset 
will be much like Set A, but the peptides would be modified in similar quantities to SuccOH 
and Cleaved1. Generally, we would expect to see similar protein profile to set A, but the 
peptides will be modified with SuccOH and Cleaved1. The comparison between sets A and 
C may give an indication to effect of NitroXL on the overall detection and identification of 
peptides as the presence of crosslinker could cause aggregation, reduce the ionisation of 
peptides and affect their fragmentation. 
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Sets A1, B1 and C1 are analogous to A, B and C and the expected results are the same; 
the use of chymotrypsin instead of trypsin may give better coverage or identification. Sets D 
and E are analogous to A and B respectively, but with DSS-OH and DSS-Gly as the 
expected adducts in set E. 
Summary 
The objective was to see what interaction partners are covalently pulled down with TST-
Rab27a. These are expected to occur mainly in sample set B. Thus, in the analysis, the 
following comparisons were proposed: 
• Sets A against C compares the effect of treating the lysate with NitroXL and UV 
irradiation. Past tests (data not shown) have demonstrated that the radiative 
conditions employed make negligible difference to the protein samples. 
• Sets A and B compares the effect of NitroXL only. 
• Sets B against C compares what effectors have been cleaved off by UV irradiation of 
the NitroXL crosslinker. 
• Sets B against D compares the difference between pulled-down crosslinked proteins 
between NitroXL and DSS respectively, but the comparison would only be pertinent if 
the same digestion enzyme was used. 
5.3 Label-Free Quantification of Unmodified Peptides 
The experiments described above were performed and the samples analysed by a Q 
Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer at Imperial College 
London’s departmental facility. MaxQuant was used to search the raw MS data and LFQ 
was performed using the software’s in-built algorithm.208 Briefly, the algorithm outputs the 
parent protein’s LFQ intensity as a composite of its constituent peptides’ AUC ion 
intensities. Search parameters may be found in the Experimental, Chapter 7. Perseus 
1.6.0.7 was used to visualise the data. Known contaminants, reverse sequences and 
peptides only identified by site were immediately excluded. All LFQ intensity values were 
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transformed with a log2(x) function. For each group of sets analysed, the results were 
filtered such that proteins appeared in at least two out of three samples in at least 
one set.  
5.3.1 Number of identified proteins – Venn diagrams 
Venn diagrams were constructed sets of samples to show the extent of overlap of identified 
proteins. This was intended to give an overview of the crude differences between sample 
sets in each experiment and between experiments. Figure 64 shows the Venn diagrams for 
the three experiments; each circle represents a set.  
5.4.1.1 By Set 
 
Figure 63 Venn diagrams of the number of protein groups found in each experiment, group by set. The 
results were filtered such that in each experiment there were at least two valid measurements in at least one set.  
For the NitroXL + trypsin experiment, only 59 proteins were found in total. This either 
indicates a very clean pull-down or a low quality experiment. Either way, it is not desirable 
because having a measurably stable level of background protein is required for the 
normalisation step of LFQ. It is clear from the Venn diagram that the control samples in set A 
contain the most unique proteins. Set C was expected to have the same composition as set 
A, but it in fact contained only a subset of proteins found in set A. This could be because the 
pulldown efficiency of proteins may be reduced after reaction with NitroXL, or because a 
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significant portion have been modified by crosslinker adducts and were not included in the 
quantification. 
The experiments with chymotrypsin and DSS identified many more proteins, 340 and 380 
respectively. For the DSS + trypsin experiment, the total number of proteins found was 
comparable to the chymotrypsin experiment. Only 21 proteins were found only in DSS 
sample set, with a fair degree of overlap, but again set E has the most proteins by far. This 
suggests that the presence of the crosslinker hinders the pull-down other proteins.  
5.4.1.2 By Experiment 
Sets A, A1 and D have exactly the same experimental conditions and should in theory have 
very similar compositions. However, the Venn diagram in Figure 64 shows 84 proteins 
identified exclusively in set A1 and 162 in set D. This either signifies major differences in the 
lysate used for the three experiments or human error in executing the protocol and requires 
investigation. 
 
Figure 64 Venn diagram showing the overlaps in protein IDs found in the non-crosslinked sets of 
samples: A, A1 and D. 
5.3.2 Statistical Analysis – Volcano Plots 
Because of the poor quality and few hits obtained from the NitroXL-trypsin dataset, only the 
chymotrypsin-NitroXL experiment was chosen for statistical analysis. The Perseus software 
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was used to compute two-sample Student’s T-tests with sets A1 vs C1 and with B1 vs C1 
and A1 vs B1 from the chymotrypsin experiment, and also sets D and E from the DSS 
experiment.  
This statistical analysis requires valid values for every replicate. However, this would mean 
that proteins that are reliable found in one set but not the other cannot be included in 
statistical tests. The Venn diagrams above revealed many such proteins. To be able to 
include them, the missing values were imputed. This means replacing the invalid values with 
a narrow distribution of numbers close to the intensities of peptides identified close to the 
detection limit of the instrument. This is akin to treating the invalid values as ones that are at 
the very left-most side of a normal distribution curve.  
Once the values were imputed, volcano plots were generated by plotting the difference 
between the averaged log2 (LFQ intensities) in the two sets on the x-axis and the significance 
expressed as  -log2(p-value) calculated from the t-test on the y-axis. The following section 
examines the volcano plots generated by Perseus. Proteins that passed the significance 
threshold value (p-value = 0.05) are highlighted in blue; proteins that were enriched in set B1 
are highlighted in red. TST-Rab27a is always labelled in green and all known effectors of 
Rab27a are highlighted in black. 
5.4.2.1 Set A1 vs C1 
Proteins on the right-hand side (RHS) with a positive difference are enriched in set A1 (no 
XL, no UV) over set C1 (NitroXL, UV). As in the Venn diagram in Figure 63, the volcano plot 
in Figure 65 shows a skew towards more protein being found in set A1. Two putative 
Rab27a effectors were identified, ATP1a1 and Iqgap1, but neither their quantities did not 
differ significantly in the sets. 
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Figure 65 Volcano plot showing the results of a T-test between set 1A (no XL, no UV) and set C1 
(NitroXL, UV). 
The presence of crosslinker adducts on binding partners could result in decreased affinity for 
Rab27a, especially if the modified residue is in or very close to the interface. It could also 
destabilise the secondary structure of the protein, or crosslink multiple proteins together, 
either of which can cause aggregation of precipitation which could preclude it from pull-down 
and analysis. Also, because the MaxQuant search only identified unmodified peptides, the 
quantity of peptides will decrease in set C1. 
5.4.2.1 Set B1 vs C1 
Figure 66 compares sets B1 and C1 in a volcano plot. Both sets were treated with NitroXL 
but C1 was exposed to UV, thus cleaving all crosslinks. Set B1 was expected to retain more 
protein and the skew of data points towards the RHS of the volcano plot appears to support 
this. However, few proteins were found to be above the significance threshold. Pleasingly, 
Iqgap1 had the highest significance value and was found to be 24-fold enriched in set B1, 
suggesting that crosslinking between Rab27a and one of its putative effectors could have 
AP1 
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been successful. However, although the interaction between Iqgap1 with Rab27a is 
supposed to require Cdc42,116 no Cdc42 was found in any of the samples. 
 
Figure 66 Volcano plot showing the results of a T-test between set B1 (NitroXL, no UV) and set C1 
(NitroXL, UV). 
5.4.2.1 Set A1 vs B1 and D vs E 
Figure 67 shows volcano plots for sets A1 vs B1 compared with sets D and E respectively, 
which had the same experimental conditions but E was crosslinked with DSS instead of 
NitroXL. This was intended to give a qualitative view of the differences caused by changing 
the crosslinker. Both experiments show more proteins identified in the sets without 
crosslinker. The reasons may be similar to those described for sets A1 vs C1 above. 
Iqgap1 was not identified in the DSS experiment, whereas Slp4 (SYLT4) was not identified 
any of the NitroXL experiments. ATP1a1 was more abundant in sets A1 and D than in B1 
and E but not be a large amount. The insignificance of change in Slp4 quantity is contrary to 
the crosslinker validation experiments with recombinant Rab27a-Slp4 described in 
Chapter 4. 
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Figure 67 Volcano plot showing the results of t-test between sets A1 (no XL, no UV) and B1 (NitroXL, no 
UV), and between sets D (no XL, no UV) and E (DSS, no UV). 
A1 vs B1 (NitroXL) 
D vs E (DSS) 
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5.3.3 Summary 
• Samples that were not treated with either DSS or NitroXL had higher quantities of 
proteins identified than those treated with crosslinker. This decrease in the LFQ 
intensities could be due to the exclusion of modified peptides, which were not 
counted in this search.  
• The differences between the proteins enriched in sets B1 and E over A1 and D 
respectively either reflect the difference between the selectivities of DSS and NitroXL 
or were simply fluctuations in the background. 
• A significant result was of Iqgap1, a known GDP-Rab27a effector, that was 
significantly enriched in set B1 over C1 and is suggestive of the successful pull-down 
of a crosslinked binder. 
The volcano plots described above have helped to visualise the data obtained from the 
newly designed workflow described at the beginning of this chapter. The next section will 
continue to explore the modified peptides in these experiments and examine the differences 
in residue selectivity between NitroXL and DSS. 
5.4 Analysis of modified peptides (PEAKS) 
5.4.1 Peptide Modifications 
PEAKS Studio 8.5. was used to search for modifications and PTMs using the same raw data 
that was used for MaxQuant. All crosslinker modifications (Figure 62) searched for on K and 
also on C, S, T,Y and N-termini to check for the extent of cross-reactivity. Table 6 shows the 
protein groups for which modified peptides were found by PEAKS for the trypsin (sets A, B 
and C) and chymotrypsin (sets A1, B1 and C1) experiments. Only modifications with an A-
score of over 20 were included, giving a total of 42 proteins that were found with NitroXL-
derived modifications. 
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Gene Description Coverage (%) #Pep 
#Mono 
OH 
#Mono 
Gly 
#Clea-
ved1 
#Succ 
OH 
1 RL27 60S ribosomal protein L27 32 3 0 0 0 1 
2 GRP78 78 kDa glucose-regulated protein 40 21 0 0 0 1 
3 TCP4 
Activated RNA 
polymerase II 
transcriptional coactivator 
p15 
77 15 0 0 0 1 
4 ADT2 ADP/ATP translocase 2 69 29 0 0 0 1 
5 ARF5 ADP-ribosylation factor 5 44 10 0 0 0 1 
6 ANXA2 Annexin A2 38 12 0 0 0 2 
7 ATPB ATP synthase subunit beta  mitochondrial 25 11 0 0 0 1 
8 DX39A ATP-dependent RNA helicase DDX39A 37 23 0 0 0 1 
9 COF1 Cofilin-1 48 9 0 0 0 2 
10 QCR2 Cytochrome b-c1 complex 
subunit 2  mitochondrial 38 17 0 0 0 1 
11 DEST Destrin 9 2 0 0 0 2 
12 RPN2 
Dolichyl-
diphosphooligosaccharide-
-protein 
glycosyltransferase 
subunit 2 
36 18 3 0 0 3 
13 ALDOA Fructose-bisphosphate 
aldolase A 36 12 1 0 0 4 
14 G3P Glyceraldehyde-3-phosphate dehydrogenase 81 36 0 0 0 5 
15 RAN GTP-binding nuclear protein Ran 54 15 1 0 0 0 
16 HSP7C Heat shock cognate 71 kDa protein 41 25 0 0 0 1 
17 HSPB1 Heat shock protein beta-1 91 24 0 0 0 2 
18 HS90B Heat shock protein HSP 90-beta 50 35 0 0 0 1 
19 HNRH1 Heterogeneous nuclear 
ribonucleoprotein H 14 6 0 0 0 2 
20 LDHB L-lactate dehydrogenase B chain 45 12 0 0 0 1 
21 NDKB Nucleoside diphosphate kinase B 26 4 1 0 0 2 
22 PPIA Peptidyl-prolyl cis-trans isomerase A 59 14 1 0 0 1 
23 MPCP Phosphate carrier protein  
mitochondrial 25 14 0 0 0 3 
120 
 
24 PROF1 Profilin-1 61 15 0 0 0 5 
25 KPYM Pyruvate kinase PKM 53 33 0 0 0 1 
26 TSTRB27A Ras-related protein Rab-27A 98 75 28 8 3 164 
27 RB27B Ras-related protein Rab-27B 32 16 4 0 0 1 
28 RACK1 Receptor of activated protein C kinase 1 24 7 0 0 0 1 
29 SRSF3 Serine/arginine-rich 
splicing factor 3 40 14 1 0 0 10 
30 SRSF7 Serine/arginine-rich 
splicing factor 7 18 4 0 0 0 1 
31 SRP14 Signal recognition particle 14 kDa protein 32 2 0 0 0 1 
32 DX39B Spliceosome RNA helicase DDX39B 24 12 0 0 0 1 
33 SFPQ Splicing factor  proline- 
and glutamine-rich 11 6 0 0 0 1 
34 TBA1C Tubulin alpha-1C chain 77 60 4 0 0 18 
35 TBA4A Tubulin alpha-4A chain 67 54 4 0 0 10 
36 TBB5 Tubulin beta chain 86 59 0 0 0 5 
37 TBB3 Tubulin beta-3 chain 59 36 0 0 0 5 
38 TBB4B Tubulin beta-4B chain 86 62 0 0 0 5 
39 TBB6 Tubulin beta-6 chain 69 43 0 0 0 5 
40 RS27A Ubiquitin-40S ribosomal protein S27a 26 4 0 0 0 1 
41 VDAC1 Voltage-dependent anion-
selective channel protein 1 30 6 0 1 0 2 
42 VDAC2 Voltage-dependent anion-
selective channel protein 2 39 9 0 0 0 1 
Table 6 List of protein groups found by PEAKS to have NitroXL-derived modifications from combined 
sets A, B and C (trypsin) and A1, B1 and C1 (chymotrypsin). The number of peptides includes unmodified 
counterparts. Modification counts are no. of different peptides found with the modification.  
Table 7 shows the list of proteins found with DSS-derived modifications from experimental 
sets D and E, which has a total of 18 proteins. However, four of them forms of keratin which 
is more than likely a contaminant, and six are forms of tubulin, which is a highly abundant 
protein in cells. This suggests that the level of non-specific background proteins is higher for 
the DSS samples. 
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 Gene Description Coverage 
(%) 
#Peptides #DSS-
OH 
#DSS-
Gly 
1 ACACA Acetyl-CoA carboxylase 1 28 46 2 2 
2 ALDOA Fructose-bisphosphate 
aldolase A 41 10 1 0 
3 CDK1 Cyclin-dependent kinase 1 60 16 2 0 
4 COPE Coatomer subunit epsilon 19 4 0 3 
5 GRP78 78 kDa glucose-regulated protein 41 27 1 0 
6 RB27B Ras-related protein Rab-27B 49 13 1 7 
7 SRSF2 Serine/arginine-rich splicing factor 2 59 13 1 0 
8 SRSF3 Serine/arginine-rich splicing factor 3 43 11 11 2 
9 TBA1C Tubulin alpha-1C chain 65 28 3 0 
10 TBA4A Tubulin alpha-4A chain 59 25 3 0 
11 TBB2B Tubulin beta-2B chain 24 24 1 0 
12 TBB3 Tubulin beta-3 chain 53 22 1 0 
13 TBB5 Tubulin beta chain 71 26 1 0 
14 TBB6 Tubulin beta-6 chain 57 21 1 0 
15 TSTRB27A Ras-related protein Rab-27A 100 44 217 79 
Table 7 List of protein groups found by PEAKS to have DSS-derived modifications from sets D and E. 
Number of peptides include unmodified counterparts. Modification counts are no. of different peptides found with 
the modification. 
5.4.1.1 Modified Peptide Spectra 
The mass spectra of well-fragmented modified peptides are given below. The spectrum, 
along with the assigned b and y ions, are generated by PEAKS. Capital letters refer to the 
unmodified amino acids; uncapitalized letters correspond to those found with a modification. 
Figure 68 shows the spectrum of a chymotrypsin-digested peptide from TST-Rab27 modified 
with Cleave1 on S13 (A-score was 25.70). This is part of the twin Strep tag which comes 
after Rab27a’s N-terminus. The peptide was fragmented at all but one of the possible sites. 
Mostly b ions were detected, that is, where the N-terminal end of the peptide fragment was 
detected. The number specifies how many amino acids from the N-terminus comprises the 
fragment. Similarly, the y ions refer to C-terminal fragments in the same way. 
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Figure 68 PEAKS-generated mass spectrum of a chymotrypsin-digested peptide on TST portion of 
Rab27a with S13 (marked by an arrow) modified by Cleaved1.  
Figure 69 shows the spectrum this time of a trypsin-digested fragment with a K47 modified 
with DSS-Gly (A-score = 101.94). This time, more y ions were detected. Nearly all bonds 
along the peptide had fragmented. Note that the enzyme cleaved at the C-terminal end of an 
unmodified lysine. 
 
Figure 69 Mass spectrum of a trypsin-digested peptide from TST-Rab27a, where K47 (marked by an arrow 
is modified by DSS-Gly) modified by Cleaved1. 
5.4.2 Overview of Coverage and Adducts on Rab27a 
PEAKS identified the most peptides for TST-Rab27a. This is not surprising as not only was it 
the target of the pull-down, but it was highly abundant in the lysate to begin with, and much 
more so than its binders expressed at native levels. In this section, we will examine the 
crosslinker coverage on TST-Rab27a to view the behaviour of NitroXL on a peptide level.  
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Figure 70 shows the peptide coverage, enzyme cleavage points and modifications for TST-
Rab27a in the three experiments. 
 
 
Figure 70 Peptide coverage and modifications of TST-Rab27a. The boundaries between the black and green 
text signify the enzyme cleavage sites. The trypsin and chymotrypsin experiments were analysed together so 
their modifications appear identical in this summary view. 
Coverage of TST-Rab27a is complete in three experiments. Interestingly, NitroXL appeared 
to label only lysine and some serines, whereas DSS was found to be less residue-specific 
and reacted with similar numbers of the S, T and Y. This result is in spite of the two 
crosslinkers having the same warhead. Table 8 compares the residues of TST-Rab27a 
found to be modified by NitroXL and DSS. NB the native sequence of Rab27a starts at M37, 
so K9, S13, K29 and S30 are all on the TST tag. 
 
 
NitroXL + trypsin 
DSS + trypsin 
NitroXL + chymotrypsin (FLWY) 
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NitroXL adduct 
residues 
DSS adduct 
residues 
K9 
S13 
K29 
S30 
 
 
K47 
 
S54 
K58 
 
K69 
K73 
K85 
 
 
 
K170 
K180 
K219 
K227 
S228 
 
 
K250 
K9 
S13 
K29 
 
Y42 
Y44 
K47 
S38 
 
K58 
Y63 
K69 
K73 
 
T98 
T121 
T122 
 
K180 
 
K227 
 
S242 
T243 
K250 
K: 12 
S: 4 
T: 0 
Y: 0 
Total: 16 
K: 9 
S: 3 
T: 4 
Y: 3 
Total: 19 
Table 8 Summary of the residues of TST-Rab27a that had crosslinker modifications. No cysteine 
modifications were found in any of the samples; however, because of a lack of a reducing agent such as DTT or 
TCEP in the solution, that a significant proportion of sulfhydryl moieties were either oxidised or bound up in a 
non-native disulfide bridge at the time of crosslinking. 
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5.4.3 Visualisation of Modified Lysines from the Crystal Structure of Rab27a 
Figure 71 displays the lysine sidechains visible in the structure of Rab27a as part of the 
Rab27a-Slp2-a heterodimeric crystal structure by Chavas et al. [PDB: 3BC1]. The residue 
numbering corresponds to that of TST-Rab27a, and residues found in the C-terminal region 
and in the TST itself are not shown. 
 
Figure 71 PyMOL-rendered images of a single Rab27a molecule from the crystal structure by Chavas et al 
[PDB: 3BC1], displaying all lysine residues. The residue numbering is for TST-Rab27a; the C-terminal region 
and the TST are not visible. Numbering is for TST-Rab27a. 
K58 and K170 are situated close to the nucleotide. If these are important for the protein’s 
interaction with the nucleotide, then they may be expected to be unreactive or at least 
labelled less frequently. Nevertheless, crosslinker adducts were seen on both of those 
lysines, but Rab27a is a flexible protein and lysines have relatively long and flexible side-
chains. How the crosslinker at these sites would affect the stability and conformation of the 
protein is unknown; it is feasible that a reaction at certain residues would render the protein 
unsuitable for effector interaction. 
No crosslinking was detected on K190 or K252 (not visible in 3BC1). Upon inspection of the 
neighbouring amino acid sequence, they may be speculated to be unreactive due to a salt 
bridge interaction with a glutamic acid residue (E) on an adjacent turn of the helix in an i, 
i + 3 relationship) i.e. ExxxK. 
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5.4.4 Crosslinker-derived adducts for tryptic digests with NitroXL and DSS 
PEAKS has an in-built function that visualises the percentage of modified vs unmodified 
residues for all residues found with modifications. The quantification is based the AUC of ion 
intensities of modified and unmodified peptides that contain the residue. 
Because every peptide identity differs in detection efficiency in MS, the values of ion 
intensities cannot be directly compared – only relative changes of the same peptide/protein 
between different samples are valid. However, these profiles may give a qualitive overview 
that may be useful in justifying or falsifying later conclusions. 
The following section looks at the profiles of NitroXL-derived modifications in the trypsin and 
chymotrypsin sample sets.  
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5.2.4.1 MonoOH  
 
Figure 72 Profile of MonoOH adducts in trypsin (A, B, C) and chymotrypsin (A1, B1 and C1) sample sets 
generated by PEAKS along with the structure of MonoOH. 
MonoOH is the hydrolysed type 0 NitroXL adduct (Figure 62). The profile in Figure 72 shows 
that it only appears in either B (trypsin) or B1 (chymotrypsin) sets, though never both. It is 
not clear why this is. What is striking is the percentage of modified peptides can have such a 
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large range, ranging from ~1% to 70%, though these numbers cannot be taken to mean the 
real percentage. Otherwise, it is in line with its expected behaviour, in that it does not appear 
in set C/C1, where the photocleaved adducts would be expected instead, nor in A/A1 which 
were not treated with crosslinker. 
5.2.4.2 MonoGly 
MonoGly is the type 0 adduct of NitroXL where the terminal NHS ester has been reacted 
with glycine from the reaction quench. A much smaller number of residues were found to be 
modified by MonoGly than by MonoOH, and the modified peptides were also found at lower 
percentages (Figure 73). This suggests that most exposed NHS esters are quenched by 
water within 1 hour, and indicates that the time required for crosslinking can be reduced in 
future experiments. 
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Figure 73 Profile of MonoGly adducts in trypsin (A, B, C) and chymotrypsin (A1, B1 and C1) sample sets 
generated by PEAKS, along with the structure of MonoGly. 
  
130 
 
5.2.4.4 SuccOH (succinylation)  
O
HO
O
SuccOH
 
 
Figure 74 Profile of SuccOH adducts in trypsin (A, B, C) and chymotrypsin (A1, B1 and 
C1) sample sets generated by PEAKS along with the structure of SuccOH. 
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SuccOH is succinylation. This is a modification may originate from photocleavage of NitroXL 
or from hydrolysis of both the NHS ester and the internal ester groups from NitroXL ( 
Figure 75), but it also occurs as an endogenous PTM.  As there was no succinylation found 
in sets A/A1, it was concluded that levels of endogenous succinylation was negligible in all 
samples. Therefore, we would expect most succinylated proteins to be found in sets C/C1, 
and indeed this was the case. Again, there was a large range of the percentage of modified 
residues versus their non-modified counterparts - between 10-100%. This implies that some 
residues are more reactive than others. 
 
Figure 75 NitroXL-derived adducts formed as a product of internal ester hydrolysis. 
Succinylation was also observed in sets B and B1. This may have been caused by 
photodegradation as the samples were exposed to light during preparation, or from ester 
and hydrolysis. Either way, they occurred in smaller ratios. A search was set up in PEAKS to 
look for AroHydro (Figure 75), but no partially hydrolysed adducts were found (data not 
shown). 
5.2.4.3 Cleaved1 
Cleaved1 is the aromatic nitroso species that is expected when the 2-nitrobenzyl group is 
cleaved by UV irradiation. As the results from PEAKS show, this species was rarely found, 
with only one modified residue found in TST-Rab27a found (Figure 76).  
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Figure 76 Profile of Cleaved1 adducts in trypsin (A, B, C) and chymotrypsin (A1, B1 and C1) sample sets 
along with the structure of Cleaved1. 
The photocleavage of NitroXL results in a nitroso aromatic species (Cleaved1) and succinic 
acid (SuccOH). Therefore, we might reasonably expect similar quantities of SuccOH to 
Cleaved1. However, it is clear that SuccOH far outnumbered Cleaved1 in the number of 
modified residues and PSMs.   
This could be because the nitroso group had reacted further or has undergone further 
photoreaction from prolonged UV exposure to give unknown adducts which no longer 
corresponded to the searched mass. It may be possible that the one residue where it was 
found was in a chemical environment that slows this process. Further investigation is 
necessary, or the photocleavable core could be changed into one that cleaves into more 
chemically stable fragments.  
5.5 Refinements for LFQ – Consideration of the Discrete 
Behaviours of Peptides 
The LFQ method used in MaxQuant earlier in this chapter assumed that the total percentage 
of modified peptides was low enough such that the overall protein quantification will not be 
affected.  
N
O
O
O
O
O
Cleaved1
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MaxQuant’s inbuilt LFQ algorithm quantifies proteins by creating a composite of its AUC 
peptide quantities. At this point, it is worth examining the different categories of peptides that 
can contribute to this composite. In theory, there are several types of peptides that exist in 
the samples which are predicted to have discrete quantification behaviours under each 
experimental conditon: 
1. Unmodifiable peptides (no reactive residues) 
2. Modified peptides 
3. Unmodified counterparts of the modified peptides 
The search method used in this chapter had put every unmodified peptide through to LFQ 
(type A and C). The validity of this rests on the assumption that the overall proportion of 
modified peptides is low, such that their behaviour will not affect the overall quantification 
behaviour of the protein. 
However, the PEAKS data in section 5.4.4 suggests that some residues are significantly 
modified. In this case, the contribution of modified peptides towards protein quantification 
could potentially change the conclusions drawn about certain proteins. 
With these considerations, a new search in MaxQuant was set up to identify all four NitroXL 
adducts from the chymotrypsin experiment. Modified peptides (type B) and their unmodified 
counterparts (type C) would be identified as part of the search, but their intensities would not 
be counted for protein quantification. This means that the quantification behaviour of proteins 
would be dependent only on their pulled-down quantities. Furthermore, inspection of the 
quantification behaviour of the peptides categories may reveal if their parent protein is a 
covalent or non-covalent binder (Figure 77). 
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Figure 77 Predicted ideal behaviour of different types of peptides in each experimental set. In the previous 
search, the behaviours of never-modified and unmodified counterpart peptides would have been summed 
together, ignoring all modified peptides. This summation is not useful if there is both significant and variable 
proportions of modified peptides. 
No XL is added in set A, so there are no modified peptides in any set A sample. Assuming 
that the same amount of TST-Rab27a is pulled down in each sample, the proportion of its 
never-modified peptides should stay constant in all sets. Because peptides are modified by 
the same proportion in sets B and C, the relative amount of unmodified counterparts will 
decrease from A. MonoOH and MonoGly adducts are expected only to occur in in set B with 
no UV treatment, and Cleaved1 and SuccOH are only expected in set C where samples 
were UV-irradiated. 
Binding 
Partners
(Covalent 
Only)
Unmodified 
remainder
Never 
modified
MonoOH, MonoGly
Nitroso, SuccOH
None
None
A
None
None
B
None
None
None
C
None
TST-Rab27a 
and
Binding Partners
(Non-covalent)
Never 
modified
Unmodified 
remainder
A B C
MonoOH, MonoGlyNone None
Nitroso, SuccOHNone None
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If it is assumed that crosslinker cleavage is complete in set C, it is relatively simple to predict 
the behaviours of peptides belonging to covalent-only binders of Rab27a. These proteins 
should only appear in set B. In a real experiment, it is envisaged that “none” means at a 
lower intensity. 
However, the nature of this more complex search was problematic when performed with our 
standard software and hardware platforms. Even after several days of run time, the searches 
had not undergone significant progress. Improved hardware and possibly alternative 
software should be considered for the next phase of the project. It is important for this 
alternative search method to be considered as far as practically possible as it would directly 
impact the nature of the conclusions drawn from the analysis. 
5.6 Future Experiments 
In this section, a novel proteomic protocol was involving the prototype photocleavable 
crosslinker NitroXL was established and tested using lysed HeLa lysate with ectopically 
expressed TST-Rab27a. The first iteration of MS data was obtained with initial best-guess 
parameters, and LFQ was performed using MaxQuant taking into account all unmodified 
peptides. However, the results from t-tests and modification data from PEAKS showing that 
some residues are very efficiently labelled suggest that precluding modified peptides from 
LFQ may invalidate the enrichment data. A new search scheme was proposed wherein LFQ 
only quantifies never-modified peptides, but this could not be completed in time. It is 
envisaged that future efforts using more powerful processors may yield more representative 
results. 
Nevertheless, these initial experiments were instrumental in revealing the non-triviality of 
interpreting the MS results and in elucidating the improvements required to contribute to the 
success of this methodology. 
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5.6.1 Sample Preparation 
To remove non-covalently bound proteins from the analysis. a precipitation step may be 
added before the pull-down After re-dissolving, the proteins will have lost much of their 
tertiary structure and will have reduced affinities for their binding partners. However, covalent 
crosslinks will be intact. 
It may also be prudent to try a different lysis buffer. The Triton, magnesium and glycerol 
content may all have adverse effects on protein stabilities and interactions and their inclusion 
in the lysis buffer needs to be scrutinised. The fact that high-throughput screens for the 
extraction medium for affinity-based capture have been published as recently as 2015278 
suggests that it could make a big difference, but also that optimisation may be required 
depending on the target protein. This would be prevented if crosslinking was done in vivo. 
Alternatively, or in addition, a milder wash buffer could be used after the pull-down step. 
A successful crosslink requires a ratio of two proteins two on one crosslinker. If the 
crosslinker is both too abundant and efficiently reactive, then there is a chance that the 
lysines on both the target protein and the effector both have singly-reacted crosslinkers, in 
which case they will not be crosslinked. It would be of use to perform a screen of crosslinker 
concentrations to minimise this. 
5.6.2 Proteomics 
Repeats of the initial experiments are necessary to establish the variation and reliability of 
the protocol. Aside from this, it would be beneficial to conduct a proteomic analysis of the 
entire HeLa lysate to check for the expression of known effectors of Rab27a. It may even be 
helpful to do this for several sources of lysate, as only a small number of Rab27a effectors 
tend to be expressed in any one cell type. Melanocytes may be considered as a control 
lysate for future experiments as the effector melanophilin is known to be robustly expressed. 
Fractionation may be required to mitigate dynamic range. 
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It would also be of interest to compare the results from crosslinking with that of a classic co-
immunoprecipitation experiment, where Rab27a is pulled down by a solid-supported 
antibody rather than via an introduced protein tag (without cross-linking). More than one 
antibody may need to be tested; however, it serves as a benchmark against which 
crosslinking methods are compared. 
5.6.3 Controls 
It may also be easier to test this methodology first on proteins with well-characterised 
effectors before applying to more elusive proteins like Rab27a. Alternatively, known effectors 
of Rab27a could be co-transfected. Already available to the group are plasmids of TS-
tagged KRas and PDE6δ. These could be used to validate changes to the proteomic 
protocol as well as new crosslinker designs. 
The behaviour of crosslinked proteins in MS can also be conducted with recombinant 
Rab27a-Slp4. In this case, it may be possible to observe the type-2 intercrosslinked 
peptides. 
5.6.4 Cells, Plasmids, Protein Constructs 
The transfection of TST-Rab27a into cell cultures means that the protein will be 
overexpressed. Such superabundance of a protein in such a short space of time (24 h) will 
inevitably cause problems such as toxicity, but will also saturate the enzymes involved in 
post-translational modifications resulting not just in incompletely prenylated Rab27a but all 
other proteins requiring prenylation, which could result in many proteins being incorrected 
localised in the cell. This means that the proportion of endogenous-like TST-Rab27a, that is 
prenylated, localised on membranes or stabilised by GDIs and otherwise behaves similarly 
to the native protein, may be very small. Furthermore, all effectors would be expressed at 
their endogenous levels, which may also be very low. Neither would not be accounted for by 
the pull-down, resulting in issues of dynamic range. 
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Different protein tags could also be considered, or change to biotin instead. Unfortunately, a 
lot of well-known peptide affinity handles have lysines in them, including TST and FLAG. The 
results from PEAKS show that the TST on Rab27a is modified by NitroXL at four residues, 
which include K and S. This obviously does not completely prevent pull-down but it is likely 
to affect its affinity to StrepTactin. Also, the TST is on the long side (>30 aa), so even though 
its PD is clean and efficient, it may adversely affect the behaviour and positioning of the 
protein in the cell. Producing a biotinylated protein prevents the affinity tag from becoming 
modified, though StreptAvidin pull-downs will also attract endogenously biotinylated proteins. 
5.6.5 Set-Up 
The experimental scheme described in Figure 40 in Chapter 4 that underpinned the 
conception of the photocleavable crosslinker approach may be reconsidered. It would 
require a set-up that would enable effective UV cleavage of a heterogenous mixture, that is, 
trying to photocleavage molecules that are attached at one end to a solid substrate. This 
would be accommodated if there was a source of agitation for the beads during UV 
irradiation, which would incur experiments to optimise the practical aspects. This approach 
would bypass the issue of dynamic range with Rab27a peptides, though it excludes type 2 
inter-crosslinks and may suffer from low signal intensity. 
5.6.6 Crosslinker Redesign 
Many options exist for improving the design of the photocleavable crosslinker. One of the 
first issues requiring resolution is possibly the solubility of NitroXL which, like DSS, requires 
10% of DMSO to achieve reasonable solubility, and even then, some precipitation was 
observed at the start of the experiment. One way of achieving water-solubility is to add 
sulfonated NHS ester groups, as for the BS3, the doubly sulfonated version of DSS.  
Alternatively, a crosslinker with improved water solubility but lacking in ionic groups may be 
suitable for crosslinking in vivo; which may allow some considerations on the choice of lysis 
buffer to be skipped, though permeability and uptake will become important factors. 
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Further, it would be desirable to have a crosslinker that does not have not have labile ester 
bonds beside the NHS esters. Although most esters would hydrolyse slowly under 
physiological pH, it would be safer to eliminate the possibility. 
Other photocleavable cores should be considered; firstly, the routes to the coumarin and 
benzoin designs should be completed. Other photocleavable cores may have better physical 
and photocleavage properties and leave behind more stable photocleavage products. More 
thorough studies on the kinetics of photocleavage should be conducted on new iterations of 
crosslinkers. 
5.6.7 Type 2 Inter-crosslinks 
Future crosslinker designs could try to target type 2 inter-crosslinks, and can be general 
enough not to require pre-tagging of proteins of interest. The crosslinker could include a 
click-taggable group to facilitate their enrichment and mass-cleavable bonds to take 
advantage of the simplification they can give for data processing.  
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6 Discussion and Conclusions 
6.1 Summary 
6.1.1 Structure-guided inhibitor development of Rab27a 
The x-ray derived structure of Rab27a-Slp4 by Chavas et al. [PDB: 3BC1] was used as the 
basis of the crystallisable Fusion-Rab27a construct protein made by M. Jamshidiha where 
the C-terminus of Rab27a was linked to the bottom helix of Slp2-a, leaving the SF4 pocket 
empty. This construct made it possible to validate the binding sites of hits obtained from a 
fragment screen using a thermal shift assay. Crystallisation of the top hits into Fusion-
Rab27a revealed two binding sites, both of which were in a narrow channel in the interface 
between two proteins that formed a repeating unit of the crystal structure. 
Analogues were developed for SAR studies of the two most synthetically attractive 
fragments based their crystal structure in Fusion-Rab27a and tested their binding by DSF 
and waterLOGSY. Unfortunately, the analogues either gave negative results or suffered from 
poor solubility.  
It was thought that their binding sites were likely to be artefactual, made possible only by the 
proximity of Rab27a units in the solid-state structure. If this was the case, then it would 
nullify the rationale behind the SAR studies. Indeed, when a new construct was made 
without the short beta-chains at the bottom of the aforementioned channel, the fragments 
failed to crystallise in the same location. 
Further work is underway by M. Jamshidiha to create new Rab27a constructs which do not 
require part of an effector to crystallise. This could also free up more of the Rab27a-effector 
interface for fragments to interact with.  
6.1.2 Peptide binders: WF and lactam bridging 
A combination of twenty amino acids are used by eukaryotes to synthesise proteins of every 
function and form in an organism. Synthetic peptides can incorporate unnatural amino acids 
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in addition, further increasing their potential versatility. SPPS using N-Fmoc-protected amino 
acids is an established methodology capable of making synthetic peptides more than 100 
residues long, though more routinely up to around 30. 
However, longer peptides are more apt to suffer from poor physical properties such as low 
solubility but especially low membrane permeabilization, which is a less useful for cytosolic 
proteins like Rab27a. The goal here was to make a short peptide that maximised ligand 
efficiency using the structure of Slp2-a as basis.  
By downsizing the Slp2-a helix down to the residues that occupied the SF4 pocket the most 
deeply, the acetylated and amidated dipeptide WF was synthesised and found to bind 
weakly to recombinant GNP-Rab27a with a kd of ~ 8mM by SPR. This was a key result as it 
was the first positive control found for Rab27a. 
Extension of the peptide sequence on either side of the WF was not successful. However, 
lactam-bridging was successful in increasing the affinity of WF for KWFRD and there is 
scope for experimenting with other combinations of amino acids that may affect its solubility 
and conformation. 
Other members of the group have participated in an in silico using WF as the model ligand in 
the hopes of obtaining a peptidomimetic that is more easily customisable than the dipeptide. 
With a library of compounds based on its results, an SPR assay was used to screen a small 
library of compounds. Current efforts are underway in validating and developing the current 
hits.  
6.1.3 Photocleavable Crosslinkers 
Three homobifunctional photocleavable crosslinkers were designed. Due to Rab27a’s limited 
number of cysteines, it was chosen to target lysines using NHS esters as the warhead. For 
the preliminary experiments, the workflow as simple as possible to make it easier to identify 
issues and bottlenecks. As such, we chose not to target type 2 inter-crosslinks at the outset, 
and thus did not include options for enriching crosslinked peptides.  
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The synthesis of NitroXL was successful in the timeframe. Its photocleavage was 
demonstrated by LCMS and its crosslinking and cleavage demonstrated by silver stained gel 
experiments with recombinant Rab27a-Slp4 heterodimer and lysates containing TST-
Rab27a. Pull-down experiments with MagStrep beads showed that TST-Rab27a can by 
pulled down along with crosslinked proteins. 
A novel proteomic workflow was designed involving NitroXL. LFQ of pulled-down peptides 
was at first envisaged to be performed using unmodified peptides, based on the assumption 
type 0 adducted peptides are in the minority and would not affect the conclusion of the 
analysis if omitted. Proteomic data were obtained for three sets of data: NitroXL-typsin, 
NitroXL-chymotrypsin and DSS-trypsin. Chymotrypsin was used to obtain shorter and more 
easily ionisable peptides: proposed to increase coverage. 
LFQ in MQ was performed and volcano plots were generated for the chymotrypsin 
experiment. The highly significant enrichment of the known Rab27a interactor Iqgap1 in set 
B1 in the chymotrypsin experiment was promising. However, the fact that many proteins 
found to be enriched in set A over C, along with the ratios of modified to unmodified residues 
found by PEAKS, suggested that the initial assumption was wrong and that a new search 
needed to be set up to take into account the modifications. 
After inspecting the predicted behaviour of different types of peptides, it was concluded that 
LFQ of never-modified peptides would be the simplest way to identify Rab27a-interacting 
proteins based on their quantification behaviour under different experimental conditions. This 
search was attempted, but this was very time-consuming and could not be completed in 
time. 
Due to the non-trivial nature of the workflow and particularly the analysis, it would be useful 
to develop robust positive controls for this methodology, for example by using proteins with 
well-validated PPIs instead of Rab27a, or with spiked in effector, or a cell line that reliably 
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expresses known Rab27a effectors. Certainly, this methodology is in its infancy and has the 
potential to be taken down a myriad of directions. 
6.2 Conclusions 
Rab27a is a challenging protein to study in our current paradigm in which structure-guided 
inhibitor development is held up as the gold standard technique in drug discovery. Certainly, 
one of the tightest bottlenecks for Rab27a appears to be the difficulty in obtaining a crystal 
structure, not just of itself but with even in co-crystals with other effectors and binders other 
than Slp2-a. To this day, Chavas’s Rab27a-Slp2-a heterodimer [PDB: 3BC1] remains the 
only crystal structure in the PDB that includes Rab27a. Closely related is the structure of 
Rab27b with the Slp homology domain of Slac2-a/melanophilin [PDB: 2ZET], but few others 
offer clues to the binding modes of Rab27a, especially with GAPs, GEFs and molecules that 
bind to its GDP-loaded form.  
Efforts are underway in the group in collaboration with ICR to obtain hits using SPR. An in 
silico screen was performed using WF as the model ligand, and a bespoke library of 
compounds was tested with a using an SPR assay. The dipeptide WF is also being made 
into a covalent binder; a judiciously placed acrylamide warhead would enable its tethering to 
one of the cysteine side chains around the rim of the SF4 pocket. These relatively new 
techniques hold promise in delivering novel hits that could be turned into a tool or drug 
molecule. However, the druggability of Rab27a still remains to be seen.  
Even if a strong and specific inhibitor were to be found, it is unknown whether its chronic 
application would cause a net benefit to the patient given the life-limiting symptoms of 
Griscelli syndrome. However, these questions are likely to remain in future projects. 
Nonetheless, any technique that delivers a validated inhibitor of Rab27a will likely work on 
other members of the Ras superfamily and would greatly increase the ease of drug 
discovery for this whole class of hitherto elusive proteins. 
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Mapping interactomes is no easy feat, and the tagged protein approach is a method of 
simplifying the sample protein profile for faster analysis, and photocleavable sites on a 
crosslinker offer an orthogonal release point to assist with enriching proteins of interest.  
It would be sensible to find a photocleavable group that reliably produces stable and easily 
detectable cleavage products before introducing and optimising other usable components 
like affinity tags or clickable groups. Further, it may be necessary to find ways of increasing 
the computational capacity for the more complex LFQ scheme proposed in Section 5.5. 
Efforts in searching for type 2 crosslinks in the future will likely require assistance in the form 
of an MS-cleavable bond in the crosslinker to separate the two peptides so they can 
fragment separately. This may require the use of triple-MS, and increase the number of 
potential adducts that the software must search for, adding to the technological load. 
The methodology is by no means tied to Rab27a, but perhaps its biggest limitation is the 
requirement of producing a tagged version of every protein whose interaction network is to 
be studied. Not only would this become labour and cost-intensive as the number of proteins 
and tags increase, it still does not solve the question of how disruptive the presence of the 
tag would be to the protein’s endogenous PPIs.  
Furthermore, each crosslinker will likely be biased towards certain PPIs, and mapping the 
full range may require synthesising crosslinkers at a variety of lengths. Depending on the 
nature of the protein of interest’s placement of lysines, the homobifunctional crosslinking 
approach may be unsuitable for some PPIs.  
Nevertheless, this is a project with much depth and untold potential still to be explored, not 
just in crosslinker design but also ways of conducting the proteomic analysis. The 
preliminary experiments reported in this project have laid out the starting point and provided 
valuable learning opportunities upon which future studies can build. 
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7 Experimental 
7.1 Chemical Synthesis 
7.1.1 General Organic Synthesis 
All reagents and solvents were purchased from Sigma-Aldrich, Novabiochem® UK or 
Fluorochem Ltd. and used without further purification. Ultrapure water was obtained from 
MilliQ® Millipore water purification system. Moisture sensitive reactions were performed 
under nitrogen atmosphere using dried glassware and standard syringe/septa techniques. 
Thin Layer Chromatography (TLC) was performed on Merck pre-coated Silica plates 
(Aluminum oxide 60 F254, Merck). Spots were visualized by UV light (operating at 254 nm), 
and using the appropriate stain (iodine, potassium permanganate, ninhydrin or p-
anisaldehyde stain). Silica gel column chromatography was carried either by hand-made 
columns with Merck Silica 60 Å, or using an Isolera (Biotage, UK) automated apparatus with 
a fraction collector equipped with SNAP cartridges columns (Biotage, UK). NMR spectra 
were recorded on 400MHz Bruker instruments and were referenced to residual solvent 
signals. Data are presented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet), coupling constant(s) in Hz and integration. NMR 
spectrometry was carried out at room temperature except were indicated otherwise.  
Mass spectrometry characterisation was obtained from the Mass Spectrometry Service of  
Department of Chemistry, Imperial College London. 
Analytical and semi-preparative RP-HPLC were carried out on a Waters 2767 system 
equipped with a photodiode array, a mass spectrometer and an X-Bridge C18 column (5 μM, 
4.6 mM × 100 mM). Except where indicated, all compounds that were analysed or purified 
by LCMS used the following gradient: 50 % to 98 % MeOH in H2O over 10 min, 98 % MeOH 
was held for 2 min, MeOH was reduced from 98 % to 50 % over 1 min, and held at 50 % 
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until 18 min. A flow rate of 1.2 mL/min was used for the analytical mode and 20 mL/min were 
used for the preparative mode. 
7.1.2 Characterisation of Fragment Analogues 
N-(3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl)formamide (58) 
 
A solution of aminopyrazole 34 (50 mg, 0.24 mmol) in tetrahydrofuran (2 mL) was cooled to 
0 °C with stirring. Sodium hydride (12 mg of 60% suspension in mineral oil, 0.29 mmol) was 
added and the mixture stirred for 20 min. Ethyl formate (40 μL, 0.48 mmol) was added. The 
reaction was then heated to 50 °C and stirred for 2 h. The reaction was diluted with ethyl 
acetate. The organic layer was washed with water and brine and dried with sodium sulfate. 
The solvent was removed in vacuo and the crude residue was purified by column 
chromatography (5% methanol in dichloromethane) to give a yellowish solid. 1H NMR 
rotameric, see Figure 78 below; HRMS (ESI, positive mode) found 236.0592 ([M + H]+, 
requires 236.0585). 
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Figure 78 H NMR spectrum of 56 showing existence of rotamers 
3-(4-chlorophenyl)-N,1-dimethyl-1H-pyrazol-5-amine (38) 
 
N-(3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl)formamide (58, 50 mg, 0.21 mmol) in a 
solution of dry tetrahydrofuran (2 mL) was cooled to -78 deg. 1.0 M lithium aluminium 
hydride in THF (1 mL, 1.0 mmol) was added dropwise. The reaction was warmed slowly to 
room temperature and then stirred for 3 h. The reaction was cooled to 0 °C and diluted with 
ethyl acetate. A saturated solution of Rochelle’s salt was added to the reaction and the 
mixture was stirred for 1 h or until two separate layers formed. The organic layer was 
separated, washed with brine and dried with sodium sulfate before removal in vacuo. The 
residue was purified by column chromatography. 1H NMR (400 MHz, CDCl3) δ 7.74 – 7.67 
(m, 2H), 7.38 – 7.32 (m, 2H), 5.78 (s, 1H), 3.68 (s, 3H), 3.37 (s, 1H), 2.92 (s, 3H). 
N-(3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl)acetamide (59) 
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To aminopyrazole 34 (200 mg, 1.0 mmol) was added neat acetic anhydride (2 mL) and the 
mixture was stirred at 40 °C for 1 h. A white solid was observed to precipitate after 20-30. 
The mixture was quenched with water and extracted with ethyl acetate. Purification by 
column chromatography on silica gel with 2.5% methanol in dichloromethane gave the 
product as a white solid (170 mg, 70%).1H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 7.81 – 
7.73 (m, 2H), 7.48 – 7.40 (m, 2H), 6.67 (s, 1H), 3.72 (s, 3H); HRMS (ESI, negative mode) 
found 248.0587 ([M - H]-, requires 248.0596). 
 
3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazole (40) 
 
A solution of 3-(4-chlorophenyl)-5-methyl-1H-pyrazole (62, 40 mg, 0.26 mmol) was dissolved 
in of tetrahydrofuran (1.3 mL) and cooled to 0 °C with stirring. Sodium hydride (12 mg of 
60% in mineral oil, 0.29 mmol) was added and the reaction was stirred for 30 min. Methyl 
iodide (18 μL, 0.29 mmol) dissolved in tetrahydrofuran (0.6 mL) was added to the reaction 
mixture dropwise. The solution was stirred at rt for 17 h. Water was added and the reaction 
was extracted with ethyl acetate. The organic layer was washed with brine and dried with 
sodium sulfate before evaporation in vacuo. The residue was purified by column 
chromatography to give the product as a pale yellow solid (5 mg, 10%). 1H NMR (400 MHz, 
CDCl3) δ 7.76 – 7.67 (m, 2H), 7.44 – 7.32 (m, 2H), 6.32 (s, 1H), 3.85 (s, 3H), 2.33 (s, 3H). 
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4-(4-chlorophenyl)thiazol-2-amine (41) 
 
A solution of 2-bromo-1-(4-chlorophenyl)ethan-1-one (63, 234 mg, 1.0 mmol) and thiourea 
(76 mg, 1.0 mmol) in ethanol (4 mL) was stirred at 50 °C for 17 h. The reaction was cooled 
to room temperature. The mixture then added to water (10 mL) and extracted with 
dichloromethane (3 x 5 mL). The organic layer was filtered through a short silica column and 
the solvent removed in vacuo. The resulting product was a white powder and did not require 
further purification. (180 mg, 85%). 1H NMR (400 MHz, CDCl3) δ 8.24 (br s, 2H), 7.84 – 7.74 
(m, 2H), 7.58 – 7.51 (m, 2H), 7.54 (m, 2H), 7.24 (s, 1H); HRMS (ESI, positive mode) found 
211.0105 ([M + H]+, requires 211.0091). 
 
3-(4-chlorophenyl)-1-ethyl-1H-pyrazol-5-amine (42) 
 
A solution of 3-(4-chlorophenyl)-3-oxopropanenitrile (64, 50 mg, 0.28 mmol) and 
ethylhydrazine oxalate (42 mg, 0.28 mmol) in ethanol (3 mL) was heated under reflux (80 
deg) for 17 h. Ethyl acetate was added and the mixture was filtered through a short Celite 
plug. The organic layer was washed with water and then fried with sodium sulfate. The 
solvent was removed in vacuo and the residue was purified by column chromatography with 
2% methanol in dichloromethane as the eluent to give a pale yellow solid (yield 40%). 
1H NMR (400 MHz, CDCl3) δ 7.72 – 7.64 (m, 2H), 7.38 – 7.31 (m, 2H), 5.84 (s, 1H), 4.05 (q, 
J = 7.3 Hz, 2H),3.56 (br s, 2H), 1.45 (t, J = 7.2 Hz, 3H); HRMS (ESI, positive mode) found 
222.0797 ([M + H]+, requires 222.0793). 
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2,2-dimethyl-6-phenyl-4H-benzo[d][1,3]dioxine (67) 
 
A solution of 3:1 ratio of dimethoxyethane and water (5 mL) was degassed under nitrogen 
for 30 minutes. 6-bromo-2,2-dimethyl-4H-benzo[d][1,3]dioxine (66, 60 mg, 0.25 mmol), 
phenylboronic acid (33 mg, 0.27 mmol), and tetrakis(triphenylphosphine)palladium(0) (14 
mg, 0.013 mmol) to the solution. The mixture was heated under reflux under nitrogen for 4 h. 
The reaction was quenched by pouring into water. The aqueous mixture was extracted with 
ethyl acetate. The organic layer was washed with brine, dried with sodium sulfate and 
evaporated in vacuo. The residue was purified by column chromatography on the Biotage 
Isolera with 5% ethyl acetate in hexane giving the product as white crystals (25 mg, 40%). 
1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 7.6 Hz, 2H), 7.48 – 7.39 (m, 3H), 7.33 (t, J = 7.4 
Hz, 1H), 7.26 – 7.20 (m, 1H), 6.92 (d, J = 8.4 Hz, 1H), 4.94 (s, 2H), 1.61 (s, 6H). 
2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)phenol (68) 
 
A solution of 3:1 ratio of dimethoxyethane and water (5 mL) was degassed under nitrogen 
for 30 minutes. 6-bromo-2,2-dimethyl-4H-benzo[d][1,3]dioxine (66, 55 mg, 0.23 mmol), (2-
hydroxypheny)lboronic acid (48 mg, 0.34 mmol), and 
tetrakis(triphenylphosphine)palladium(0) (13 mg, 0.012 mmol) to the solution. The mixture 
was heated under reflux under nitrogen for 4 h. The reaction was quenched by pouring into 
water. The aqueous mixture was extracted with ethyl acetate. The organic layer was washed 
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with brine, dried with sodium sulfate and evaporated in vacuo. The residue was purified with 
the Biotage Isolera,with 100% dichloromethane giving the product as white crystals (12 mg, 
20%). 1H NMR (400 MHz, CO(CD3)2) δ 7.35 – 7.19 (m, 3H), 7.14 – 7.08 (m, 1H), 7.04 – 6.93 
(m, 3H), 4.92 (s, 2H), 1.62 (s, 6H). 
(2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)phenyl)methanol (69) 
 
Synthesis as for 67 (17 mg, 25%) 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.51 (m, 1H), 7.44 – 
7.32 (m, 2H), 7.33 – 7.23 (m, 2H), 7.20 (app dd, J = 8.3, 2.1 Hz, 1H), 7.13 – 7.00 (m, 1H), 
6.99 – 6.86 (m, 1H), 4.96 – 4.89 (m, 2H), 4.68 – 4.61 (m, 2H). 
3-(hydroxymethyl)-[1,1'-biphenyl]-4-ol (55) 
 
2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)phenol (67, 20 mg, 0.08 mmol) was dissolved in 
methanol (3 mL). Five drops of 5 M hydrochloric acid was added and the solution stirred at 
room temperature for 2 h. Water was added and the reaction was extracted with ethyl 
acetate. The organic layer was washed with brine, dried with sodium sulfate and evaporated 
in vacuo. The residue was purified by column chromatography with 25% ethyl acetate in 
hexane (7 mg, 40%); 1H NMR (400 MHz, acetone-d6) δ 8.58 (s, 1H, ArOH), 7.64 – 7.57 (m, 
3H), 7.47 – 7.38 (m, 3H), 7.34 – 7.24 (m, 1H), 6.92 (app d, J = 8.3 Hz, 1H), 4.83 (d, J = 5.4 
Hz, 2H), 4.50 (t, J = 5.5 Hz, 1H, CH2OH); HRMS (ESI, negative mode) found 199.0763 ([M - 
H]-, requires 199.0765). 
152 
 
3'-(hydroxymethyl)-[1,1'-biphenyl]-2,4'-diol (56) 
 
Synthesis as for 55. The residue was purified by column chromatography with 50% ethyl 
acetate in hexane. 1H NMR (400 MHz, acetone-d6) δ 8.25 (s, 1H), 8.13 (s, 1H), 7.49 (d, J = 
2.3 Hz, 1H), 7.38 (dd, J = 8.3, 2.3 Hz, 1H), 7.26 (dd, J = 7.7, 1.8 Hz, 1H), 7.19 – 7.09 (m, 
1H), 7.00 – 6.86 (m, 3H), 4.58 (s, 2H),2.93 (s, 1H, OH). 
(4'-hydroxy-[1,1'-biphenyl]-2,3'-diyl)dimethanol (57) 
 
Synthesis as for 55. 1H NMR (400 MHz, acetone-d6) δ 8.58 (br s, 1H), 7.64 – 7.52 (m, 
1H),7.36 – 7.06 (m, 5H), 6.89 – 6.80 (m, 1H), 4.89 (s, 1H), 4.79 (s, 1H), 4.57-4.54 (m, 2H), 
3.55 (br s, 2H); HRMS (ESI, negative mode) found 229.0860 ([M - H]-, requires 229.0870). 
7.1.3 Solution-Phase Synthesis of Ac-WF-NH2 
 
N,N'-Diisopropylcarbodiimide (DIC, 517 μL, 3.3 mmol), hydroxybenzotriazole (HOBt, 445 
mg, 3.3 mmol) was added to a solution of N-acetyl-L-tryptophan (815 mg, 3.3 mmol) in 
chloroform (10 mL). The mixture was stirred at rt for 15 min before it was added to a solution 
of L-phenylalanine (500 mg, 3.0 mmol) in chloroform (20 mL). The solution was stirred at rt 
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for 2 h and monitored by TLC. The reaction mixture was filtered and the residue was washed 
with dichloromethane. The solvent was removed in vacuo and the residue was purified by 
column chromatography with the Biotage Isolera (5% methanol in dichloromethane), yielding 
the product as a white solid (100 mg, 8%). 1H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 8.00 
(d, J = 7.7 Hz, 1H), 7.93 (d, J = 7.7 Hz, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.33-7.16 (m, 7H), 
7.12-6.93 (m, 4H), 4.60-4.37 (m, 2H),3.07-2.96 (m, 2H), 2.88-2.76 (m, 2H), 1.74 (s, 3H); 13C 
NMR (101 MHz, DMSO) δ 172.69, 171.36, 169.29, 137.85, 136.02, 129.19, 127.99, 127.28, 
126.20, 123.40, 120.79, 118.31, 118.16, 111.24, 110.21, 53.68, 53.52, 37.37, 27.33, 22.52; 
HRMS (ESI, positive mode) found 393.1926 ([M + H]+, requires 393.1921). 
7.1.4 Synthesis of Photocleavable Crosslinkers 
4,4'-(((2-nitro-1,4-phenylene)bis(ethane-1,1-diyl))bis(oxy))bis(4-oxobutanoic acid) (109)  
 
The diol 1,1'-(2-nitro-1,4-phenylene)bis(ethan-1-ol) 103 was synthesised according to the 
methods described by Piggott et al.273 103 (50 mg, 0.24 mmol) in dry dichloromethane was 
added succinyl anhydride (142 mg, 1.42 mmol), followed by triethylamine (234 μL, 
1.68 mmol) and 4-dimethylaminopyridine (DMAP, 3 mg, 0.02 mmol). The resulting mixture 
was stirred in the dark at room temperature for 16 h, or overnight. Water was added to the 
solution and the organic layer was washed with water at pH 3-4 to protonate the acid. The 
organic layer was washed with brine and dried with anhydrous sodium sulfate. The solvent 
was evaporated under reduced pressure at 40°C, leaving a sticky residue that as dissolved 
in 50 % methanol in water and purified by LCMS using a 50-98 % methanol gradient over 18 
min. The solvent was removed from the fractions using a GeneVac. The fractions were 
combined by dissolving the residue in pure methanol and combining them before being 
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evaporated off by a stream of air, giving the produce as a clear viscous oil that was used 
immediately in the next step. Mixture of diasteromers.1H NMR (400 MHz, acetone-d6) δ 8.01-
7.87 (1H, m), 7.69-7.60 (2H, m), 6.38-5.74 (2H, m), 2.89-2.38 (8H, m), 1.71-1.45 (6H, m); 
LCMS Rt 4.4 min, m/z 434.1 (ESI+, [m + Na]+), 410.2 (ESI-, [m-1]-). 
Bis(2,5-dioxopyrrolidin-1-yl) O,O'-((2-nitro-1,4-phenylene)bis(ethane-1,1-diyl)) 
disuccinate (NitroXL) 
 
Dry dichloromethane (30 mL) was added to diacid 109 (estimated 100 mg, 0.24 mmol). N-
hydroxysuccinimide (134 mg 1.16 mmol) was added to the solution, followed by 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl, 234 mg, 1.22 mmol). The 
solution was stirred at room temperature in the dark for 17 h. The reaction was diluted with 
more dichloromethane (10 mL) and the organic layer was washed with water and brine and 
dried with anhydrous sodium sulfate. The solvent was evaporated at 40 °C under reduced 
pressure. The residue was dissolved in 50% acetonitrile in water and purified by LCMS using 
a 50-98% acetonitrile gradient over 18 min. The fractions were combined by dissolving the 
residue in pure methanol and combining them before being evaporated off in the Genevac 
(66 mg, 58%). 1H NMR (400 MHz, CDCl3) δ 7.95 (1H, m), 7.62 (2H, m), 6.36 (1H, m), 5.95 
(1H, m), 3.05-2.6 (16H, m), 1.67 (3H, m), 1.57 (3H, m’); 13C NMR (101 MHz, CDCl3) δ 
170.18, 169.88, 169.05, 168.99, 167.76, 147.90, 142.53, 137.09, 131.67, 131.59, 127.85, 
127.77, 122.32, 122.09, 71.93, 69.06, 68.95, 29.06, 28.96, 26.40, 26.32, 25.71, 21.95; 
LCMS Rt 4.4 min, m/z found 628.3 (ESI+, [m + Na]+); HRMS (ESI, positive mode) found 
606.1563 ([M + H] +, requires 606.1566).
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7.2 Solid Phase Peptide Synthesis 
7.2.1 General Peptide Synthesis 
All peptide synthesis reagents and solvents were purchased from Sigma-Aldrich, Merck 
Chemicals or National Diagnostics UK and used without further purification. Synthesis was 
carried out in peptide synthesis grade N-methylpyrrolidine (NMP) and dimethylformamide 
(DMF). Peptides were synthesised by automated solid phase peptide synthesis with a 
ResPep SL apparatus (Intavis, Germany). 
All peptides were synthesised using Tentagel® S RAM resin (substitution: 0.3 mmol/g).  
The resin (20 μmol per well) was swelled in DMF for 30 min before deprotection of the N-
terminal Fmoc protecting group with 20% piperidine (v/v) in DMF for 10 min (400 µL; 3 
repeats). 4.38 equivalents of the incoming N-Fmoc protected amino acid (as a 0.5 M solution 
in DMF; 87.5 µmol) was activated in a separate vial with HBTU (0.5 M solution in DMF; 85 
μmol, 4.25 eq), N-methyl pyrrolidinone (NMP) (5 μL) and N-methyl-morpholine (4 M; 52 μL; 
208 μmol, 10.4 eq). The activated amino acid was added to the resin and allowed to couple 
for 35 min (repeated twice). The peptide was capped with a solution of 5% (v/v) acetic 
anhydride in NMP (400 μL). The resin was washed with dichloromethane (2x) and DMF (6x) 
and the cycle of deprotection, DMF wash, amino acid couplings, capping and DMF wash 
was repeated for each amino acid in the peptide sequence. After the final amino acid 
coupling, the N-terminal Fmoc was cleaved using 20% piperidine (v/v) in DMF (400 μL, 3× 
10 min).  
For any modifications to the resin bound crude peptides after synthesis, resin was 
transferred to a fritted 5 mL syringe, washed (DMF 3 × 1 mL, DCM 3 × 1 mL, DMF 3 × 1 mL) 
and swelled in DMF, for a minimum of 1 h with shaking, before subjection to the required 
conditions. 
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7.2.1.1 Deprotection, cleavage and purification of peptides 
The resin was placed in a 5 mL syringe equipped with a polyethylene frit and a syringe cap. 
The resin bound peptide was then washed with DMF (3×), dichloromethane (3×), MeOH (3×) 
and Et2O (3×) before being dried in a vacuum desiccator overnight. The peptide was 
deprotected and cleaved from the resin using a mixture of 95% TFA, 2.5% water, 2.5% TIS. 
6 mL of this mixture was added to the resin-bound peptide and it was shaken at room 
temperature for 3 h. The liquid was filtered and the resin washed with 1 mL of deprotection 
mixture. To the solution was added 10 mL of ice-cold tert-diethyl ether to precipitate the 
peptide. The mixture was centrifuged (4000 rpm, 4 °C, 10 min) and the solid washed with 10 
mL diethyl ether two more times. The peptide was then placed in a vacuum desiccator 
overnight before being purified by semi-preparative HPLC. 
7.2.1.2 Lactam Bridged Peptides 
Peptides were synthesized by automated SPPS as in the procedure above up until just 
before the final Fmoc-deprotection of the N-terminal amino acid. Fmoc-Lys(Mmt) and Fmoc 
Asp(Opp) in were treated as unnatural amino acids and were preactivated with HATU: HATU 
(3 eq, 60 umol) and the amino acid (3 eq, 70 umol) and N-methyl-morpholine (6 eq, 120 
umol) were mixed in DMF in a separate vial. The activated amino acid was added to the 
resin and allowed to couple for 35 min (repeated twice). The resin was transferred to a fritted 
syringe and washed with  DMF (3 mL x3) and dichloromethane (3 mL x 3). 1 mL of 3% TFA 
in dichloromethane was added and the syringe shaken for 1 min. This was repeated five 
times. The resin was washed with dichloromethane (3 mL x 3) and DMF (3 mL x3). DIC (5 
eq, 0.1 mmol) and HOBt (5 eq, 0.1 mmol) were dissolved in 2 mL of DMF and was added to 
the resin to couple the Lys and Asp side-chains. The resin was incubated at room 
temperature with shaking for 2 h. The coupling procedure repeated, before washing the resin 
was washed with DMF (3 mL x 3). Fmoc deprotection and N-terminal acetylation were 
performed using standard procedures. The chloranil test 98 was used to confirm coupling and 
deprotection, and analytical LCMS was used to monitor side-chain cyclisation.  
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7.2.1.3 N-terminal coupling to FITC 
FITC (100 μmol, 5 eq.) was dissolved in 0.5 mL DMF and DIPEA (100 μmol, 5 eq.). HATU 
(98 μmol, 4.9 eq.) was added, and the mixture agitated for 5 min. After this time the 
preactivated FITC mixture was added to a slurry of resin bound peptide in 0.5 mL DMF and 
DIPEA (20 μmol, 1 eq.) and shaken vigorously for 1.5 h. The solution was removed by 
suction, the resin washed and the process was repeated. 
7.2.2 Peptide Characterisation 
Ref Sequence MW (mono) Rt (min) ES+ ES- Yield (%) 
69 FW 392.174 7.2 415.5 (m+23) 391.4 32 
70 wF 392.174 5.9 415.5 (m+23) 391.5 32 
71 Fluorescein-WF 708.483 5.9, 6.4* 709.6 707.5 8 
72 QWF 520.232 4.8 
543.5 
(m+23) 519.5 26 
73 GWF 449.195 8.1 472.6 (m+23) 448.6 37 
74 H-WAF 422.184 3.0 422.5 420.4 20 
75 H-WFY 513.227 5.9 514.5 512.5 39 
76 WFYE 684.280 4.0 707.6 (m+23) 683.5 24 
77 GQWFYE 869.36 5.1 892.7 (m+23) 868.6 28 
78 WFYK 683.332 6.5 684.7 682.6 22 
79 QWFYE 812.338 5.2 835.6 (m+23) 811.6 23 
80 WFYEAK 883.412 2.0 884.9 882.8 14 
81 WFYQAK 882.428 5.4 883.8 (m+1) 881.7 30 
82 WFYQHK 948.450 4.0 949.8 947.7 23 
83 WFYEAKA 954.449 5.7 955.9 953.8 8 
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Table 9 LCMS characterization of peptides. Retention times are from preparative runs. All proteins were 
prepared with a 50-95% MeOH/H2O gradient. Masses for ES+ and ES- are m+1 and m-1 (plus and minus a 
proton) respectively unless specified.  
7.3 Biophysical Assay Methods  
7.3.1 Differential Scanning Fluorimetry 
All samples for the DSF experiments contained 2 µM protein, 2 mM GNP, 150 mM NaCl, 5 
mM MgCl2, 20 mM HEPES at pH 7.4 and 1:1000 dilution of SYPROTM orange. Compounds 
were tested at 2 mM and the maximum DMSO concentration was 2% v/v. The well volume 
was 20 μL. 
All DSF experiments were performed on a Mx3005P qPCR System. Experiments were 
recorded on a stepwise increment of temperature from 25-96°C in 71 cycles. SYPROTM was 
used as the preferred fluorescent dye at an excitation and emission wavelength of 492 nm 
and 610 nm respectively. Results obtained from these experiments were extracted into Excel 
files using the MxPro software. The melting point of the protein, Tm, in each condition is 
defined as the 50% point of each curve and obtained by fitting the data using a sigmoidal 
equation.257 
7.3.2 WaterLOGSY NMR 
All waterLOGSY NMR experiments were recorded at 298K on a 600 MHz or 800 MHz 
Bruker AVANCE II spectrometer equipped with triple resonance inverse cryoprobes with a 
single axis z gradient. All experiments were processed and visualized using the Bruker 
TopSpin3.5 program. All protein-ligand interaction samples were made with a buffer 
containing 150 mM NaCl, 5 mM MgCl2, 20 mM HEPES at pH 7.4 ,10% D2O and 4% DMSO.  
84 YY 385.153 5.8 
408.6 
(m+23) 384.4 30 
85 KQWFD (lactam) 745.825 8.0 746.5 744.4 27 
86 KRWFD (lactam) 773.885 6.2 774.7 772.6 22 
87 KWFRD (lactam) 773.885 5.6 774.7 772.6 34 
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All samples for WaterLOGSY experiments were prepared in buffer containing 150 mM NaCl, 
5 mM MgCl2, 20 mM HEPES at pH 7.4 and 10% v/v D2O at 298K otherwise indicated. The 
ligand/protein ratio was kept at 100/1, with 1 mM ligand concentration and 10 µM protein 
concentration. The ePHOGSY pulse sequence with 128 scans was used for WaterLOGSY 
experiments. Selective water saturation was achieved using a 7.5 ms 180° selective 
Gaussian pulse. Solvent suppression was accomplished using two 2.5 ms 10% truncated 
Gaussian pulses. The relaxation and mixing times were 2.5 and 1.2 s, respectively. 
7.3.3 Surface Plasmon Resonance (SPR) 
SPR experiments were conducted by Mostafa Jamshidina, Charlotte Sutherell and Martin 
Rowlands (ICR). More information may be obtained from M. Jamshidiha’s PhD thesis. All 
SPR assays were performed on a T100 Biacore instrument with a T200 upgrade from GE 
Health Care and analyzed using the Biacore T200 evaluation software. All experiments were 
done using filtered and degassed buffer containing 10 mM HEPES, 150 mM NaCl, 10 mM 
MgCl2, 1 mM TCEP and 0.05% v/v Surfactant P20. For assays involving chemical 
molecules, fresh DMSO was used to adjust the organic solvent’s content to 5% DMSO. All 
experiments were carried out by immobilizing biotinylated Rab27a on Neutravidin-coated 
CM5 chips. All data analysis was carried out by BiacoreTM evaluation software. 
7.4 Biological and Biochemical Methods 
7.4.1 General 
Ultrapure water was obtained using a MilliQ® Millipore purification system. Absorbance in 
96-well plates was measured using an EnVision 2104 Multilabel Reader (PerkinElmer). 
Protein concentration was determined using the BioRad DC Protein Assay following the 
manufacturer’s instructions, measuring absorbance at 750 nm, using BSA as a protein 
standard. All biological and chemical reagents were purchased from Sigma-Aldrich and 
Invitrogen and used without further purification. All crosslinkers were prepared as DMSO 
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stocks unless otherwise stated, stored at -20 ˚C and thawed on the day of use. All solutions 
and reagents for proteomics were freshly prepared on the day of sample preparation.  
7.4.2 Cell Culture 
MDA-MB-231 cells were grown in low glucose Dulbecco's Modified Eagle's medium (DMEM) 
with 5% foetal bovine serum (FBS), incubated at 10% CO2 and 37 °C. HeLa cells were 
grown in low glucose Dulbecco's Modified Eagle's medium (DMEM) with 10% foetal bovine 
serum (FBS), incubated at 10% CO2 and 37 °C.  
7.4.3 Cell Lysis 
Cells were washed with PBS x 3. 700 μL of lysis buffer was added per 10 cm plate. The lysis 
buffer used for all experiments described in the thesis comprises the following: 
1% Triton 
10% glycerol 
50 mM HEPES 
100 mM NaCl 
5 mM MgCl2 
This solution will be referred to as Lysis Buffer. 
The cells were scraped from the plate with a cell scraper and homogenised by pipetting up 
and down with a 1 mL tip. The lysate mixture was transferred to an Eppendorf and left on ice 
for 10 minutes before centrifuging at maximum speed for 10 minutes to separate out the 
pellet. 
7.4.4 Plasmids for TST-tagged proteins 
A plasmid of N-terminally tagged TST-Rab27a was bought from InVitrogen; please see 
Appendix D for the plasmid map and nucleotide sequences. The plasmid was dissolved as 
per the manufacturer’s instructions. 
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Plasmids were transformed into competent DH5α -alpha cells (Invitrogen, MAX Efficiency™ 
DH5α™ Competent Cells) following standard protocols. The bacteria were amplified in LB 
agar (Merck Millipore) inoculated with ampicillin (100 μg/mL). 
A single colony was selected for amplification in LB broth (Merk Millipore) and maxiprep was 
performed with a HiSpeed® Plasmid Maxi Kit (Qiagen) following the manufacturer’s 
instructions. Plasmid concentrations were tested with a NanoDrop 1000 Spectrophotometer 
(ThermoScientific). 
7.4.5 Transfection Protocol 
HeLa cells were grown in 10 cm plates to a confluency of 80-90%.  The old media was 
aspirated and replaced with 6 mL of fresh media per plate. 16.8 μL of Lipofectamine 2000 
(ThermoFisher) was added to 310 μL of Opti-MEMTM Reduced Serum Media (ThermoFisher) 
in a plastic tube, labelled A. A specified amount of plasmid was added to 310 μL of OptiMEM 
in another tube, labelled B. A and B were mixed together and incubated at room temperature 
for 10 min.  
The following quantities of DNA plasmid were used (per 10 cm plate): 
TST-Rab27a - 1 ug 
TST-KRas - 6 ug 
TST-PDE6d - 6 ug 
After 10 min, the mixture was then added to the plate dropwise and incubated at 10% CO2 
and 37 ° C for 16 h. The media was aspirated and replaced with 6 mL of fresh media and 
incubated at 37 ° C for another 6 h. The media was aspirated and the cells washed 3 times 
with sterile PBS. The cells were lysed with 0.7 mL of Lysis Buffer per plate. The lysed 
mixture was incubated in ice for 10 min before centrifuging at full speed for 10 min to 
separate the pellet. The resulting clear lysate was used directly in experiments or aliquotted 
and stored at -80 °C. 
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All transfections were tested by Western Blot by blotting with Streptactin-HRP and against 
the protein itself if a reliable antibody was available. 
7.5 Gel and Western Blot experiments 
7.5.1 Gel Electrophoresis 
Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) using hand-cast gels with the Mini PROTEAN Tetra Cell system by Bio-Rad. 
Bis-tris gels were cast in 1.0 mm glass plates with 12% and 4% acrylamide for the resolving 
and stacking gels respectively using the recipes given in Table 10 
Component Volume (mL) for 10 mL 
resolving gel (12%) 
Volume (mL) for 2.5 
mL stacking gel (4%) 
30 % acrylamide/bis-acrylamide 4.0 0.33 
1.25 M Bis-tris (pH 6.7) 2.9 0.71 
H2O (MilliQ) 3.0 1.5 
10 % w/v ammonium persulfate 0.1 0.0125 
N,N,N’N’-
Tetramethylethylenediamine 4 μL 2 μL 
Table 10 Components for hand-cast bis-tris gels with 12% resolving and 4% stacking gels. The recipe is 
enough for two gels. 
Samples were mixed in a 3:1 ratio of 4 × NuPAGE® LDS sample loading buffer containing 
20% mercaptoethanol and boiled for 10 min at 95 °C before loading onto the gel.  
Precision Plus Protein All Blue Standards (Bio-Rad) was used as the molecular weight 
ladder. Gels were run using the Mini-PROTEAN Tetra Cell system (Bio-Rad) with MOPS 
buffer (Invitrogen) and a PowerPac™ Basic Power Supply (Bio-Rad). Gels were run at 85 
mV for 15 min and 180 mV for 45-50 min. 
Silver staining was achieved by following the manufacturer’s instructions in the standard 
non-heating protocol with the Novex™ SilverQuest™ Silver Staining Kit (Invitrogen™ 
LC6070).  
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Coomassie staining was achieved with an in-house stain (50 g ammonium sulfate and 59 mL 
phosphoric acid) were dissolved in 200 mL water. The solution was topped up with more 
water up to 400 mL. 1.2 g of Brilliant Blue G (50% dye content) was added. Finally, 100 mL 
of methanol was added and the mixture stirred until all solids were dissolved. The solution 
was stored in the dark at room temperature). The SDS-PAGE gel was immersed in the 
Coomassie solution overnight. The Coomassie solution was decanted and the gel destained 
in water for a further 24 h before imaging with the ImageQuant LAS4000 (GE Healthcare Life 
Sciences). 
7.5.2 Western Blotting 
After electrophoresis, proteins were transferred from non-fixed gels to nitrocellulose 
membranes (GE Healthcare Life Sciences, AmershamTM Protran® Premium 0.45 μM NC) by 
wet transfer using a Mini Trans-Blot® Cell (Bio-Rad) according to the manufacturer’s 
guidelines. After transfer, membranes were blocked in 5% (w/v) dried skimmed milk or 1% 
BSA in TBS plus 0.1% (v/v) Tween-20 (TBST) for 2 h at room temperature and incubated 
with the appropriate primary antibody in blocking solution with gentle agitation overnight at 4 
˚C with anti-Rab27a (Santa Cruz Biotechnology (discontinued), C-20, sc-22990, goat 
polyclonal, dilution 1:100), anti -PDE6d (Santa Cruz Biotechnology, A-8, sc-376724, mouse 
monoclonal IgG, dilution 1:100), anti-HSP90 (Santa Cruz Biotechnology, 4F10, sc-69703, 
mouse monoclonal, dilution 1:2000), or anti-tubulin (Santa Cruz Biotechnology, TU-02, sc-
8035, mouse monoclonal, dilution 1:500). 
Membranes were then washed 3 × TBST before being incubated with the appropriate 
secondary antibody in blocking solution with gentle agitation for 2 h at room temperature 
secondary antibody or horseradish peroxidase (HRP) conjugate: goat anti-rabbit IgG-HRP 
(Invitrogen, dilution 1:5,000), goat anti-mouse IgG-HRP (BD Pharminigen, dilution 1:10,000), 
rabbit anti-goat IgG-HRP (Santa Cruz Biotechnology, sc-2922, dilution 1:10,000), 
NeutrAvidin™-HRP (ThermoFisher Scientific, A2664, dilution 1:500) or StrepTactin-HRP 
(Bio-Rad Precision Protein™ StrepTactin-HRP Conjugate, #1610381, dilution 1:5000). 
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Membranes were then washed with 3 × TBST before being developed with LuminataTM 
Crescendo Western HRP Substrate (Merck Millipore, cat. no. WBLUR0100) according to the 
supplier’s protocol. The chemiluminescent signal on the membrane was visualised using the 
ImageQuant LAS4000 (GE Healthcare Life Sciences).  
7.5.3 Crosslinking Protocol 
10 μL of DMSO was added to 100 μL of 1 μL recombinant protein or 1 mg/ml lysate in Lysis 
Buffer.1 μL of 100 mM of NitroXL or DSS in DMSO or neat DMSO was added and the 
solution was mixed by inverting the tube several times to homogenise the mixture. The 
samples were wrapped in foil and incubated at room temperature on a rotator for 1 h. The 
reaction was quenched by adding 100 mM glycine (final concentration) and left for an 
additional 20 minutes. Samples to be irradiated were pipetted into a 96 well plate. For the 
experiments described in Chapter 4, the plate was placed under the UV lamp in a TLC 
visualisation box for 1 h 30 min. All other experiments used a SpectrolinkerTM XL-1500 UV 
Crosslinker (Spectroline) with 352 nm UV lamps (Sankyo Denki, Blacklight F15T8BL, 
FL15BL, 352 nm, 15W). Samples were irradiated for 1 h or a specified time before 
separation by SDS-PAGE. The gel was visualised by silver staining or Western Blot. 
7.6 Proteomics 
7.6.1 Sample Preparation Protocol (Sets A, B and C) 
HeLa cells were cultured until 90% confluent. The cells were transfected with TST-Rab27a 
plasmid with Lipofectamine 2000 as described above. The cells were lysed and their 
concentration adjust to 1 mg/mL. The success of the transfection was validated by Western 
Blot with Streptactin-HRP (Bio-Rad Precision Protein™ StrepTactin-HRP Conjugate, 
#1610381, dilution 1:5000) and α-Rab27a antibody (Santa Cruz Biotechnology, C-20, sc-
22990, goat polyclonal (discontinued), dilution 1:100). 
100 μL the 1 mg/mL lysate was aliquotted into a plastic tube for each sample. 10 μL of 
DMSO was added to each sample, and the tubes were inverted or gently until it became 
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homogenous.1 μL of 100 mM NitroXL or DSS in DMSO was added to all the samples in sets 
B and C and mixed by pumping gently with a pipette. Some NitroXL was seen to precipitate, 
but the solution became clear with time. The tubes were wrapped with foil and incubated on 
a rotator for 1 h at room temperature. Then, all samples were quenched with 50 mM glycine 
(final concentration) and rotated for a further 20 minutes. 5 μL of a bead suspension of 
MagStrep "type3" XT beads were added to into nine fresh Eppendorf® LoBind 
microcentrifuge tubes and washed with 3 x 50 μL of Lysis Buffer.  
Samples requiring irradiation were transferred into individual wells in a clear 96-well plate. 
The plate was placed directly on top of ice and positioned 1-3 cm below the bank of UV 
lights in a SpectrolinkerTM XL-1500 UV Crosslinker (Spectroline) with 352 nm UV lamps 
(Sankyo Denki, Blacklight F15T8BL, FL15BL, 352 nm, 15W). The samples were irradiated at 
365 nm for 30 minutes at full power. Samples from set A were left in the dark at rt for the 
same time. Each sample was transferred to a tube the washed MagStrep beads. They were 
cover with foil and incubated on a rotator at 4 °C for 2 hours or overnight. 
The MagStrep beads were pelleted using a magnetic tube rack. The supernatants were 
transferred into fresh LoBind tubes and kept frozen at -80 deg. The remaining beads were 
washed with 3 x 100 μL of Lysis Buffer, followed by 3 x 100 μL of AMBIC. (Because the 
TST/Streptactin interaction is much weaker than the biotin/neutravidin interaction, harsher 
detergents containing high levels of SDS must be avoided).  
All cysteines were reduced and alkylated by simultaneously adding 5 mM TCEP and 15 mM 
chloroacetamide (final concentrations) and incubating at rt in the dark for 45 min. For trypsin 
digestion, the beads were washed with 3 x 100 μL HEPES pH 8. For chymotrypsin, the 
beads were washed with 3 x 100 μL of 100mM Tris-HCl and 10mM CaCl2. After the final 
wash, add a fresh 50 μL of of fresh enzyme buffer was added. Trypsin (Sequencing Grade 
Modified Trypsin 
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(Promega) or chymotrypsin (Promega) was added at a concentration of 0.1 μg of trypsin per 
100 μg of protein and the samples were incubated at 37 °C overnight with gentle agitation. 
Samples were then centrifuged and the supernatant transferred to a new tube.  
The beads were washed with 0.1% formic acid in water and centrifuged and this supernatant 
added to the same tube. The peptide solutions were then stage-tipped according to a 
published protocol 279. Briefly, stage tips were prepared by fitting C18 Empore disks (SDC-
XC, 3M) into 200 μL pipette tips. The stage tip was initially washed by centrifuging (2000 × g, 
2 min) with MeOH (150 μL) followed by water (150 μL). Peptide solutions were then added 
to the top of the stage tip and centrifuged (2000 × g, 2 min) to load the peptides onto the 
C18 sorbent followed by desalting by washing with water (150 μL). Peptides were eluted 
with 79% acetonitrile in water and dried with speed-vac-assisted solvent removal. Dried 
samples were stored at -80 °C if not required for immediate analysis. Peptides were then re-
dissolved in 0.5% TFA, 2% acetonitrile in water and transferred to LC-MS sample vials for 
LC-MS/MS analysis. 
7.6.2 LCMS/MS Runs 
7.6.3 The Q-Exactive 
The proteomic experiments in this thesis were performed with a Q-Exactive mass 
spectrometer. Figure 79 depicts its main features. Each sample undergoes a 90-minute 
HPLC run with a hydrophobic C18 column. The eluted sample enters the mass spectrometer 
via the NanoSpray Source at A. The ion stream is directed to the quadrupole mass filter (B), 
which selects precursor ions based on their mass and sends them through to the (HCD) 
collision cell (C) where collision-induced dissociation (CID) occurs. The fragmented ions are 
gathered in the C-trap (D) before they are progress to the Orbitrap mass analyser (E) where 
the signal output undergoes Fourier transform to yield high resolution spectra280. 
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Figure 79 Diagram of the Q-Exactive, a quadrupole orbitrap mass spectrometer. Adapted from a diagram by 
Michalski et al. 280. A: ionization at NanoSpray Source; B: mass selection by quadrupole mass filter; C: 
fragmentation in the HCD cell; D: C-Trap; E: Orbitrap mass analyser. 
7.6.4 Proteomics Facility, Imperial College London  
The analysis was performed using reverse phase Acclaim PepMap RSLC column 50 cm × 
75 μm inner diameter (Thermo Fisher Scientific) using a 2 h acetonitrile gradient in 0.1 % 
formic acid at a flow rate of 250 nL/min. Easy nLC-1000 was coupled to Q Exactive™ Hybrid 
Quadrupole-Orbitrap™ Mass Spectrometer via an easy-spray source (all Thermo Fisher 
Scientific). The Q Exactive was operated in data-dependent mode with survey scans 
acquired at a resolution of 75 000 at m/z 200 (transient time 256 ms). Up to the top 10 most 
abundant isotope patterns with charge +2 from the survey scan were selected with an 
isolation window of 3.0 m/z and fragmented by HCD with normalized collision energies of 25 
W. The maximum ion injection times for the survey scan and the MS/MS scans (acquired 
with a resolution of 17,500 at m/z 200) were 250 and 80 ms, respectively. The ion target 
value for MS was set to 106 and for MS/MS to 105. 
7.6.5 Data Analysis 
7.6.5.1 Peptide Modifications with PEAKS 
The search for modified peptides was processed using PEAKS Studio 8.5, which as a 
default performs de novo peptide sequencing prior to database search. The software also 
A 
B
E 
C 
D 
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searches for common PTMs (PEAKS PTM) and amino acid mutations (SPIDER). Peptides 
identified from the MS/MS spectra were searched against the human UniProt database 
(2015) with the Rab27a sequence replaced with TST-Rab27a as detailed in Appendix C (WZ 
UniProt + TST-Rab27a). Digestion: Trypsin and chymotrypsin-FLWY (specific, up to two 
missed cleavages allowed) were selected for database searches. The number of non-
specific cleavages was set to none. Modifications: Cysteine carbamidomethylation (+57.02 
Da) was selected as a fixed modification. Variable modifications included Cleaved1: 
(+275.08 Da), MonoGlycine: (+450.13 Da), MonoOH: (+393.11 Da) and SuccOH (+100.02 
Da) and were specified to occur on K, C, S, T and Y. The maximum number of PTMs per 
peptide was set to three. Mass error tolerance: The maximum mass error was set to 5 ppm 
for precursor (parent) ions and 0.01 Da for product (fragment) ions. Identification: The false 
discovery rate was set to 0.01 for peptides and a minimum of 2 unique peptides per protein 
was required. Modifications required an A-score of ≥ 20, de novo ALC score required ≥ 80%, 
and peptide- and protein-10lgP required ≥ 38.1 and ≥ 20 respectively. Identified peptides 
from one gene were grouped together into protein groups. Data were analysed using 
Microsoft Office Excel 2016. 
7.6.5.2 Label Free Quantification 
The raw data file obtained from each LC-MS/MS acquisition was directly processed with the 
software MaxQuant 1.5.8.3, with the peptides being identified from the MS/MS spectra 
searched against the WZ UniProt + TST-Rab27a database using the Andromeda search 
engine. Cysteine carbamidomethylation (+57.021 Da) was set as a fixed modification and 
methionine oxidation (+15.995 Da) as well as the crosslinker-derived adducts (Chapter 5), 
were set as variable modifications for the search. LFQ with ‘match between runs’ was 
selected. The minimum length of a peptide was set to 7 residues, the maximum amount of 
missed trypsin cleavages was set to 2, the maximum number of modifications per peptide 
was set to 5 and the maximum charge of a peptide as +7. Peptide and protein FDRs were 
set to 0.01. Quantification of peptides was allowed for ‘razor + unique’ peptides carrying no 
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modifications as well as methionine oxidation or carbamidomethylation (razor peptides are 
uniquely assigned to protein groups and not to individual proteins). All other parameters 
were used as pre-set by the software. 
Data outputted from MaxQuant was analysed using Perseus 1.6.0.7. Protein identifications 
by MaxQuant based on ‘contaminants’, ‘only identified by site’ and ‘reverse’ were filtered out. 
Further filtering only allowed identification of a protein target if it contained at least two 
‘razor+unique peptides’ in both biological duplicates for at least one experimental condition 
(sample set). Two-sample t-tests (S0 = 1, FDR = 0.01) were carried out between relevant 
sample sets.  LFQ intensities were logarithmised to base 2 (function log2(x)). 
LFQ was performed in MaxQuant 1.5.8.3 using the built-in LFQ algorithm. 208 The output 
datasets were analyzed with Perseus 1.6.0.7. The label-free approach chosen was based on 
intensities of proteins calculated by MaxQuant from peak intensities and based on the ion 
currents carried by several peptides whose sequences match a specific protein to provide an 
approximation of abundance. 
Triplicates were grouped together for each type of treatment (sets A, B, C). For each two-
sample test, at least two valid values out of three replicates was required for at least one 
sample set. For statistical analysis, missing values were imputed by a random number 
drawn from a normal distribution that mimics low abundance measurements close to the 
detection limit (imputation criteria: width 0.3 and down shift 1.8). This allows for proteins that 
were not detected in one of the sample sets to be included in statistical tests. Statistical 
tests: Two-sample, both-sided Student’s T-tests were performed between selected sample 
sets. S0 and was set to 1 to separate outliers from the background distribution. The p-value 
was set to 0.05 as the significance threshold. The difference between the means of 
logarithmised LFQ intensities of proteins in the two sets (x axis) was plotted against -log10p 
(y axis) values to obtain volcano plots showing the relative distribution of proteins in two 
experimental conditions.
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9 Appendices 
Appendix A: DSF Spectra 
In quadruplicates unless specified otherwise. Graphs show normalised results except 62. 
Rab27a Only 
 
Buffer only has eight replicates. 
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Top Fragment Hits from DSF Screen 
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Synthesised Analogues  
 
 
  
41
0
0.2
0.4
0.6
0.8
1
0 10 20 30 40 50 60 70 80 90
R
e
la
tiv
e
 
flu
o
re
sc
e
n
ce
Temperature [°C]
42
0
0.2
0.4
0.6
0.8
1
0 10 20 30 40 50 60 70 80 90
R
e
la
tiv
e
 
flu
o
re
sc
e
n
ce
Temperature [°C]
58 62
1900
2000
2100
2200
2300
2400
2500
0 10 20 30 40 50 60 70 80 90 100
Ff
lu
o
re
sc
e
n
ce
 
[A
.
U.
]
Temperature [°C]
59
0
0.2
0.4
0.6
0.8
1
0 10 20 30 40 50 60 70 80 90
R
e
la
tiv
e
 
flu
o
re
sc
e
n
ce
Temperature [°C]
0
0.2
0.4
0.6
0.8
1
0 10 20 30 40 50 60 70 80 90
R
e
la
tiv
e
 
flu
o
re
sc
e
n
ce
Temperature [°C]
WF
0
0.2
0.4
0.6
0.8
1
0 10 20 30 40 50 60 70 80 90
Re
la
tiv
e
 
flu
o
re
sc
e
n
ce
Temperature [°C]
188 
 
Numerical Data 
Compound Tm 1 Tm 2 Tm 3 Tm 4 Avg Tm ΔTm* 
Buffer only 
60.2 60.5 60.3 60.1 
60.5 -0.2 
60.8 60.3 61.0 61.1 
2% DMSO 60.8 60.6 60.9 60.5 60.7 0.0 
32 60.7 59.7 60.3 60.4 60.3 -0.4 
34 60.4 60.4 60.4 60.6 60.4 -0.2 
35 N/A N/A 60.3 60.4 60.4 -0.3 
36 N/A N/A 60.3 60.4 60.4 -0.3 
37 60.6 59.9 60.4 60.5 60.3 -0.4 
41 N/A N/A N/A N/A N/A N/A 
42 60.6 60.6 60.1 60.4 60.4 -0.3 
58 60.5 60.5 63.0 60.3 61.1 0.4 
59 60.5 60.5 60.4 60.3 60.4 -0.3 
62 N/A N/A N/A N/A N/A N/A 
WF 60.7 60.5 60.7 60.6 60.6 -0.1 
 
Melting point values could not be calculated where the melting point curves did not conform 
to the expected sigmoidal shape. 
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Appendix B: WaterLOGSY Spectra 
Green – 1D (scaled down x 0.1) 
Blue – waterLOGSY with 1 mM ligand 
Red – waterLOGSY with 1 mM ligand and 10 μM Rab27a 
 
Ref Sequence waterLOGSY overlay 
- WF 
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with WT-Rab27a-Slp1 complex, 800 MHz (above) 
34 Pyrazole 
Fragment 
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69 FW 
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71 Fluorescein
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78 QWFYE 
 
79 GQWFYE 
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80 WFYEAK 
 
81 WFYQAK 
 
197 
 
82 WFYQHK 
 
83 WFYEAKA 
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Appendix C: Protein Sequences 
Wild Type Rab27a 
SDGDYDYLIKFLALGDSGVGKTSVLYQYTDGKFNSKFITTVGIDFREKRVVYRASGPDGATG
RGQRIHLQLWDTAGQERFRSLTTAFFRDAMGFLLLFDLTNEQSFLNVRNWISQLQMHAYC
ENPDIVLCGNKSDLEDQRVVKEEEAIALAEKYGIPYFETSAANGTNISQAIEMLLDLIMKRME
RCVDKSWIPEGVVRSNGHASTDQLSEEKEKGACGC 
Recombinant Rab27a 
SDGDYDYLIKFLALGDSGVGKTSVLYQYTDGKFNSKFITTVGIDFREKRVVYRASGPDGATG
RGQRIHLQLWDTAGQERFRSLTTAFFRDAMGFLLLFDLTNEQSFLNVRNWISQLQMHAYC
ENPDIVLCGNKSDLEDQRVVKEEEAIALAEKYGIPYFETSAANGTNISQAIEMLLDLIMKRME
RCVDKS 
Biotin-Rab27a 
GLNDIFEAQKIEWHEGSGSGSGMSDGDYDYLIKFLALGDSGVGKTSVLYQYTDGKFNSKFI
TTVGIDFREKRVVYRASGPDGATGRGQRIHLQLWDTAGQERFRSLTTAFFRDAMGFLLLFD
LTNEQSFLNVRNWISQLQMHAYCENPDIVLCGNKSDLEDQRVVKEEEAIALAEKYGIPYFET
SAANGTNISQAIEMLLDLIMKRMERCVDKS 
Fusion-Rab27a 
SSGRENLYFQGHMSFLTEEEQEAIMKVLQRDAALKRAEEERGSGSGSGMSDGDYDYLIKF
LALGDSGVGKTSVLYQYTDGKFNSKFITTVGIDFREKRVVYRASGPDGATGRGQRIHLQLW
DTAGLERFRSLTTAFFRDAMGFLLLFDLTNEQSFLNVRNWISQLQMHAYSENPDIVLCGNK
SDLEDQRVVKEEEAIALAEKYGIPYFETSAANGTNISQAIEMLLDLIMKRMERSVDKS 
Slp4 
SFLSEEEKDLILSVLQRDEEVRKADEKRIRRLKNELLEIKRKGAKRGSQHYSDRTCARCQES
LGRLSPKTNTCRGCNHLVCRDCRIQESNGTWRCKVCAKEIELKKATGDWFYDQ 
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TST-Rab27a 
MWSHPQFEKGGGSGGGSGGSAWSHPQFEKSGLRSRAMSDGDYDYLIKFLALGDSGVGK
TSVLYQYTDGKFNSKFITTVGIDFREKRVVYRASGPDGATGRGQRIHLQLWDTAGQERFRS
LTTAFFRDAMGFLLLFDLTNEQSFLNVRNWISQLQMHAYCENPDIVLCGNKSDLEDQRVVK
EEEAIALAEKYGIPYFETSAANGTNISQAIEMLLDLIMKRMERCVDKSWIPEGVVRSNGHAST
DQLSEEKEKGACGC 
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Appendix D: TST-Rab27a plasmid 
Description 
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Documentation 
 
TST-Rab27a only nucleotide sequence 
AAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCATGTGGTCCCATC
CTCAGTTCGAGAAAGGCGGCGGATCTGGCGGTGGAAGCGGAGGATCTGCTTGGAGCC
ATCCACAGTTTGAAAAGTCCGGCCTGCGGAGCAGAGCCATGTCCGATGGCGATTACGA
CTACCTGATCAAGTTTCTGGCCCTGGGCGATAGCGGCGTGGGCAAAACATCTGTGCTG
TACCAGTACACCGACGGCAAGTTCAACAGCAAGTTCATCACCACCGTGGGCATCGACT
TCCGCGAGAAGAGAGTGGTGTACAGAGCCAGCGGACCTGATGGCGCTACTGGCAGAG
GACAGAGAATCCATCTGCAGCTGTGGGACACAGCCGGCCAAGAGAGATTCAGAAGCCT
GACCACCGCCTTTTTCCGGGACGCCATGGGATTTCTGCTGCTGTTCGACCTGACCAAC
GAGCAGAGCTTCCTGAACGTGCGGAACTGGATCAGCCAGCTCCAGATGCACGCCTACT
GCGAGAACCCCGATATCGTGCTGTGCGGCAACAAGAGCGACCTGGAAGATCAGCGGG
TCGTGAAAGAGGAAGAGGCAATCGCCCTGGCCGAGAAGTACGGCATCCCCTACTTTGA
GACAAGCGCCGCCAACGGCACCAACATCTCTCAGGCCATTGAGATGCTGCTGGACCTG
ATCATGAAGCGGATGGAAAGATGCGTGGACAAGAGCTGGATTCCCGAGGGCGTCGTG
CGGTCTAATGGACACGCTAGCACAGACCAGCTGTCCGAGGAAAAAGAGAAGGGCGCC
TGCGGCTGTTGAGAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAG 
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Appendix E: MaxQuant Statistical Tests – Tables 
The following abbreviations are used: 
• #Pep – number of razor and unique peptides 
• Cov [%] – sequence coverage of unique and razor peptides 
• #MS/MS – number of assigned MS/MS spectra 
• -log p – minus log2 (student t-test significance value) 
• Diff – t-test difference between the compared sets 
Imputed values are in italic red text. Proteins that are enriched in sets containing crosslinker are labelled in red text in the “Diff” column. 
Proteins are ordered in descending value of -log p. Only significant values with -Log p ≥ 2.00 are reported here. 
A1 vs B1 
 
Log2 (LFQ intensity)    Student t-
test A1 B1    
 
Protein names Gene 1 2 3 4 5 6 #Pep 
Cov 
[%] 
#MS/ 
MS 
-Log 
p Diff 
1 ATP-binding cassette 
sub-family F member 3 
ABCF3 26.18 26.36 26.23 23.92 23.89 23.90 6 13 10 5.76 2.35 
2 Transportin-1 TNPO1 28.60 29.05 28.93 23.99 24.22 23.63 21 24 51 4.63 4.91 
3 Coatomer subunit beta COPB1 28.39 29.09 28.88 23.84 23.67 24.07 36 45 150 4.50 4.93 
4 Exportin-T XPOT 26.72 27.32 27.01 23.44 23.08 23.28 16 20 31 4.30 3.75 
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5 Signal peptidase 
complex catalytic 
subunit SEC11A 
SEC11A 28.33 29.26 28.83 23.85 23.84 23.98 9 43 43 4.26 4.92 
6 Serine/threonine-
protein kinase mTOR 
MTOR 30.09 30.79 30.81 23.54 23.79 24.48 3 1 5 4.26 6.63 
7 Surfeit locus protein 4 SURF4 26.38 26.46 26.56 23.67 23.60 23.15 3 14 10 4.20 2.99 
8 Coatomer subunit 
gamma-1 
COPG1 27.83 28.41 28.44 23.38 23.99 23.54 33 39 113 4.15 4.59 
9 Eukaryotic initiation 
factor 4A-III 
EIF4A3 22.93 23.20 23.41 26.39 26.39 26.82 4 11 6 4.13 -3.35 
10 Vesicle-fusing ATPase NSF 27.56 27.95 28.52 23.35 23.25 23.49 24 38 50 4.06 4.65 
11 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
UQCRC2 29.32 30.55 29.90 23.35 23.95 23.52 22 72 99 4.04 6.32 
12 60S ribosomal protein 
L38 
RPL38 28.65 28.81 28.47 24.42 24.87 24.00 6 59 24 4.00 4.21 
13 Calcium-binding 
mitochondrial carrier 
protein SCaMC-1 
SLC25A24 28.51 27.52 28.22 23.75 23.66 23.35 8 18 16 3.85 4.50 
14 Tubulin alpha-1B chain TUBA1B 34.99 35.65 35.57 31.94 32.38 32.22 57 80 1029 3.72 3.22 
15 Acetyl-CoA carboxylase 
1; Biotin carboxylase 
ACACA 27.07 27.58 27.57 23.41 23.37 24.11 33 18 71 3.68 3.77 
16 Importin-7 IPO7 26.56 27.08 27.05 23.85 23.51 23.12 13 14 33 3.64 3.40 
17 Putative tubulin-like TUBA4B 29.02 29.53 30.52 23.30 23.80 23.92 11 23 10 3.63 6.02 
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protein alpha-4B 
18 Tubulin beta-4B chain TUBB4B 33.78 34.33 34.35 31.20 31.63 31.36 58 84 1246 3.60 2.76 
19 Signal peptidase 
complex subunit 2 
SPCS2 27.90 28.76 28.88 23.74 24.12 24.47 13 58 51 3.53 4.40 
20 GTP-binding protein 
Rheb 
RHEB 25.71 25.81 26.33 23.70 23.69 23.77 6 30 21 3.48 2.23 
21 Actin, alpha cardiac 
muscle 1; Actin, alpha 
skeletal muscle 
ACTC1; 
ACTA1 
29.76 30.40 30.16 26.85 26.16 25.92 31 72 92 3.46 3.80 
22 Acylglycerol kinase, 
mitochondrial 
AGK 26.44 27.11 26.68 23.64 23.88 24.19 6 19 13 3.45 2.84 
23 Basic leucine zipper and 
W2 domain-containing 
protein 1 
BZW1 27.89 28.21 27.95 22.93 24.25 23.62 13 34 33 3.44 4.42 
24 ADP/ATP translocase 3 SLC25A6 28.71 29.77 29.42 23.81 24.90 24.02 22 63 132 3.42 5.05 
25 ATPase family AAA 
domain-containing 
protein 3A 
ATAD3A 27.17 26.63 26.65 24.01 24.07 24.51 10 19 20 3.42 2.62 
26 Phosphate carrier 
protein, mitochondrial 
SLC25A3 28.02 28.66 29.05 24.07 23.60 22.89 11 25 51 3.42 5.05 
27 Sarcoplasmic/endoplas
mic reticulum calcium 
ATPase 2 
ATP2A2 28.51 28.83 29.05 22.27 23.97 23.33 22 24 83 3.38 5.61 
28 Protein transport 
protein Sec61 subunit 
SEC61A1;
SEC61A2 
27.99 29.36 28.46 23.66 24.06 24.17 14 33 30 3.38 4.64 
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alpha isoform 1 and 2 
29 Translation machinery-
associated protein 7 
TMA7 29.05 29.21 30.41 24.06 24.44 23.43 5 64 39 3.36 5.58 
30 Voltage-dependent 
anion-selective channel 
protein 3 
VDAC3 28.58 29.10 28.78 22.52 23.91 24.00 13 49 55 3.35 5.34 
31 Pyridoxal-dependent 
decarboxylase domain-
containing protein 1 
PDXDC1 25.70 26.31 25.73 23.73 23.52 23.32 9 18 9 3.30 2.39 
32 EH domain-containing 
protein 4 
EHD4 27.67 28.38 28.16 22.52 23.98 23.63 18 36 47 3.19 4.69 
33 Cyclin-dependent 
kinase 1 
CDK1 26.57 26.78 26.73 23.36 24.12 24.27 17 60 54 3.19 2.78 
34 Ataxin-10 ATXN10 26.77 27.43 27.46 23.56 24.00 22.91 9 24 26 3.18 3.73 
35 ATP-dependent Clp 
protease ATP-binding 
subunit clpX-like, 
mitochondrial 
CLPX 27.41 27.86 27.76 24.00 24.50 23.23 8 13 51 3.18 3.77 
36 Translational activator 
GCN1 
GCN1L1 27.94 28.65 28.33 23.89 24.77 23.39 43 21 81 3.16 4.29 
37 Dolichyl-
diphosphooligo-
saccharide--protein 
glycosyltransferase 
subunit 1 
RPN1 30.06 30.27 29.90 26.89 27.62 26.57 35 60 145 3.13 3.05 
38 Tubulin beta-6 chain TUBB6 25.40 26.06 26.05 23.57 23.74 23.82 45 73 103 3.12 2.13 
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39 U4/U6.U5 small nuclear 
ribonucleoprotein 27 
kDa protein 
SNRNP27 26.69 26.97 27.59 23.43 23.73 24.33 5 32 25 3.02 3.26 
40 Uncharacterized protein 
C2orf47, mitochondrial 
C2orf47 25.85 26.63 26.87 23.69 23.29 23.77 6 21 8 2.96 2.87 
41 Transmembrane 9 
superfamily member 2 
TM9SF2 27.18 27.81 27.93 24.52 23.57 24.67 8 13 14 2.91 3.39 
42 NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 10 
NDUFB10 26.27 26.80 26.55 23.79 24.38 23.36 4 22 7 2.90 2.70 
43 Vacuole membrane 
protein 1 
VMP1 27.15 28.52 27.12 23.88 23.86 23.79 3 9 7 2.90 3.75 
44 Tubulin beta-3 chain TUBB3 25.78 26.35 26.09 23.36 23.73 24.18 36 60 10 2.90 2.32 
45 Cystine/glutamate 
transporter 
SLC7A11 27.17 28.12 27.79 23.14 24.51 23.76 8 15 23 2.88 3.89 
46 Glutaminase kidney 
isoform, mitochondrial 
GLS 27.32 28.15 27.94 22.60 23.81 24.17 13 26 27 2.87 4.27 
47 Carnitine O-
palmitoyltransferase 1, 
liver isoform 
CPT1A 25.98 26.13 26.22 23.24 23.85 24.22 15 26 30 2.87 2.34 
48 Solute carrier family 2, 
facilitated glucose 
transporter member 1 
SLC2A1 27.85 28.96 28.29 23.33 24.91 23.82 12 21 52 2.81 4.35 
49 Lysophosphatidylcholin
e acyltransferase 1 
LPCAT1 26.56 27.63 26.83 23.85 23.53 24.37 8 16 18 2.80 3.09 
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50 Very-long-chain 3-
oxoacyl-CoA reductase 
HSD17B1
2 
25.19 25.56 26.01 23.88 23.61 23.71 8 35 13 2.77 1.85 
51 DNA mismatch repair 
protein Msh2 
MSH2 27.36 28.06 27.99 22.96 24.56 24.10 26 34 62 2.77 3.93 
52 NAD(P) 
transhydrogenase, 
mitochondrial 
NNT 27.91 30.01 28.82 22.96 24.20 23.88 36 34 127 2.74 5.23 
53 Tubulin beta chain TUBB 32.29 32.36 33.17 29.46 30.25 30.04 53 80 344 2.73 2.69 
54 Calcium-binding 
mitochondrial carrier 
protein Aralar2 
SLC25A13 26.56 26.71 27.20 22.69 23.70 24.12 20 41 36 2.69 3.32 
55 Proteasome-associated 
protein ECM29 homolog 
ECM29 25.77 26.80 26.53 23.61 23.27 24.05 16 11 29 2.69 2.72 
56 ER membrane protein 
complex subunit 1 
EMC1 24.81 25.42 25.49 23.46 22.78 23.23 8 11 8 2.68 2.08 
57 Signal recognition 
particle receptor 
subunit beta 
SRPRB 27.02 27.68 27.49 23.34 23.63 24.81 7 27 31 2.68 3.47 
58 Nuclear pore complex 
protein Nup93 
NUP93 25.90 26.40 26.82 23.73 23.47 24.29 13 18 24 2.68 2.54 
59 Dual specificity 
mitogen-activated 
protein kinase kinase 3 
MAP2K3 27.01 27.74 27.72 21.83 23.23 23.84 15 38 45 2.67 4.52 
60 Sodium/potassium-
transporting ATPase 
subunit alpha-1 
ATP1A1 26.59 27.55 27.34 24.44 24.99 24.21 35 41 188 2.67 2.61 
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61 60S ribosomal protein 
L27 
RPL27 28.09 26.99 27.52 22.57 24.24 23.73 2 27 6 2.62 4.02 
62 Voltage-dependent 
anion-selective channel 
protein 2 
VDAC2 26.25 26.71 26.08 23.68 24.55 24.32 7 30 17 2.60 2.16 
63 Activated RNA 
polymerase II 
transcriptional 
coactivator p15 
SUB1 30.61 30.98 31.28 24.33 26.79 24.15 17 79 230 2.60 5.87 
64 Tubulin alpha-1C chain TUBA1C 26.99 27.67 27.54 22.60 24.31 23.97 54 80 22 2.59 3.77 
65 60S ribosomal protein 
L9 
RPL9 26.26 25.87 25.74 27.31 27.58 27.10 5 41 20 2.56 -1.37 
66 Prelamin-A/C;Lamin-A/C LMNA 27.24 26.65 26.64 28.86 28.26 28.98 15 23 44 2.47 -1.86 
67 Elongation factor Tu, 
mitochondrial 
TUFM 28.05 27.90 28.19 28.58 28.61 28.55 21 48 108 2.47 -0.53 
68 Protein unc-45 homolog 
A 
UNC45A 26.76 27.25 27.05 23.98 23.08 24.73 23 30 46 2.47 3.09 
69 Importin-5 IPO5 26.42 27.18 27.05 23.25 24.69 23.67 23 27 61 2.46 3.02 
70 FACT complex subunit 
SSRP1 
SSRP1 27.25 27.62 28.27 22.63 24.67 23.65 6 13 10 2.45 4.06 
71 Ras-related protein Rab-
27A 
RAB27A 37.14 37.37 37.45 35.38 34.43 35.56 61 99 4265 2.42 2.19 
72 Leucine-rich PPR motif-
containing protein, 
mitochondrial 
LRPPRC 28.51 28.97 29.16 23.35 25.79 24.32 36 33 76 2.41 4.39 
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73 GTP-binding nuclear 
protein Ran 
RAN 27.46 27.11 27.12 29.31 30.41 29.19 13 49 48 2.40 -2.40 
74 Translocon-associated 
protein subunit delta 
SSR4 26.23 27.04 26.91 22.21 23.73 23.92 7 43 30 2.35 3.44 
75 Acyl-CoA desaturase SCD 25.71 26.53 27.04 23.19 22.40 23.84 5 18 9 2.35 3.28 
76 Nuclear pore membrane 
glycoprotein 210 
NUP210 22.56 23.47 22.54 26.95 25.24 26.25 2 1 4 2.31 -3.29 
77 STE20/SPS1-related 
proline-alanine-rich 
protein kinase 
STK39 25.26 25.69 25.95 23.41 24.15 24.09 3 10 6 2.30 1.75 
78 Structural maintenance 
of chromosomes 
protein 4 
SMC4 26.37 26.07 26.15 24.94 24.26 23.85 4 4 5 2.29 1.85 
79 Tubulin alpha-4A chain TUBA4A 30.63 31.36 31.07 28.36 28.47 29.45 49 68 118 2.29 2.26 
80 Monocarboxylate 
transporter 4 
SLC16A3 28.46 28.54 29.05 21.83 24.05 24.85 13 23 45 2.29 5.11 
81 Multidrug resistance-
associated protein 1 
ABCC1 25.84 26.50 26.06 22.60 24.13 23.64 14 14 24 2.26 2.67 
82 Glutamate--cysteine 
ligase regulatory 
subunit 
GCLM 26.46 26.98 26.69 23.56 24.85 23.21 7 30 27 2.26 2.84 
83 Epidermal growth factor 
receptor 
EGFR 25.41 25.74 25.80 23.75 24.62 24.04 6 7 12 2.23 1.52 
84 Calcium uniporter 
protein, mitochondrial 
MCU 25.63 26.64 25.84 22.64 23.95 23.61 8 26 15 2.22 2.64 
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85 Reticulocalbin-2 RCN2 26.02 26.25 26.16 22.70 24.29 23.83 5 22 11 2.21 2.53 
86 Peptidyl-prolyl cis-trans 
isomerase FKBP11 
FKBP11 24.03 23.63 23.27 26.29 25.36 26.82 2 10 3 2.20 -2.52 
87 ATP-dependent 6-
phosphofructokinase, 
platelet type 
PFKP 27.49 28.72 28.18 23.69 25.67 24.08 32 40 166 2.19 3.65 
88 ADP/ATP translocase 
2;ADP/ATP translocase 
2, N-terminally 
processed 
SLC25A5 28.03 29.33 28.55 26.07 24.01 24.74 22 63 54 2.19 3.70 
89 Nucleolin NCL 26.17 26.35 26.37 26.85 27.24 27.37 11 17 19 2.14 -0.86 
90 Exportin-2 CSE1L 29.50 29.81 29.76 27.80 25.83 26.71 43 46 151 2.14 2.91 
91 ATP synthase subunit 
alpha, mitochondrial 
ATP5A1 30.44 31.03 30.79 28.56 29.59 28.98 38 62 245 2.11 1.71 
92 Importin-4 IPO4 25.40 25.92 25.62 23.86 24.66 24.34 9 12 16 2.11 1.36 
93 ATP-dependent 6-
phosphofructokinase, 
muscle type 
PFKM 26.69 27.89 28.10 25.43 25.15 24.38 23 31 61 2.06 2.57 
94 Pachytene checkpoint 
protein 2 homolog 
TRIP13 30.04 29.98 29.94 23.90 26.11 26.95 31 69 143 2.05 4.34 
95 High mobility group 
protein B1; Putative 
high mobility group 
protein B1-like 1 
HMGB1; 
HMGB1P
1 
28.09 29.03 28.58 25.53 25.89 23.55 17 47 84 2.00 3.58 
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B1 vs C1 
 
 
Log2 (LFQ intensity)    
Student t-test 
B1 C1    
 
Protein names Gene 4 5 6 7 8 9 #Pep Cov [%] 
#MS/ 
MS -Log p Diff 
1 Ras GTPase-activating-
like protein IQGAP1 
IQGAP1 26.65 27.18 27.55 22.75 23.09 23.10 8 4.8 17 3.89 4.15 
2 Clathrin heavy chain 1 CLTC 26.66 27.85 26.55 24.25 23.20 23.63 12 11 16 2.52 3.32 
3 Activated RNA polymerase 
II transcriptional 
coactivator p15 
SUB1 23.40 26.79 22.92 31.67 31.36 30.79 17 78.7 230 2.29 -6.90 
4 Nuclear pore membrane 
glycoprotein 210 
NUP210 26.95 25.24 26.25 23.18 22.80 23.59 2 1.3 4 2.25 2.95 
5 60S ribosomal protein L30 RPL30 26.21 28.02 26.04 22.39 22.94 23.58 2 26.1 7 2.20 3.78 
6 Epiplakin EPPK1 26.43 26.73 27.31 23.37 24.72 22.65 10 15.5 13 2.10 3.25 
7 Importin subunit beta-1 KPNB1 26.27 27.49 26.00 24.54 24.06 23.62 19 23.4 51 2.05 2.51 
8 EH domain-containing 
protein 2 
EHD2 24.05 24.23 24.25 22.89 23.44 23.44 14 34.4 24 2.03 0.92 
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A1 vs C1 
 Log2 (LFQ intensity)    Student t-
test A1 C1    
 
Protein names Gene 1 2 3 7 8 9 #Pep Cov [%] 
#MS/ 
MS 
-Log 
p Diff 
1 ATP-binding cassette sub-
family F member 3 
ABCF3 26.18 26.36 26.23 23.28 23.34 23.46 6 13 10 5.57 2.90 
2 Transportin-1 TNPO1 28.60 29.05 28.93 22.55 22.73 22.97 21 24 51 5.33 6.11 
3 Translational activator GCN1 GCN1L1 27.94 28.65 28.33 23.12 23.32 23.28 43 21 81 4.72 5.07 
4 ATP-dependent Clp protease 
ATP-binding subunit clpX-
like, mitochondrial 
CLPX 27.41 27.86 27.76 23.48 23.54 23.84 8 13 51 4.66 4.06 
5 Coatomer subunit gamma-1 COPG1 27.83 28.41 28.44 23.20 23.42 23.04 33 39 113 4.59 5.01 
6 T-complex protein 1 subunit 
alpha 
TCP1 26.23 26.06 26.51 22.67 22.99 22.89 7 17 14 4.51 3.42 
7 60S ribosomal protein L38 RPL38 28.65 28.81 28.47 22.68 23.53 22.87 6 59 24 4.46 5.62 
8 Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 
ATP2A2 28.51 28.83 29.05 22.94 23.68 23.62 22 24 83 4.33 5.38 
9 Serine/threonine-protein 
kinase mTOR 
MTOR 30.09 30.79 30.81 22.92 23.92 22.95 3 1 5 4.26 7.30 
10 Acetyl-CoA carboxylase 1; 
Biotin carboxylase 
ACACA 27.07 27.58 27.57 23.17 23.18 23.65 33 18 71 4.21 4.07 
11 Voltage-dependent anion-
selective channel protein 3 
VDAC3 28.58 29.10 28.78 24.37 23.59 24.12 13 49 55 4.20 4.79 
12 Exportin-T XPOT 26.72 27.32 27.01 23.12 23.53 23.20 16 20 31 4.19 3.73 
13 Transmembrane 9 
superfamily member 2 
TM9SF2 27.18 27.81 27.93 23.51 23.54 23.64 8 13 14 4.17 4.07 
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14 Importin subunit beta-1 KPNB1 26.54 26.63 26.45 22.94 23.50 23.47 19 23 51 4.15 3.24 
15 NAD(P)H dehydrogenase 
[quinone] 1 
NQO1 26.59 26.04 26.44 23.22 23.04 23.42 7 25 12 4.04 3.13 
16 UDP-glucose 6-
dehydrogenase 
UGDH 26.31 26.21 26.31 23.74 23.17 23.20 7 18 8 4.01 2.91 
17 Calcium-binding 
mitochondrial carrier protein 
Aralar2 
SLC25A1
3 
26.56 26.71 27.20 23.54 23.56 23.77 20 41 36 3.99 3.20 
18 Phosphate carrier protein, 
mitochondrial 
SLC25A3 28.02 28.66 29.05 22.28 23.10 22.62 11 25 51 3.99 5.91 
19 Microsomal glutathione S-
transferase 1 
MGST1 26.42 26.98 26.67 23.27 23.36 23.71 4 25 8 3.97 3.24 
20 Leucine-rich PPR motif-
containing protein, 
mitochondrial 
LRPPRC 28.51 28.97 29.16 22.47 22.33 23.47 36 33 76 3.95 6.12 
21 Basic leucine zipper and W2 
domain-containing protein 1 
BZW1 27.89 28.21 27.95 23.12 24.06 23.28 13 34 33 3.91 4.53 
22 Pachytene checkpoint 
protein 2 homolog 
TRIP13 30.04 29.98 29.94 24.38 24.43 23.16 31 69 143 3.87 6.00 
23 Carnitine O-
palmitoyltransferase 1, liver 
isoform 
CPT1A 25.98 26.13 26.22 22.73 23.39 23.22 15 26 30 3.85 2.99 
24 DNA mismatch repair protein 
Msh2 
MSH2 27.36 28.06 27.99 23.94 23.66 23.22 26 34 62 3.78 4.19 
25 Multidrug resistance-
associated protein 1 
ABCC1 25.84 26.50 26.06 22.57 23.08 22.61 14 14 24 3.74 3.38 
26 Tubulin beta-3 chain TUBB3 25.78 26.35 26.09 22.82 23.36 22.89 36 60 10 3.69 3.05 
27 Vesicle-fusing ATPase NSF 27.56 27.95 28.52 22.88 23.66 22.75 24 38 50 3.60 4.91 
28 Cystine/glutamate 
transporter 
SLC7A11 27.17 28.12 27.79 23.90 24.23 24.12 8 15 23 3.59 3.61 
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29 Tubulin alpha-1C chain TUBA1C 26.99 27.67 27.54 23.06 23.86 23.08 54 80 22 3.57 4.07 
30 Putative tubulin-like protein 
alpha-4B 
TUBA4B 29.02 29.53 30.52 23.11 24.02 23.40 11 23 10 3.56 6.18 
31 D-3-phosphoglycerate 
dehydrogenase 
PHGDH 29.41 29.77 30.22 26.63 26.28 26.75 30 65 154 3.55 3.24 
32 60S ribosomal protein L27 RPL27 28.09 26.99 27.52 23.72 23.25 23.16 2 27 6 3.50 4.16 
33 DNA-dependent protein 
kinase catalytic subunit 
PRKDC 28.23 29.37 28.19 23.11 22.85 23.75 48 15 99 3.47 5.36 
34 Protein unc-45 homolog A UNC45A 26.76 27.25 27.05 23.39 23.41 22.46 23 30 46 3.47 3.93 
35 Solute carrier family 2, 
facilitated glucose transporter 
member 1 
SLC2A1 27.85 28.96 28.29 22.95 23.54 23.97 12 21 52 3.44 4.88 
36 Signal peptidase complex 
subunit 3 
SPCS3 26.03 26.33 25.71 23.08 22.64 23.33 7 39 13 3.44 3.01 
37 STE20/SPS1-related proline-
alanine-rich protein kinase 
STK39 25.26 25.69 25.95 23.25 22.94 23.24 3 10 6 3.42 2.49 
38 T-complex protein 1 subunit 
gamma 
CCT3 26.70 26.69 27.05 23.02 23.09 23.97 14 30 40 3.34 3.46 
39 Protein transport protein 
Sec61 subunit alpha isoform 
1; Protein transport protein 
Sec61 subunit alpha 
isoform 2 
SEC61A1
; 
SEC61A2 
27.99 29.36 28.46 23.65 24.32 23.85 14 33 30 3.32 4.66 
40 Epidermal growth factor 
receptor 
EGFR 25.41 25.74 25.80 22.95 23.56 23.46 6 7 12 3.32 2.33 
41 Glutaminase kidney isoform, 
mitochondrial 
GLS 27.32 28.15 27.94 23.46 24.13 22.99 13 26 27 3.31 4.27 
42 Cyclin-dependent kinase 1 CDK1 26.57 26.78 26.73 22.95 23.90 22.88 17 60 54 3.30 3.45 
43 Uncharacterized protein 
C2orf47, mitochondrial 
C2orf47 25.85 26.63 26.87 22.94 22.73 23.25 6 21 8 3.27 3.47 
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44 Calpain-2 catalytic subunit CAPN2 26.18 26.69 26.88 22.40 22.07 23.23 6 12 9 3.24 4.02 
45 EH domain-containing 
protein 4 
EHD4 27.67 28.38 28.16 21.84 23.08 23.51 18 36 47 3.20 5.25 
46 Coatomer subunit beta COPB1 28.39 29.09 28.88 23.35 23.67 24.86 36 45 150 3.18 4.83 
47 Translation machinery-
associated protein 7 
TMA7 29.05 29.21 30.41 24.13 23.27 22.34 5 64 39 3.14 6.31 
48 Importin-7 IPO7 26.56 27.08 27.05 22.75 22.49 23.75 13 14 33 3.13 3.90 
49 Translocon-associated 
protein subunit delta 
SSR4 26.23 27.04 26.91 23.94 23.37 23.09 7 43 30 3.11 3.26 
50 ATP-dependent 6-
phosphofructokinase, platelet 
type 
PFKP 27.49 28.72 28.18 23.43 23.30 24.34 32 40 166 3.11 4.44 
51 Surfeit locus protein 4 SURF4 26.38 26.46 26.56 22.13 23.33 23.25 3 14 10 3.11 3.57 
52 Transketolase TKT 26.55 26.16 26.18 28.06 27.85 28.38 18 37 46 3.09 -1.80 
53 HLA class I histocompatibility 
antigen, alpha chains 
HLA-A 25.67 26.40 26.32 23.34 23.44 23.90 6 23 15 3.05 2.57 
54 Long-chain-fatty-acid--CoA 
ligase 3 
ACSL3 27.79 28.40 27.25 23.46 23.70 22.40 27 46 52 3.05 4.62 
55 Kinesin-like protein KIF23 KIF23 26.90 26.08 25.99 23.70 23.65 23.84 5 7 9 3.03 2.59 
56 Calcium-binding 
mitochondrial carrier protein 
SCaMC-1 
SLC25A2
4 
28.51 27.52 28.22 24.15 22.50 23.12 8 18 16 3.00 4.83 
57 Tubulin beta-4B chain TUBB4B 33.78 34.33 34.35 32.14 31.49 32.01 58 84 1246 2.95 2.28 
58 FACT complex subunit 
SSRP1 
SSRP1 27.25 27.62 28.27 23.71 24.73 23.64 6 13 10 2.88 3.69 
59 Signal recognition particle 
receptor subunit beta 
SRPRB 27.02 27.68 27.49 22.78 23.27 24.35 7 27 31 2.84 3.93 
60 Nuclear pore complex protein 
Nup93 
NUP93 25.90 26.40 26.82 23.33 22.85 23.83 13 18 24 2.84 3.04 
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61 Acylglycerol kinase, 
mitochondrial 
AGK 26.44 27.11 26.68 22.81 24.04 23.69 6 19 13 2.84 3.23 
62 Vacuole membrane protein 1 VMP1 27.15 28.52 27.12 22.06 22.87 23.46 3 9 7 2.83 4.80 
63 Monocarboxylate transporter 
4 
SLC16A3 28.46 28.54 29.05 22.87 24.61 24.59 13 23 45 2.82 4.67 
64 Aldehyde dehydrogenase X, 
mitochondrial 
ALDH1B1 26.09 26.72 26.68 22.32 22.54 23.71 6 14 12 2.80 3.64 
65 Structural maintenance of 
chromosomes protein 4 
SMC4 26.37 26.07 26.15 23.91 22.99 22.60 4 4 5 2.79 3.03 
66 Lysophosphatidylcholine 
acyltransferase 1 
LPCAT1 26.56 27.63 26.83 22.56 23.97 22.92 8 16 18 2.72 3.85 
67 Calcium uniporter protein, 
mitochondrial 
MCU 25.63 26.64 25.84 22.47 22.59 23.47 8 26 15 2.72 3.19 
68 Proteasome-associated 
protein ECM29 homolog 
ECM29 25.77 26.80 26.53 22.87 23.64 23.73 16 11 29 2.69 2.95 
69 Propionyl-CoA carboxylase 
alpha chain, mitochondrial 
PCCA 23.85 23.21 24.44 28.45 27.04 27.56 8 13 19 2.68 -3.85 
70 Exportin-2 CSE1L 29.50 29.81 29.76 23.28 25.50 25.32 43 46 151 2.65 4.99 
71 T-complex protein 1 subunit 
zeta 
CCT6A 27.59 27.13 26.85 23.58 22.03 23.75 11 27 17 2.64 4.07 
72 Importin-5 IPO5 26.42 27.18 27.05 24.33 23.88 24.86 23 27 61 2.64 2.53 
73 CAD protein; Glutamine-
dependent carbamoyl-
phosphate synthase; 
Aspartate 
carbamoyltransferase; 
Dihydroorotase 
CAD 26.60 26.20 26.11 23.62 22.49 21.90 17 13 24 2.64 3.64 
74 Acyl-CoA desaturase SCD 25.71 26.53 27.04 23.50 23.28 23.83 5 18 9 2.63 2.89 
75 Signal peptidase complex 
subunit 2 
SPCS2 27.90 28.76 28.88 23.99 24.30 22.14 13 58 51 2.61 5.04 
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76 ATPase family AAA domain-
containing protein 3A 
ATAD3A 27.17 26.63 26.65 24.30 22.71 23.53 10 19 20 2.60 3.30 
77 Tubulin alpha-1B chain TUBA1B 34.99 35.65 35.57 32.62 31.34 32.66 57 80 1029 2.57 3.19 
78 Mitochondrial import receptor 
subunit TOM40 homolog 
TOMM40 26.38 27.52 27.21 24.50 23.87 24.63 13 37 32 2.55 2.71 
79 Epiplakin EPPK1 26.86 26.53 27.83 23.87 22.36 23.38 10 16 13 2.55 3.87 
80 Putative elongation factor 1-
alpha-like 3; Elongation 
factor 1-alpha 1 
EEF1A1P
5; 
EEF1A1 
32.38 32.58 32.22 31.51 31.12 30.95 33 63 421 2.46 1.20 
81 Serine/arginine-rich splicing 
factor 1 
SRSF1 26.64 27.29 26.89 28.47 28.76 28.19 12 43 73 2.44 -1.53 
82 GTP-binding nuclear protein 
Ran 
RAN 27.46 27.11 27.12 30.37 29.03 30.17 13 49 48 2.42 -2.62 
83 Cytochrome b-c1 complex 
subunit 2, mitochondrial 
UQCRC2 29.32 30.55 29.90 23.36 22.51 25.66 22 72 99 2.42 6.08 
84 Importin-4 IPO4 25.40 25.92 25.62 23.96 23.87 23.01 9 12 16 2.42 2.03 
85 Lamina-associated 
polypeptide 2 
TMPO 25.36 24.91 25.35 23.76 22.92 22.72 4 11 8 2.38 2.07 
86 ATP-dependent 6-
phosphofructokinase, muscle 
type 
PFKM 26.69 27.89 28.10 24.68 24.60 23.61 23 31 61 2.38 3.26 
87 Voltage-dependent anion-
selective channel protein 2 
VDAC2 26.25 26.71 26.08 24.39 23.01 23.82 7 30 17 2.37 2.60 
88 Pyruvate kinase PKM PKM 29.28 28.63 28.64 30.85 30.52 30.17 38 54 265 2.34 -1.66 
89 Elongation factor 1-gamma EEF1G 27.35 26.87 27.11 26.07 26.25 26.32 12 28 33 2.33 0.89 
90 Eukaryotic translation 
initiation factor 5A-1 
EIF5A 24.26 26.18 24.23 28.27 29.05 29.25 7 48 28 2.30 -3.97 
91 Eukaryotic initiation factor 
4A-I 
EIF4A1 27.97 27.33 27.61 30.49 29.24 30.17 24 55 128 2.29 -2.33 
92 Unconventional myosin-Ic MYO1C 28.64 26.49 26.80 23.93 23.10 23.20 13 16 17 2.25 3.90 
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93 U4/U6.U5 small nuclear 
ribonucleoprotein 27 kDa 
protein 
SNRNP2
7 
26.69 26.97 27.59 23.82 23.03 24.85 5 32 25 2.25 3.19 
94 Coatomer subunit alpha; 
Xenin; Proxenin 
COPA 27.10 26.45 27.45 22.69 23.23 24.66 19 20 41 2.22 3.48 
95 ATP synthase subunit alpha, 
mitochondrial 
ATP5A1 30.44 31.03 30.79 27.22 28.37 28.78 38 62 245 2.21 2.63 
96 40S ribosomal protein S7 RPS7 26.99 25.57 26.08 23.88 23.95 23.17 7 51 13 2.20 2.55 
97 Ataxin-10 ATXN10 26.77 27.43 27.46 22.47 23.99 24.63 9 24 26 2.18 3.52 
98 ATP synthase subunit 
gamma, mitochondrial 
ATP5C1 25.88 26.38 26.94 22.81 24.26 23.88 8 31 16 2.18 2.75 
99 Bifunctional purine 
biosynthesis protein PURH; 
Phosphoribosylaminoimidazo
lecarboxamide 
formyltransferase; IMP 
cyclohydrolase 
ATIC 24.45 24.68 23.88 23.18 23.15 22.89 8 18 8 2.10 1.26 
100 Sodium/potassium-
transporting ATPase subunit 
alpha-1 
ATP1A1 26.59 27.55 27.34 23.38 25.08 24.54 35 41 188 2.09 2.82 
101 Glyceraldehyde-3-phosphate 
dehydrogenase 
GAPDH 30.92 29.89 29.96 31.97 31.86 31.82 34 77 212 2.07 -1.63 
102 Tubulin beta chain TUBB 32.29 32.36 33.17 30.81 29.35 30.30 53 80 344 2.06 2.45 
103 Methionine--tRNA ligase, 
cytoplasmic 
MARS 26.21 24.93 26.71 23.14 23.66 23.33 17 25 43 2.02 2.57 
104 T-complex protein 1 subunit 
epsilon 
CCT5 24.83 24.71 24.85 23.84 22.73 23.33 4 11 5 2.01 1.50 
105 Geranylgeranyl transferase 
type-2 subunit beta 
RABGGT
B 
25.53 25.96 25.51 24.23 23.73 24.69 3 14 7 2.01 1.45 
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D vs E 
 
 Log2 (LFQ intensity)    Student  
t-test D E    
 
Protein names Gene 1 2 3 4 5 6 #Pep Cov [%] 
#MS/ 
MS 
-Log 
p Diff 
1 Mitochondrial import 
inner membrane 
translocase subunit 
Tim23 
TIMM23 25.27 25.32 25.40 22.31 21.99 22.30 4 37 8 5.03 3.13 
2 Multidrug resistance-
associated protein 1 
ABCC1 27.18 27.19 27.39 21.76 21.62 22.23 14 14 24 4.97 5.38 
3 V-type proton ATPase 
subunit H 
ATP6V1H 25.41 25.18 25.21 22.98 23.11 22.99 4 11 8 4.96 2.24 
4 Serine/arginine-rich 
splicing factor 1 
SRSF1 24.41 24.13 23.84 28.48 28.36 28.32 12 43 73 4.82 -4.26 
5 Serine/arginine-rich 
splicing factor 6 
SRSF6 22.54 22.19 22.15 27.78 27.47 27.17 3 11 6 4.77 -5.18 
6 Exportin-T XPOT 26.21 26.27 26.06 22.36 22.60 22.08 16 20 31 4.72 3.83 
7 Mitochondrial import 
receptor subunit TOM40 
homolog 
TOMM40 26.60 26.15 26.13 22.80 22.61 22.64 13 37 32 4.60 3.61 
8 Ribonucleoside-
diphosphate reductase 
large subunit 
RRM1 25.65 25.89 25.52 23.03 22.76 22.84 8 14 10 4.49 2.81 
9 ATP synthase subunit f, 
mitochondrial 
ATP5J2 26.46 26.34 26.61 21.61 22.39 22.16 2 26 21 4.24 4.42 
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10 Signal peptidase 
complex subunit 3 
SPCS3 26.70 26.72 26.36 22.46 21.86 22.54 7 39 13 4.21 4.31 
11 Extended 
synaptotagmin-2 
ESYT2 26.22 25.98 26.51 22.31 22.56 22.81 8 12 19 4.20 3.67 
12 Cystine/glutamate 
transporter 
SLC7A11 26.21 25.91 25.56 22.73 22.55 22.61 8 15 23 4.12 3.26 
13 Heterogeneous nuclear 
ribonucleoprotein 
A1;Heterogeneous 
nuclear 
ribonucleoprotein A1, N-
terminally processed 
HNRNPA1 22.47 22.23 22.02 25.53 25.88 25.33 8 23 19 4.08 -3.34 
14 ATP-citrate synthase ACLY 25.73 25.50 25.63 23.04 22.59 22.50 16 19 28 4.06 2.91 
15 Calcium-binding 
mitochondrial carrier 
protein SCaMC-1 
SLC25A24 25.85 25.91 25.97 22.67 23.29 22.97 8 18 16 4.05 2.93 
16 Tricarboxylate transport 
protein, mitochondrial 
SLC25A1 26.06 25.48 25.59 22.33 22.17 21.79 4 14 12 3.94 3.61 
17 Serine/arginine-rich 
splicing factor 10 
SRSF10 21.93 21.86 22.10 27.22 26.19 26.48 6 24 13 3.92 -4.67 
18 NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 9, 
mitochondrial 
NDUFA9 25.35 25.35 25.93 22.34 22.41 22.05 5 17 5 3.89 3.28 
19 Importin-7 IPO7 26.66 26.90 27.39 22.95 23.31 23.44 13 14 33 3.88 3.75 
20 Proteasome subunit 
alpha type-7; 
Proteasome subunit 
alpha type-7-like 
PSMA7; 
PSMA8 
24.11 24.32 24.12 22.08 21.60 21.61 3 19 7 3.84 2.42 
21 Serine/arginine-rich 
splicing factor 3 
SRSF3 28.99 28.81 29.03 31.58 31.79 31.21 16 52 192 3.84 -2.58 
22 Rab GDP dissociation GDI2; GDI1 23.30 22.17 22.96 28.51 27.83 28.20 11 32 18 3.80 -5.37 
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inhibitor beta;Rab GDP 
dissociation inhibitor 
alpha 
23 Translational activator 
GCN1 
GCN1L1 28.41 28.68 28.99 23.26 23.33 24.28 43 21 81 3.79 5.07 
24 EH domain-containing 
protein 2 
EHD2 26.20 26.15 26.94 22.71 22.63 22.91 14 34 24 3.78 3.68 
25 Uridine-cytidine kinase 2 UCK2 25.76 25.53 25.73 22.30 21.60 22.40 5 28 12 3.78 3.57 
26 Transportin-1 TNPO1 27.46 27.41 26.43 22.60 22.29 22.32 21 24 51 3.75 4.70 
27 RuvB-like 1 RUVBL1 27.00 26.90 27.43 23.00 22.30 21.93 10 28 25 3.73 4.70 
28 Proteasome-associated 
protein ECM29 homolog 
ECM29 26.40 27.16 27.33 22.65 22.04 22.67 16 11 29 3.67 4.51 
29 Peptidyl-prolyl cis-trans 
isomerase B 
PPIB 28.65 28.22 28.05 23.28 22.44 21.85 19 62 79 3.67 5.78 
30 Heterogeneous nuclear 
ribonucleoprotein A0 
HNRNPA0 25.43 26.04 25.35 22.80 22.51 22.75 5 19 10 3.62 2.92 
31 Tubulin alpha-1C chain TUBA1C 26.40 26.33 26.33 21.90 22.99 22.47 54 80 22 3.60 3.90 
32 Fanconi anemia group I 
protein 
FANCI 25.50 25.51 26.07 22.73 22.92 23.16 10 10 12 3.59 2.76 
33 ADP/ATP translocase 2 SLC25A5 27.64 28.15 28.75 22.84 22.09 23.17 22 63 54 3.58 5.48 
34 Dynein assembly factor 
5, axonemal 
DNAAF5 26.03 25.88 26.82 22.79 22.63 22.64 8 12 14 3.57 3.56 
35 Glutathione S-
transferase Mu 3 
GSTM3 25.74 25.35 25.81 22.57 21.81 22.49 4 24 7 3.55 3.35 
36 Cleavage and 
polyadenylation 
specificity factor 
subunit 5 
NUDT21 22.14 22.38 22.68 25.11 25.12 24.67 2 13 3 3.55 -2.56 
37 Tubulin beta-4B chain TUBB4B 33.56 33.24 33.29 32.07 32.10 32.21 58 84 1246 3.51 1.23 
38 Epidermal growth factor EGFR 25.15 25.24 25.45 23.48 23.63 23.17 6 7 12 3.47 1.85 
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receptor 
39 Serine/arginine-rich 
splicing factor 2 
SRSF2 26.45 26.03 25.90 29.84 29.40 29.02 10 29 81 3.47 -3.29 
40 Actin, cytoplasmic 1 ACTB 32.44 32.18 32.38 31.44 31.41 31.37 39 85 683 3.46 0.93 
41 Rab proteins 
geranylgeranyl-
transferase component 
A 1 and 2 
CHM; 
CHML 
22.18 21.75 21.20 26.56 25.60 26.19 2 4 6 3.43 -4.41 
42 General transcription 
factor IIF subunit 1 
GTF2F1 25.24 24.74 25.30 22.93 23.01 22.68 4 11 5 3.38 2.22 
43 Myosin light 
polypeptide 6 
MYL6 25.49 24.83 25.15 22.15 21.52 21.25 9 58 23 3.38 3.52 
44 Eukaryotic initiation 
factor 4A-I 
EIF4A1 27.11 26.75 26.87 30.10 29.48 29.32 24 55 128 3.32 -2.73 
45 Protein QIL1 QIL1 26.19 26.26 27.11 23.21 22.58 23.01 2 36 7 3.30 3.59 
46 ADP/ATP translocase 3 SLC25A6 30.49 30.55 30.80 28.39 27.89 28.59 22 63 132 3.28 2.32 
47 Voltage-dependent 
anion-selective channel 
protein 3 
VDAC3 29.19 28.83 28.68 22.93 23.32 24.58 13 49 55 3.27 5.30 
48 ATP synthase subunit 
alpha, mitochondrial 
ATP5A1 30.57 30.45 30.71 29.70 29.55 29.72 38 62 245 3.26 0.92 
49 Cancer-related 
nucleoside-
triphosphatase 
NTPCR 26.05 25.44 26.55 22.55 22.81 22.42 5 38 9 3.25 3.42 
50 Heat shock 70 kDa 
protein 1B; Heat shock 
70 kDa protein 1A 
HSPA1B; 
HSPA1A 
25.81 25.26 25.26 27.41 27.25 27.32 18 35 27 3.24 -1.88 
51 NAD(P)H 
dehydrogenase 
[quinone] 1 
NQO1 24.78 24.74 25.15 22.11 21.06 21.63 7 25 12 3.24 3.29 
52 Sodium/potassium- ATP1A1 30.22 30.11 30.39 27.91 28.34 28.53 35 41 188 3.23 1.99 
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transporting ATPase 
subunit alpha-1 
53 Splicing factor U2AF 35 
kDa subunit 
U2AF1 25.76 25.25 25.91 27.64 27.94 27.95 5 21 20 3.23 -2.21 
54 DnaJ homolog subfamily 
A member 1 
DNAJA1 27.33 27.44 27.49 22.64 22.28 23.79 8 29 24 3.22 4.51 
55 Transmembrane protein 
165 
TMEM165 26.38 26.19 26.25 23.40 22.75 22.16 4 20 22 3.19 3.50 
56 Mitofusin-1 MFN1 26.00 26.10 25.79 22.95 22.44 21.70 3 5 12 3.19 3.60 
57 Importin-4 IPO4 25.86 26.60 25.53 22.91 22.46 22.74 9 12 16 3.19 3.30 
58 Coatomer subunit 
alpha;Xenin;Proxenin 
COPA 27.26 27.02 27.37 23.70 22.26 22.50 19 20 41 3.18 4.39 
59 Histone H2A type 1 HIST1H2A 27.49 27.19 26.37 22.83 21.80 22.85 8 61 64 3.14 4.52 
60 Succinate 
dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
SDHA 24.70 24.98 24.19 26.75 26.69 26.67 7 13 20 3.07 -2.08 
61 60 kDa heat shock 
protein, mitochondrial 
HSPD1 28.24 28.08 28.36 29.37 29.20 29.54 25 49 123 3.07 -1.14 
62 Splicing factor, proline- 
and glutamine-rich 
SFPQ 22.29 23.00 21.72 25.71 26.29 26.40 4 6 9 3.05 -3.80 
63 Ataxin-10 ATXN10 27.25 27.27 26.57 22.89 22.81 21.41 9 24 26 3.03 4.66 
64 Vesicle-fusing ATPase NSF 28.09 27.66 28.43 23.59 23.26 24.68 24 38 50 3.02 4.22 
65 Sister chromatid 
cohesion protein PDS5 
homolog A 
PDS5A 24.85 24.73 25.17 22.66 21.90 21.67 5 5 11 3.02 2.84 
66 Tubulin alpha-4A chain TUBA4A 30.01 30.42 30.40 28.72 28.12 28.38 49 68 118 2.98 1.87 
67 Cytochrome b-c1 
complex subunit Rieske, 
mitochondrial; 
Cytochrome b-c1 
UQCRFS1; 
UQCRFS1
P1 
25.54 24.86 24.77 22.55 21.70 22.20 3 19 6 2.96 2.91 
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complex subunit 11 
68 Fatty acid desaturase 2 FADS2 24.67 24.76 25.08 22.85 22.03 21.98 2 7 3 2.93 2.55 
69 ATP synthase subunit g, 
mitochondrial 
ATP5L 26.95 26.65 27.12 23.75 22.37 23.56 8 83 20 2.90 3.68 
70 DNA-directed RNA 
polymerases I, II, and III 
subunit RPABC3 
POLR2H 21.69 21.19 22.36 25.58 25.05 26.22 2 19 2 2.89 -3.87 
71 Mitochondrial carrier 
homolog 1 
MTCH1 25.38 25.14 25.53 21.97 22.61 23.10 3 11 9 2.89 2.79 
72 Tubulin alpha-1B chain TUBA1B 34.83 34.60 34.90 33.24 32.68 33.28 57 80 1029 2.88 1.71 
73 Glutaryl-CoA 
dehydrogenase, 
mitochondrial 
GCDH 25.77 25.47 26.02 23.46 22.87 22.29 7 26 9 2.82 2.88 
74 Large neutral amino 
acids transporter small 
subunit 1 
SLC7A5 28.16 27.60 27.86 25.58 25.73 26.27 13 21 60 2.80 2.01 
75 Importin-9 IPO9 26.59 26.53 27.03 22.12 21.43 23.34 8 12 20 2.79 4.42 
76 Phosphatidate 
cytidylyltransferase, 
mitochondrial 
TAMM41 25.42 25.21 25.09 23.01 21.70 22.16 4 11 9 2.77 2.95 
77 Dolichyl-
diphosphooligosacchari
de--protein 
glycosyltransferase 
subunit STT3A 
STT3A 24.09 24.53 24.44 22.42 22.14 21.46 5 10 8 2.76 2.35 
78 Heterogeneous nuclear 
ribonucleoprotein K 
HNRNPK 27.20 26.81 26.77 28.17 28.13 28.50 17 39 71 2.75 -1.34 
79 Monocarboxylate 
transporter 1 
SLC16A1 26.55 26.59 26.98 24.53 24.54 25.23 6 10 18 2.70 1.94 
80 Very-long-chain 3-
oxoacyl-CoA reductase 
HSD17B12 26.09 25.24 26.01 22.18 22.51 23.35 8 35 13 2.67 3.10 
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81 78 kDa glucose-
regulated protein 
HSPA5 29.62 29.12 29.79 31.54 31.17 31.04 34 50 156 2.65 -1.74 
82 Importin-8 IPO8 25.07 25.35 24.82 23.13 22.10 22.05 4 5 8 2.65 2.65 
83 Cleft lip and palate 
transmembrane protein 
1-like protein 
CLPTM1L 23.56 23.71 24.24 22.27 22.47 22.29 2 6 5 2.64 1.49 
84 Exportin-1 XPO1 29.11 29.28 29.49 22.94 22.59 25.21 29 33 118 2.64 5.72 
85 ATP synthase subunit 
O, mitochondrial 
ATP5O 24.47 24.14 24.42 22.68 21.92 22.69 5 27 7 2.63 1.91 
86 Tubulin alpha-1A 
chain;Tubulin  alpha-
3C/D chain; Tubulin 
alpha-3E chain 
TUBA1A; 
TUBA3C; 
TUBA3E 
26.04 25.54 26.61 22.86 22.49 21.29 55 80 37 2.61 3.85 
87 Translation machinery-
associated protein 7 
TMA7 27.30 26.99 27.07 23.49 21.82 23.72 5 64 39 2.61 4.10 
88 Mitochondrial import 
inner membrane 
translocase subunit 
TIM50 
TIMM50 26.35 25.73 25.89 23.32 21.63 22.40 8 28 14 2.60 3.54 
89 Protein transport protein 
Sec61 subunit alpha 
isoform 1; Protein 
transport protein Sec61 
subunit alpha isoform 2 
SEC61A1; 
SEC61A2 
27.03 27.01 27.16 24.29 24.75 25.43 14 33 30 2.59 2.24 
90 Armadillo repeat-
containing protein 6 
ARMC6 25.09 24.55 24.29 22.50 21.79 22.61 3 9 8 2.59 2.34 
91 Elongation factor 2 EEF2 26.85 26.86 26.99 28.21 27.96 27.68 27 37 71 2.58 -1.05 
92 Transketolase TKT 25.15 24.96 24.68 27.19 26.73 26.36 18 37 46 2.57 -1.83 
93 Transmembrane 9 
superfamily member 2 
TM9SF2 26.95 26.32 26.15 22.89 24.14 23.67 8 13 14 2.57 2.91 
94 Replication factor C RFC3 25.15 24.50 24.55 23.18 23.07 22.61 4 17 5 2.55 1.78 
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subunit 3 
95 Coiled-coil domain-
containing protein 47 
CCDC47 25.25 24.99 25.55 23.12 22.21 23.27 5 17 8 2.55 2.40 
96 Manganese-transporting 
ATPase 13A1 
ATP13A1 24.43 24.88 25.00 23.26 22.81 23.42 4 4 6 2.50 1.61 
97 Exportin-2 CSE1L 30.05 29.62 29.95 23.73 25.50 26.21 43 46 151 2.49 4.73 
98 Dolichol-phosphate 
mannosyltransferase 
subunit 1 
DPM1 25.52 26.02 26.52 23.33 22.29 23.49 5 21 12 2.48 2.98 
99 Desmoglein-1 DSG1 23.97 24.49 24.77 26.06 26.16 25.80 11 12 32 2.46 -1.60 
100 SRA stem-loop-
interacting RNA-binding 
protein, mitochondrial 
SLIRP 24.48 25.96 25.36 21.75 22.68 21.79 3 35 11 2.43 3.20 
101 Acylglycerol kinase, 
mitochondrial 
AGK 25.21 24.73 25.08 23.26 22.45 23.39 6 19 13 2.42 1.97 
102 Methylcrotonoyl-CoA 
carboxylase subunit 
alpha, mitochondrial 
MCCC1 26.10 25.75 26.05 27.08 26.85 27.38 9 17 23 2.41 -1.14 
103 Heterogeneous nuclear 
ribonucleoproteins 
A2/B1 
HNRNPA2
B1 
22.76 22.20 23.23 25.51 24.82 24.75 8 26 28 2.40 -2.30 
104 ATP-dependent RNA 
helicase DDX39A 
DDX39A 30.02 29.69 29.84 29.23 29.29 29.28 26 52 115 2.40 0.59 
105 Protein unc-45 
homolog A 
UNC45A 27.98 27.67 26.56 23.23 24.29 24.43 23 30 46 2.40 3.42 
106 MICOS complex subunit 
MIC60 
IMMT 23.60 23.82 23.53 22.38 21.54 21.41 3 6 4 2.39 1.87 
107 DNA mismatch repair 
protein Msh2 
MSH2 28.04 28.71 28.62 25.56 24.10 25.76 26 34 62 2.38 3.31 
108 Glutaminase kidney 
isoform, mitochondrial 
GLS 27.06 26.92 26.75 24.00 21.51 22.28 13 26 27 2.36 4.31 
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109 Microtubule-associated 
protein RP/EB family 
member 2 
MAPRE2 25.30 24.62 25.09 22.65 21.07 22.28 2 12 3 2.36 3.00 
110 Replication factor C 
subunit 4 
RFC4 24.25 24.29 24.62 23.10 22.48 22.09 3 12 6 2.35 1.83 
111 Calcium uniporter 
protein, mitochondrial 
MCU 25.24 25.19 26.21 23.35 22.97 22.22 8 26 15 2.34 2.70 
112 Dolichyl-
diphosphooligosacchari
de--protein 
glycosyltransferase 
subunit 1 
RPN1 29.88 29.70 29.73 27.07 27.13 28.28 35 60 145 2.34 2.28 
113 ATP-dependent 6-
phosphofructokinase, 
platelet type 
PFKP 29.76 29.75 30.07 29.04 28.71 29.10 32 40 166 2.32 0.91 
114 Elongation factor 1-
gamma 
EEF1G 26.30 26.19 26.45 25.41 25.62 25.10 12 28 33 2.31 0.93 
115 Plasma membrane 
calcium-transporting 
ATPase 1 and 4  
ATP2B1; 
ATP2B4 
23.98 23.88 23.83 23.03 22.39 22.89 3 4 5 2.30 1.13 
116 Heterogeneous nuclear 
ribonucleoprotein H 
HNRNPH1 26.62 26.25 26.44 27.31 27.88 27.96 10 27 46 2.29 -1.28 
117 High mobility group 
protein HMG-I/HMG-Y 
HMGA1 25.40 24.95 25.71 26.80 27.67 27.67 6 51 31 2.28 -2.02 
118 Long-chain-fatty-acid--
CoA ligase 3 
ACSL3 28.27 26.72 27.49 23.14 21.83 24.20 27 46 52 2.25 4.44 
119 Exportin-7 XPO7 24.11 23.52 23.40 22.54 22.48 22.48 5 5 7 2.24 1.18 
120 Importin subunit beta-1 KPNB1 28.02 27.90 28.45 26.37 25.82 26.81 19 23 51 2.24 1.79 
121 Serpin H1 SERPINH1 25.55 25.43 25.30 26.88 26.57 27.53 15 45 32 2.23 -1.56 
122 Up-regulated during 
skeletal muscle growth 
USMG5 25.15 24.80 24.07 22.53 22.11 22.94 3 45 5 2.23 2.14 
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protein 5 
123 Importin-5 IPO5 29.01 29.12 29.07 21.20 22.67 25.10 23 27 61 2.22 6.08 
124 NADH-ubiquinone 
oxidoreductase 75 kDa 
subunit, mitochondrial 
NDUFS1 24.79 24.55 24.29 22.84 22.02 23.11 2 5 3 2.22 1.89 
125 Signal transducer and 
activator of transcription 
1-alpha/beta 
STAT1 27.21 27.88 27.83 24.51 24.81 25.93 17 27 42 2.22 2.56 
126 Basic leucine zipper and 
W2 domain-containing 
protein 2 
BZW2 24.90 24.83 25.52 23.04 21.21 21.96 6 15 16 2.20 3.01 
127 Voltage-dependent 
anion-selective channel 
protein 1 
VDAC1 24.41 23.78 23.40 25.31 25.59 25.56 8 40 42 2.20 -1.62 
128 Tubulin beta chain TUBB 32.84 32.89 32.56 31.10 30.36 31.47 53 80 344 2.19 1.79 
129 Coatomer subunit 
gamma-1 
COPG1 29.24 29.08 29.15 27.07 27.62 28.10 33 39 113 2.19 1.56 
130 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
UQCRC2 29.97 29.98 29.70 27.54 26.71 28.26 22 72 99 2.19 2.38 
131 Stress-70 protein, 
mitochondrial 
HSPA9 26.64 25.80 25.90 27.94 27.38 27.86 20 31 65 2.16 -1.61 
132 Eukaryotic translation 
initiation factor 4 
gamma 1 
EIF4G1 24.23 23.80 24.15 22.87 23.22 23.28 7 7 12 2.15 0.94 
133 Minor histocompatibility 
antigen H13 
HM13 25.15 24.87 25.04 23.35 21.70 21.78 3 15 17 2.14 2.74 
134 Tubulin-specific 
chaperone D 
TBCD 27.16 26.63 27.29 23.62 24.00 25.29 12 13 32 2.13 2.73 
135 Replication factor C 
subunit 5 
RFC5 25.39 24.95 25.01 21.49 22.92 23.09 7 28 9 2.12 2.61 
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136 T-complex protein 1 
subunit alpha 
TCP1 25.26 24.75 24.19 22.73 21.80 22.88 7 17 14 2.11 2.26 
137 Elongation factor Tu, 
mitochondrial 
TUFM 26.73 27.15 27.21 28.84 28.43 28.01 21 48 108 2.11 -1.40 
138 40S ribosomal protein 
S2 
RPS2 23.95 24.59 24.17 22.68 21.24 22.06 6 17 17 2.10 2.25 
139 Acetyl-CoA carboxylase 
1; Biotin carboxylase 
ACACA 28.47 28.49 28.66 24.36 25.43 26.55 33 18 71 2.09 3.09 
140 Protein TBRG4 TBRG4 26.46 26.12 25.83 23.12 23.53 24.65 12 27 17 2.07 2.37 
141 Sideroflexin-1 SFXN1 29.14 29.04 29.16 28.29 28.63 28.09 19 60 90 2.07 0.78 
142 Actin, alpha cardiac 
muscle 1; Actin, alpha 
skeletal muscle 
ACTC1; 
ACTA1 
29.98 29.59 29.64 27.55 27.85 28.68 31 72 92 2.06 1.71 
143 Heat shock cognate 71 
kDa protein 
HSPA8 28.42 27.76 27.60 29.51 29.22 29.09 30 46 141 2.06 -1.35 
144 Dimethyladenosine 
transferase 2, 
mitochondrial 
TFB2M 24.38 24.46 24.94 22.05 23.21 22.93 4 11 5 2.05 1.86 
145 Dermcidin; Survival-
promoting peptide; 
DCD-1 
DCD 26.63 26.82 26.50 28.71 27.92 29.34 5 35 28 2.05 -2.00 
146 Non-histone 
chromosomal protein 
HMG-17 
HMGN2 27.20 26.96 26.33 22.65 23.72 24.75 3 37 10 2.05 3.12 
147 ATP-dependent 6-
phosphofructokinase, 
muscle type 
PFKM 27.83 28.79 28.32 26.55 25.09 26.06 23 31 61 2.04 2.41 
148 Transmembrane 9 
superfamily member 3 
TM9SF3 24.42 24.83 24.98 22.70 23.65 22.64 4 8 7 2.04 1.74 
149 Coatomer subunit beta COPB1 29.53 29.23 29.91 25.81 26.43 27.77 36 45 150 2.04 2.89 
150 Surfeit locus protein 4 SURF4 25.06 26.56 26.15 22.50 21.41 23.44 3 14 10 2.03 3.47 
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151 Leucine-rich PPR motif-
containing protein, 
mitochondrial 
LRPPRC 28.70 28.11 28.65 22.06 21.56 25.29 36 33 76 2.02 5.52 
152 Fatty acid synthase FASN 24.76 24.73 25.23 26.23 25.69 26.26 19 10 32 2.02 -1.15 
153 Signal peptidase 
complex subunit 2 
SPCS2 27.52 27.12 27.55 24.50 25.71 25.81 13 58 51 2.01 2.06 
154 Mitochondrial 2-
oxoglutarate/malate 
carrier protein 
SLC25A11 26.67 26.78 27.08 25.45 25.35 26.09 9 39 28 2.00 1.21 
 
  
233 
 
Appendix F: PEAKS Modified Peptides 
The following abbreviations for common PTMs are used in the table: 
• Ac -Acetylation (Protein N-term) 
• Cbm - Carbamidomethylation 
• Ox – Oxidation 
• Phos – Phosphorylation 
• Deam – Deamidation 
• Dehyd – Dehydration 
• #Spec – number of spectral counts 
The tables are ordered by gene in alphabetical order. Full stops indicate sites of enzyme cleavage. 
NitroXL (Sets A, A1, B, B1, C, C1) 
 
Gene Peptide #Spec PTM & A-Score 
1 ADT2 F.AK(+100.02)DFLAGGVAAAIS(+100.02)KTAVAPIERVK(+100.02)L.L 1 K2: SuccOH: 0.00 
S14: SuccOH: 0.00 
K25: SuccOH: 41.41 
2 ADT2 L.AADVGK(+100.02)AGAEREF.R 2 K6: SuccOH: 80.35 
3 ALDOA L.AADESTGSIAK(+393.11)RL.Q 1 K11: MonoOH: 32.97 
4 ALDOA L.AADESTGSIAK(+100.02)RL.Q 4 K11: SuccOH: 29.32 
5 ANXA2 Y.KT(+100.02)DLEK(+100.02)DIISDTSGDF.R 2 T2: SuccOH: 9.34 
K6: SuccOH: 29.96 
6 ARF5 W.DVGGQDK(+100.02)IRPL.W 1 K7: SuccOH: 50.87 
7 ATPB Y.MVGPIEEAVAK(+393.11)ADKLAEEHSS 1 K11: MonoOH: 28.36 
8 COF1 M.A(+42.01)SGVAVSDGVIK(+100.02)VF.N 2 A1: Ac: 1000.00 
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K12: SuccOH: 46.62 
9 DEST L.VGDVGVTITDPFK(+100.02)HF.V 2 K13: SuccOH: 25.11 
10 DX39A R.DFLLK(+100.02)PELLR.A 1 K5: SuccOH: 61.69 
11 DX39B R.DFLLK(+100.02)PELLR.A 1 K5: SuccOH: 61.69 
12 G3P R.GALQNIIPASTGAAK(+100.02)AVGK(+100.02)VIPELNGK.L 2 K15: SuccOH: 3.97 
K19: SuccOH: 47.82 
13 G3P F.HGTVK(+100.02)AENGKL.V 1 K5: SuccOH: 22.85 
14 G3P Y.DDIKKVVK(+100.02)QASEGPL.K 1 K8: SuccOH: 28.36 
15 G3P M.G(+100.02)KVKVGVN(+.98)GF.G 1 G1: SuccOH: 8.14 
N8: Deam (NQ): 1000.00 
16 GRP78 L.VGGSTRIPK(+100.02)IQQL.V 1 K9: SuccOH: 32.94 
17 HNRH1 F.VVK(+100.02)VRGLPW.S 2 K3: SuccOH: 26.31 
18 HS90B M.P(+100.02)EEVHHGEEEVETF.A 1 P1: SuccOH: 64.80 
19 HSP7C Y.GLDK(+100.02)KVGAERNVL.I 1 K4: SuccOH: 37.81 
20 HSPB1 F.ESRAQLGGPEAAKSDETAAK(+100.02) 2 K20: SuccOH: 21.15 
21 K1C17 R.TIVEEVQDGK(+100.02)VISSR.E 1 K10: SuccOH: 47.09 
22 K22E F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
23 K2C1 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
24 K2C1B F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
25 K2C3 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
26 K2C5 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
27 K2C7 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
28 K2C8 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
29 KPYM R.SVETLK(+100.02)EMIK.S 1 K6: SuccOH: 26.31 
30 LDHB L.TSVINQK(+100.02)LKDDEVAQL.K 1 K7: SuccOH: 41.83 
31 MPCP F.SVTLK(+100.02)EDGVRGL.A 3 K5: SuccOH: 39.97 
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32 NDKB F.IAIK(+393.11)PDGVQRGL.V 1 K4: MonoOH: 32.97 
33 NDKB F.IAIK(+100.02)PDGVQRGL.V 2 K4: SuccOH: 38.16 
34 PPIA F.ELFADK(+393.11)VPKTAENF.R 1 K6: MonoOH: 44.84 
35 PPIA F.ELFADK(+100.02)VPKTAENF.R 1 K6: SuccOH: 53.53 
36 PROF1 K.TFVNITPAEVGVLVGK(+100.02)DR.S 4 K16: SuccOH: 67.24 
37 PROF1 L.VGK(+100.02)DRSSF.Y 1 K3: SuccOH: 24.24 
38 QCR2 L.IGLGVSHPVLK(+100.02)QVAEQF.L 1 K11: SuccOH: 22.07 
39 RACK1 W.DLEGK(+100.02)IIVDEL.K 1 K5: SuccOH: 22.37 
40 RAN F.HTNRGPIK(+100.02)F.N 1 K8: SuccOH: 59.64 
41 RB27B F.ITTVGIDFREK(+100.02)RVVY.N 4 K11: SuccOH: 38.03 
42 RL27 Y.SVDIPLDK(+100.02)TVVNKDVF.R 1 K8: SuccOH: 23.10 
43 RPN2 W.NVADVVIK(+393.11)FPEEEAPSTVL.S 2 K8: MonoOH: 38.64 
44 RPN2 F.TPK(+393.11)QEIQHLF.R 1 K3: MonoOH: 25.66 
45 RPN2 W.NVADVVIK(+100.02)FPEEEAPSTVL.S 2 K8: SuccOH: 38.64 
46 RPN2 F.TPK(+100.02)QEIQHLF.R 1 K3: SuccOH: 28.86 
47 RS27A L.IFAGK(+100.02)QLEDGRTL.S 1 K5: SuccOH: 67.69 
48 SFPQ L.TTTPRPVIVEPLEQLDDEDGLPEK(+100.02)L.A 1 K24: SuccOH: 40.11 
49 SRP14 M.V(+100.02)LLESEQFLTELTR.L 1 V1: SuccOH: 87.62 
50 SRSF3 Y.VGNLGNN(+.98)GNK(+393.11)TELERAF.G 1 N7: Deam (NQ): 26.02 
K10: MonoOH: 17.01 
51 SRSF3 Y.VGNLGNN(+.98)GNK(+100.02)TELERAF.G 1 N7: Deam (NQ): 30.46 
K10: SuccOH: 10.11 
52 SRSF3 Y.VGNLGNNGNK(+100.02)TELERAF.G 1 K10: SuccOH: 24.44 
53 SRSF3 R.VRVELSNGEK(+100.02)R.S 1 K10: SuccOH: 42.89 
54 SRSF3 Y.VGNLGNNGNK(+100.02)T(-18.01)ELERAF.G 7 K10: SuccOH: 128.00 
T11: Dehyd: 1000.00 
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55 SRSF7 Y.VGNLGTGAGK(+100.02)GELERAF.S 1 K10: SuccOH: 49.79 
56 TBA1C F.HPEQLITGK(+393.11)EDAANNY.A 2 K9: MonoOH: 22.85 
57 TBA1C Y.APVISAEK(+393.11)AYHEQL.T 2 K8: MonoOH: 33.18 
58 TBA1C R.QLFHPEQLITGK(+100.02)EDAANNYAR.G 1 K12: SuccOH: 26.31 
59 TBA1C R.GHYTIGK(+100.02)EIIDLVLDR.I 1 K7: SuccOH: 32.97 
60 TBA1C Y.APVISAEK(+100.02)AYHEQL.T 6 K8: SuccOH: 40.00 
61 TBA1C F.FSETGAGK(+100.02)HVPRAVF.V 6 K8: SuccOH: 25.11 
62 TBA1C F.SETGAGK(+100.02)HVPRAVF.V 1 K7: SuccOH: 25.70 
63 TBA1C L.FHPEQLITGK(+100.02)EDAANNY.A 1 K10: SuccOH: 22.85 
64 TBA1C Y.APVISAEK(+100.02)AY.H 2 K8: SuccOH: 32.97 
65 TBA4A F.HPEQLITGK(+393.11)EDAANNY.A 2 K9: MonoOH: 22.85 
66 TBA4A Y.APVISAEK(+393.11)AYHEQL.S 2 K8: MonoOH: 33.18 
67 TBA4A R.QLFHPEQLITGK(+100.02)EDAANNYAR.G 1 K12: SuccOH: 26.31 
68 TBA4A Y.APVISAEK(+100.02)AYHEQL.S 6 K8: SuccOH: 40.00 
69 TBA4A L.FHPEQLITGK(+100.02)EDAANNY.A 1 K10: SuccOH: 22.85 
70 TBA4A Y.APVISAEK(+100.02)AY.H 2 K8: SuccOH: 32.97 
71 TBB3 L.RFPGQLNADLRK(+100.02)L.A 5 K12: SuccOH: 88.25 
72 TBB4B L.RFPGQLNADLRK(+100.02)L.A 5 K12: SuccOH: 88.25 
73 TBB5 L.RFPGQLNADLRK(+100.02)L.A 5 K12: SuccOH: 88.25 
74 TBB6 L.RFPGQLNADLRK(+100.02)L.A 5 K12: SuccOH: 88.25 
75 TCP4 W.SQLKEQISDIDDAVRK(+100.02)L 1 K16: SuccOH: 49.35 
76 TSTRB27A M(+42.01)(+15.99)WSHPQFEK(+450.13)GGGSGGGSGGSAW.S 1 M1: Ac: 1000.00 
M1: Ox (M): 1000.00 
K9: MonoGly: 34.30 
77 TSTRB27A M(+42.01)(+15.99)WSHPQFEK(+393.11)GGGSGGGSGGSAW.S 4 M1: Ac: 1000.00 
M1: Ox (M): 1000.00 
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K9: MonoOH: 37.35 
78 TSTRB27A M(+42.01)(+15.99)WSHPQFEK(+100.02)GGGSGGGSGGSAW.S 9 M1: Ac: 1000.00 
M1: Ox (M): 1000.0 
K9: SuccOH: 28.70 
79 TSTRB27A M(+42.01)(+15.99)WSHPQFEK(+100.02)GGGSGGGSGGSAWSHPQFEKSGLR.S 1 M1: Ac: 1000.00 
M1: Ox (M): 1000.00 
K9: SuccOH: 25.70 
80 TSTRB27A M(+42.01)WSHPQFEK(+393.11)GGGSGGGSGGSAW.S 4 M1: Ac: 1000.00 
K9: MonoOH: 34.81 
81 TSTRB27A M(+42.01)WSHPQFEK(+100.02)GGGSGGGSGGSAWS(+100.02)HPQFEKSGLR.S 6 M1: Ac: 1000.00 
K9: SuccOH: 77.13 
S23: SuccOH: 0.00 
82 TSTRB27A M(+42.01)WSHPQFEK(+100.02)GGGSGGGSGGSAW.S 8 M1: Ac: 1000.00 
K9: SuccOH: 58.99 
83 TSTRB27A M(+42.01)WSHPQFEKGGGS(+100.02)GGGSGGSAW.S 1 M1: Ac: 1000.00 
S13: SuccOH: 0.00 
84 TSTRB27A M(+42.01)WSHPQFEK(+100.02)GGGS(+275.08)GGGSGGSAW.S 2 M1: Ac: 1000.00; 
K9: SuccOH: 25.70 
S13: Cleaved1: 25.70 
85 TSTRB27A R.C(+57.02)VDK(+100.02)SWIPEGVVR.S 14 C1: Cbm: 1000.00; 
K4: SuccOH: 26.02 
86 TSTRB27A L.C(+57.02)GNKSDLEDQRVVKEEEAIALAEK(+100.02)Y.G 6 C1: Cbm: 1000.00 
K24: SuccOH: 9.34 
87 TSTRB27A L.C(+57.02)GNKSDLEDQRVVK(+100.02)EEEAIAL.A 6 C1: Cbm: 1000.00 
K14: SuccOH: 30.19 
88 TSTRB27A L.C(+57.02)GNK(+100.02)SDLEDQRVVK(+100.02)EEEAIAL.A 3 C1: Cbm: 1000.00 
K4: SuccOH: 17.01 
K14: SuccOH: 38.24 
89 TSTRB27A R.C(+57.02)VDK(+100.02)S(+100.02)WIPEGVVR.S 2 C1: Cbm: 1000.00 
K4: SuccOH: 1000.00 
S5: SuccOH: 1000.00 
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90 TSTRB27A L.C(+57.02)GNK(+100.02)SDLEDQRVVKEEEAIAL.A 1 C1: Cbm: 1000.00 
K4: SuccOH: 40.00 
91 TSTRB27A R.AMSDGDYDY(+275.08)LIK(+100.02)FLALGDSGVGK.T 1 Y9: Cleaved1: 11.10 
K12: SuccOH: 32.97 
92 TSTRB27A R.AMSDGDYDYLIK(+450.13)FLALGDSGVGK.T 4 K12: MonoGly: 68.47 
93 TSTRB27A W.SHPQFEK(+450.13)SGL.R 2 K7: MonoGly: 33.98 
94 TSTRB27A F.LALGDSGVGK(+450.13)TSVL.Y 1 K10: MonoGly: 20.92 
95 TSTRB27A R.AMSDGDYDYLIK(+393.11)FLALGDSGVGK.T 5 K12: MonoOH: 77.24 
96 TSTRB27A K.TSVLYQYTDGK(+393.11)FNSK.F 3 K11: MonoOH: 26.52 
97 TSTRB27A W.SHPQFEK(+393.11)GGGSGGGSGGSAW.S 7 K7: MonoOH: 30.10 
98 TSTRB27A K.FNSK(+393.11)FITTVGIDFR.E 1 K4: MonoOH: 27.96 
99 TSTRB27A W.SHPQFEK(+393.11)SGL.R 4 K7: MonoOH: 30.46 
100 TSTRB27A K.YGIPYFETSAANGTNISQAIEMLLDLIMK(+100.02)R.M 4 K29: SuccOH: 123.16 
101 TSTRB27A K.TSVLYQYTDGK(+100.02)FNSK(+100.02)FITTVGIDFR.E 1 K11: SuccOH: 26.52 
K15: SuccOH: 11.06 
102 TSTRB27A R.AMSDGDYDYLIK(+100.02)FLALGDSGVGK.T 3 K12: SuccOH: 68.47 
103 TSTRB27A K.SDLEDQRVVK(+100.02)EEEAIALAEK.Y 3 K10: SuccOH: 66.45 
104 TSTRB27A K.TSVLYQYTDGK(+100.02)FNSK.F 31 K11: SuccOH: 32.97 
105 TSTRB27A K.FNSK(+100.02)FITTVGIDFR.E 13 K4: SuccOH: 30.46 
106 TSTRB27A W.SHPQFEK(+100.02)GGGSGGGSGGSAW.S 6 K7: SuccOH: 37.35 
107 TSTRB27A R.SNGHAS(+100.02)TDQLSEEK(+100.02)EK.G 3 S6: SuccOH: 0.00 
K14: SuccOH: 22.85 
108 TSTRB27A W.SHPQFEK(+100.02)GGGS(+100.02)GGGSGGSAW.S 1 K7: SuccOH: 53.33 
S11: SuccOH: 11.12 
109 TSTRB27A R.AMSDGDYDYLIK(+100.02)FLALGDS(+100.02)GVGK.T 1 K12: SuccOH: 29.32 
S19: SuccOH: 16.76 
110 TSTRB27A F.LALGDSGVGK(+100.02)TSVL.Y 7 K10: SuccOH: 33.98 
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111 TSTRB27A W.SHPQFEK(+100.02)SGL.R 12 K7: SuccOH: 26.02 
112 TSTRB27A L.ALGDSGVGK(+100.02)TSVL.Y 2 K9: SuccOH: 23.10 
113 TSTRB27A R.SNGHASTDQLSEEK(+100.02)EK.G 2 K14: SuccOH: 32.97 
114 TSTRB27A K.FLALGDS(+100.02)GVGK.T 1 S7: SuccOH: 26.57 
115 TSTRB27A F.ITTVGIDFREK(+100.02)RVVY.R 4 K11: SuccOH: 38.03 
116 TSTRB27A W.SHPQFEK(+100.02)S(+100.02)GL.R 3 K7: SuccOH: 45.03 
S8: SuccOH: 58.52 
117 TSTRB27A L.EDQRVVK(+100.02)EEEAIAL.A 1 K7: SuccOH: 22.09 
118 TSTRB27A Y.TDGKFNSK(+100.02)F.I 1 K8: SuccOH: 26.02 
119 TSTRB27A Y.QYTDGK(+100.02)FNSK(+100.02)F.I 2 K6: SuccOH: 11.12 
K10: SuccOH: 21.94 
120 TSTRB27A W.SHPQFEK(+100.02)GGGS(-18.01)GGGSGGSAW.S 2 K7: SuccOH: 13.99 
S11: Dehyd: 22.59 
121 TSTRB27A W.SHPQFEK(+100.02)GGGSGGGSGGSAW(+15.99).S 1 K7: SuccOH: 26.50 
W20: Ox(HW): 74.98 
122 VDAC1 Y.TQTLK(+450.13)PGIKL.T 1 K5: MonoGly: 25.11 
123 VDAC1 Y.TQTLK(+100.02)PGIKL.T 2 K5: SuccOH: 32.28 
124 VDAC2 L.SALVDGK(+100.02)SINAGGHK(+100.02)VGL.A 1 K7: SuccOH: 30.46 
K15: SuccOH: 52.22 
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DSS (Sets E, D) 
 
Gene Peptide #Spec PTM & A-Score 
1 ADT2 F.AK(+100.02)DFLAGGVAAAIS(+100.02)KTAVAPIERVK(+100.02)L.L 1 K2: SuccOH: 0.00 
S14: SuccOH: 0.00 
K25: SuccOH: 41.41 
2 ADT2 L.AADVGK(+100.02)AGAEREF.R 2 K6: SuccOH: 80.35 
3 ALDOA L.AADESTGSIAK(+393.11)RL.Q 1 K11: MonoOH: 32.97 
4 ALDOA L.AADESTGSIAK(+100.02)RL.Q 4 K11: SuccOH: 29.32 
5 ANXA2 Y.KT(+100.02)DLEK(+100.02)DIISDTSGDF.R 2 T2: SuccOH: 9.34 
K6: SuccOH: 29.96 
6 ARF5 W.DVGGQDK(+100.02)IRPL.W 1 K7: SuccOH: 50.87 
7 ATPB Y.MVGPIEEAVAK(+393.11)ADKLAEEHSS 1 K11: MonoOH: 28.36 
8 COF1 M.A(+42.01)SGVAVSDGVIK(+100.02)VF.N 2 A1: Ac: 1000.00 
K12: SuccOH: 46.62 
9 DEST L.VGDVGVTITDPFK(+100.02)HF.V 2 K13: SuccOH: 25.11 
10 DX39A R.DFLLK(+100.02)PELLR.A 1 K5: SuccOH: 61.69 
11 DX39B R.DFLLK(+100.02)PELLR.A 1 K5: SuccOH: 61.69 
12 G3P R.GALQNIIPASTGAAK(+100.02)AVGK(+100.02)VIPELNGK.L 2 K15: SuccOH: 3.97 
K19: SuccOH: 47.82 
13 G3P F.HGTVK(+100.02)AENGKL.V 1 K5: SuccOH: 22.85 
14 G3P Y.DDIKKVVK(+100.02)QASEGPL.K 1 K8: SuccOH: 28.36 
15 G3P M.G(+100.02)KVKVGVN(+.98)GF.G 1 G1: SuccOH: 8.14 
N8: Deam (NQ): 1000.00 
16 GRP78 L.VGGSTRIPK(+100.02)IQQL.V 1 K9: SuccOH: 32.94 
17 HNRH1 F.VVK(+100.02)VRGLPW.S 2 K3: SuccOH: 26.31 
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18 HS90B M.P(+100.02)EEVHHGEEEVETF.A 1 P1: SuccOH: 64.80 
19 HSP7C Y.GLDK(+100.02)KVGAERNVL.I 1 K4: SuccOH: 37.81 
20 HSPB1 F.ESRAQLGGPEAAKSDETAAK(+100.02) 2 K20: SuccOH: 21.15 
21 K1C17 R.TIVEEVQDGK(+100.02)VISSR.E 1 K10: SuccOH: 47.09 
22 K22E F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
23 K2C1 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
24 K2C1B F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
25 K2C3 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
26 K2C5 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
27 K2C7 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
28 K2C8 F.ASFIDK(+100.02)VRF.L 4 K6: SuccOH: 39.44 
29 KPYM R.SVETLK(+100.02)EMIK.S 1 K6: SuccOH: 26.31 
30 LDHB L.TSVINQK(+100.02)LKDDEVAQL.K 1 K7: SuccOH: 41.83 
31 MPCP F.SVTLK(+100.02)EDGVRGL.A 3 K5: SuccOH: 39.97 
32 NDKB F.IAIK(+393.11)PDGVQRGL.V 1 K4: MonoOH: 32.97 
33 NDKB F.IAIK(+100.02)PDGVQRGL.V 2 K4: SuccOH: 38.16 
34 PPIA F.ELFADK(+393.11)VPKTAENF.R 1 K6: MonoOH: 44.84 
35 PPIA F.ELFADK(+100.02)VPKTAENF.R 1 K6: SuccOH: 53.53 
36 PROF1 K.TFVNITPAEVGVLVGK(+100.02)DR.S 4 K16: SuccOH: 67.24 
37 PROF1 L.VGK(+100.02)DRSSF.Y 1 K3: SuccOH: 24.24 
38 QCR2 L.IGLGVSHPVLK(+100.02)QVAEQF.L 1 K11: SuccOH: 22.07 
39 RACK1 W.DLEGK(+100.02)IIVDEL.K 1 K5: SuccOH: 22.37 
40 RAN F.HTNRGPIK(+100.02)F.N 1 K8: SuccOH: 59.64 
41 RB27B F.ITTVGIDFREK(+100.02)RVVY.N 4 K11: SuccOH: 38.03 
42 RL27 Y.SVDIPLDK(+100.02)TVVNKDVF.R 1 K8: SuccOH: 23.10 
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43 RPN2 W.NVADVVIK(+393.11)FPEEEAPSTVL.S 2 K8: MonoOH: 38.64 
44 RPN2 F.TPK(+393.11)QEIQHLF.R 1 K3: MonoOH: 25.66 
45 RPN2 W.NVADVVIK(+100.02)FPEEEAPSTVL.S 2 K8: SuccOH: 38.64 
46 RPN2 F.TPK(+100.02)QEIQHLF.R 1 K3: SuccOH: 28.86 
47 RS27A L.IFAGK(+100.02)QLEDGRTL.S 1 K5: SuccOH: 67.69 
48 SFPQ L.TTTPRPVIVEPLEQLDDEDGLPEK(+100.02)L.A 1 K24: SuccOH: 40.11 
49 SRP14 M.V(+100.02)LLESEQFLTELTR.L 1 V1: SuccOH: 87.62 
50 SRSF3 Y.VGNLGNN(+.98)GNK(+393.11)TELERAF.G 1 N7: Deam (NQ): 26.02 
K10: MonoOH: 17.01 
51 SRSF3 Y.VGNLGNN(+.98)GNK(+100.02)TELERAF.G 1 N7: Deam (NQ): 30.46 
K10: SuccOH: 10.11 
52 SRSF3 Y.VGNLGNNGNK(+100.02)TELERAF.G 1 K10: SuccOH: 24.44 
53 SRSF3 R.VRVELSNGEK(+100.02)R.S 1 K10: SuccOH: 42.89 
54 SRSF3 Y.VGNLGNNGNK(+100.02)T(-18.01)ELERAF.G 7 K10: SuccOH: 128.00 
T11: Dehyd: 1000.00 
55 SRSF7 Y.VGNLGTGAGK(+100.02)GELERAF.S 1 K10: SuccOH: 49.79 
56 TBA1C F.HPEQLITGK(+393.11)EDAANNY.A 2 K9: MonoOH: 22.85 
57 TBA1C Y.APVISAEK(+393.11)AYHEQL.T 2 K8: MonoOH: 33.18 
58 TBA1C R.QLFHPEQLITGK(+100.02)EDAANNYAR.G 1 K12: SuccOH: 26.31 
59 TBA1C R.GHYTIGK(+100.02)EIIDLVLDR.I 1 K7: SuccOH: 32.97 
60 TBA1C Y.APVISAEK(+100.02)AYHEQL.T 6 K8: SuccOH: 40.00 
61 TBA1C F.FSETGAGK(+100.02)HVPRAVF.V 6 K8: SuccOH: 25.11 
62 TBA1C F.SETGAGK(+100.02)HVPRAVF.V 1 K7: SuccOH: 25.70 
63 TBA1C L.FHPEQLITGK(+100.02)EDAANNY.A 1 K10: SuccOH: 22.85 
64 TBA1C Y.APVISAEK(+100.02)AY.H 2 K8: SuccOH: 32.97 
65 TBA4A F.HPEQLITGK(+393.11)EDAANNY.A 2 K9: MonoOH: 22.85 
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66 TBA4A Y.APVISAEK(+393.11)AYHEQL.S 2 K8: MonoOH: 33.18 
67 TBA4A R.QLFHPEQLITGK(+100.02)EDAANNYAR.G 1 K12: SuccOH: 26.31 
68 TBA4A Y.APVISAEK(+100.02)AYHEQL.S 6 K8: SuccOH: 40.00 
69 TBA4A L.FHPEQLITGK(+100.02)EDAANNY.A 1 K10: SuccOH: 22.85 
70 TBA4A Y.APVISAEK(+100.02)AY.H 2 K8: SuccOH: 32.97 
71 TBB3 L.RFPGQLNADLRK(+100.02)L.A 5 K12: SuccOH: 88.25 
72 TBB4B L.RFPGQLNADLRK(+100.02)L.A 5 K12: SuccOH: 88.25 
73 TBB5 L.RFPGQLNADLRK(+100.02)L.A 5 K12: SuccOH: 88.25 
74 TBB6 L.RFPGQLNADLRK(+100.02)L.A 5 K12: SuccOH: 88.25 
75 TCP4 W.SQLKEQISDIDDAVRK(+100.02)L 1 K16: SuccOH: 49.35 
76 TSTRB27A M(+42.01)(+15.99)WSHPQFEK(+450.13)GGGSGGGSGGSAW.S 1 M1: Ac: 1000.00 
M1: Ox (M): 1000.00 
K9: MonoGly: 34.30 
77 TSTRB27A M(+42.01)(+15.99)WSHPQFEK(+393.11)GGGSGGGSGGSAW.S 4 M1: Ac: 1000.00 
M1: Ox (M): 1000.00 
K9: MonoOH: 37.35 
78 TSTRB27A M(+42.01)(+15.99)WSHPQFEK(+100.02)GGGSGGGSGGSAW.S 9 M1: Ac: 1000.00 
M1: Ox (M): 1000.00 
K9: SuccOH: 28.70 
79 TSTRB27A M(+42.01)(+15.99)WSHPQFEK(+100.02)GGGSGGGSGGSAWSHPQFEKSGLR.S 1 M1: Ac: 1000.00 
M1: Ox (M): 1000.00 
K9: SuccOH: 25.70 
80 TSTRB27A M(+42.01)WSHPQFEK(+393.11)GGGSGGGSGGSAW.S 4 M1: Ac: 1000.00 
K9: MonoOH: 34.81 
81 TSTRB27A M(+42.01)WSHPQFEK(+100.02)GGGSGGGSGGSAWS(+100.02)HPQFEKSGLR.S 6 M1: Ac: 1000.00 
K9: SuccOH: 77.13 
S23: SuccOH: 0.00 
82 TSTRB27A M(+42.01)WSHPQFEK(+100.02)GGGSGGGSGGSAW.S 8 M1: Ac: 1000.00 
K9: SuccOH: 58.99 
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83 TSTRB27A M(+42.01)WSHPQFEKGGGS(+100.02)GGGSGGSAW.S 1 M1: Ac: 1000.00 
S13: SuccOH: 0.00 
84 TSTRB27A M(+42.01)WSHPQFEK(+100.02)GGGS(+275.08)GGGSGGSAW.S 2 M1: Ac: 1000.00 
K9: SuccOH: 25.70 
S13: Cleaved1: 25.70 
85 TSTRB27A R.C(+57.02)VDK(+100.02)SWIPEGVVR.S 14 C1: Cbm: 1000.00 
K4: SuccOH: 26.02 
86 TSTRB27A L.C(+57.02)GNKSDLEDQRVVKEEEAIALAEK(+100.02)Y.G 6 C1: Cbm: 1000.00 
K24: SuccOH: 9.34 
87 TSTRB27A L.C(+57.02)GNKSDLEDQRVVK(+100.02)EEEAIAL.A 6 C1: Cbm: 1000.00 
K14: SuccOH: 30.19 
88 TSTRB27A L.C(+57.02)GNK(+100.02)SDLEDQRVVK(+100.02)EEEAIAL.A 3 C1: Cbm: 1000.00 
K4: SuccOH: 17.01 
K14: SuccOH: 38.24 
89 TSTRB27A R.C(+57.02)VDK(+100.02)S(+100.02)WIPEGVVR.S 2 C1: Cbm: 1000.00 
K4: SuccOH: 1000.00 
S5: SuccOH: 1000.00 
90 TSTRB27A L.C(+57.02)GNK(+100.02)SDLEDQRVVKEEEAIAL.A 1 C1: Cbm: 1000.00 
K4: SuccOH: 40.00 
91 TSTRB27A R.AMSDGDYDY(+275.08)LIK(+100.02)FLALGDSGVGK.T 1 Y9: Cleaved1: 11.10 
K12: SuccOH: 32.97 
92 TSTRB27A R.AMSDGDYDYLIK(+450.13)FLALGDSGVGK.T 4 K12: MonoGly: 68.47 
93 TSTRB27A W.SHPQFEK(+450.13)SGL.R 2 K7: MonoGly: 33.98 
94 TSTRB27A F.LALGDSGVGK(+450.13)TSVL.Y 1 K10: MonoGly: 20.92 
95 TSTRB27A R.AMSDGDYDYLIK(+393.11)FLALGDSGVGK.T 5 K12: MonoOH: 77.24 
96 TSTRB27A K.TSVLYQYTDGK(+393.11)FNSK.F 3 K11: MonoOH: 26.52 
97 TSTRB27A W.SHPQFEK(+393.11)GGGSGGGSGGSAW.S 7 K7: MonoOH: 30.10 
98 TSTRB27A K.FNSK(+393.11)FITTVGIDFR.E 1 K4: MonoOH: 27.96 
99 TSTRB27A W.SHPQFEK(+393.11)SGL.R 4 K7: MonoOH: 30.46 
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100 TSTRB27A K.YGIPYFETSAANGTNISQAIEMLLDLIMK(+100.02)R.M 4 K29: SuccOH: 123.16 
101 TSTRB27A K.TSVLYQYTDGK(+100.02)FNSK(+100.02)FITTVGIDFR.E 1 K11: SuccOH: 26.52 
K15: SuccOH: 11.06 
102 TSTRB27A R.AMSDGDYDYLIK(+100.02)FLALGDSGVGK.T 3 K12: SuccOH: 68.47 
103 TSTRB27A K.SDLEDQRVVK(+100.02)EEEAIALAEK.Y 3 K10: SuccOH: 66.45 
104 TSTRB27A K.TSVLYQYTDGK(+100.02)FNSK.F 31 K11: SuccOH: 32.97 
105 TSTRB27A K.FNSK(+100.02)FITTVGIDFR.E 13 K4: SuccOH: 30.46 
106 TSTRB27A W.SHPQFEK(+100.02)GGGSGGGSGGSAW.S 6 K7: SuccOH: 37.35 
107 TSTRB27A R.SNGHAS(+100.02)TDQLSEEK(+100.02)EK.G 3 S6: SuccOH: 0.00 
K14: SuccOH: 22.85 
108 TSTRB27A W.SHPQFEK(+100.02)GGGS(+100.02)GGGSGGSAW.S 1 K7: SuccOH: 53.33; 
S11: SuccOH: 11.12 
109 TSTRB27A R.AMSDGDYDYLIK(+100.02)FLALGDS(+100.02)GVGK.T 1 K12: SuccOH: 29.32 
S19: SuccOH: 16.76 
110 TSTRB27A F.LALGDSGVGK(+100.02)TSVL.Y 7 K10: SuccOH: 33.98 
111 TSTRB27A W.SHPQFEK(+100.02)SGL.R 12 K7: SuccOH: 26.02 
112 TSTRB27A L.ALGDSGVGK(+100.02)TSVL.Y 2 K9: SuccOH: 23.10 
113 TSTRB27A R.SNGHASTDQLSEEK(+100.02)EK.G 2 K14: SuccOH: 32.97 
114 TSTRB27A K.FLALGDS(+100.02)GVGK.T 1 S7: SuccOH: 26.57 
115 TSTRB27A F.ITTVGIDFREK(+100.02)RVVY.R 4 K11: SuccOH: 38.03 
116 TSTRB27A W.SHPQFEK(+100.02)S(+100.02)GL.R 3 K7: SuccOH: 45.03 
S8: SuccOH: 58.52 
117 TSTRB27A L.EDQRVVK(+100.02)EEEAIAL.A 1 K7: SuccOH: 22.09 
118 TSTRB27A Y.TDGKFNSK(+100.02)F.I 1 K8: SuccOH: 26.02 
119 TSTRB27A Y.QYTDGK(+100.02)FNSK(+100.02)F.I 2 K6: SuccOH: 11.12 
K10: SuccOH: 21.94 
120 TSTRB27A W.SHPQFEK(+100.02)GGGS(-18.01)GGGSGGSAW.S 2 K7: SuccOH: 13.99 
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S11: Dehyd: 22.59 
121 TSTRB27A W.SHPQFEK(+100.02)GGGSGGGSGGSAW(+15.99).S 1 K7: SuccOH: 26.50 
W20: Ox(HW): 74.98 
122 VDAC1 Y.TQTLK(+450.13)PGIKL.T 1 K5: MonoGly: 25.11 
123 VDAC1 Y.TQTLK(+100.02)PGIKL.T 2 K5: SuccOH: 32.28 
124 VDAC2 L.SALVDGK(+100.02)SINAGGHK(+100.02)VGL.A 1 K7: SuccOH: 30.4 
 K15: SuccOH: 52.22 
 
